annual review troper launna enilkhtimsoxalg feel well live long improve performance day wwwgskcom annual report glaxosmithkline mission global quest improve quality human life glaxosmithkline plc enable people feel well live long annual report year end st december spirit undertake quest enthusiasm entrepreneur excite constant search innovation value performance achieve integrity attain success world class global leader people contribute passion unmatched sense urgency strategic intent want indisputable leader industry glaxosmithkline plc english public limited company share list london stock exchange new york stock exchange content report annual report glaxosmithkline plc year end st december prepare accordance report director united kingdom requirement financial summary summary report year annual review joint statement chairman chief executive officer intend investor need detail description business annual report produce separate document corporate governance annual review include joint statement chairman remuneration report chief executive officer summary review operation operate financial review prospect summary financial statement summary remuneration report financial statement director statement responsibility annual review issue shareholder annual independent auditor report report issue shareholder elect receive consolidated statement profit loss document available glaxosmithkline corporate consolidated statement total recognise gain loss website wwwgskcom consolidate statement cash flow consolidated balance sheet website reconciliation movement equity shareholder fund glaxosmithkline website wwwgskcom give additional company balance sheet information group information available note financial statement website constitute annual report investor information cover live welsh coastline uk naturally draw financial record young jack fraser sea chance develop shareholder return surfing skill asthma symptom shareholder information tightness chest mean breathe properly share capital reluctant outside mother catherine hear taxation information shareholder seretide friend eventually obtain glossary term prescription son annual report approve board result jack see practise surfing skill director rd march publish regular basis develop keen interest golf th march contact details glaxosmithkline glaxosmithkline financial summary joint statement chairman chief executive officer growth statutory result cer fundamentally pharmaceutical industry bright future place debate right wrong turnover ageing population develop world continue unmet challenge pharmaceutical industry traditional business medical need disease mean demand new model place reassure shareholder trading profit well pharmaceutical product continue grow strongly aspect model review order continue profit taxation year ahead development medicine basis reconcile earningsnet income responsibility society fair return shareholder industry face formidable challenge determine change time imaginatively flexibly basic earning share p p threaten pharmaceutical industry traditional business effectively fight believe well serve model shareholder reassure glaxosmithkline dividend share p p long term interest glaxosmithkline world management understand challenge company lead producer medicine make substantial progress respond merger restructure disposal subsidiary industry currently experience decline research robust financial performance trading profit development productivity glaxosmithkline tackle business performance earning share grow profit taxation radically redesign rd organisation new structure cent line guidance issue earningsnet income base seven centre excellence drug discovery trading profit rise cent billion work develop high quality compound operate cash flow billion raise dividend earning share p p december rd day able penny demonstrate progress building business performance exceptionally strong product pipeline provide fuel total pharmaceutical turnover grow cent billion sale cent billion turnover future growth achievement confirm underlying strength resilience trading profit see increasingly aggressive generic industry business particularly give continue generic erosion profit taxation erode period medicine patent year sale augmentin introduction generic protect protection crucial enable competition paxil september adjust earningsnet income pharmaceutical industry sustain huge investment rd adjust earning share p p consumer healthcare business make trading glaxosmithkline course continue defend intellectual profit million year cent property vigorously mitigate impact business performance primary performance measure management present exclude merger item generic competition introduce improved version integration restructuring cost disposal business management believe exclusion item provide well year transition return growth establish medicine drive growth key reflection way business manage give indication performance group term element particularly challenging year product enable glaxosmithkline deliver robust revenue expenditure local management able influence information provide addition statutory impact generic competition paxil introduction financial performance despite generic competition result prepare uk gaap give assist shareholder gain clear understanding underlying performance business generic wellbutrin product sale important product year increase comparability period present billion year company threat sale pricing pressure continue usa come scale catastrophic expect able weather merger integration item represent item arise result merger glaxo wellcome smithkline beecham pressure cut pharmaceutical price senior citizen effort impact partly size partly acquisition block drug restructuring cost arise merger acquisition manufacturing restructuring allow unregulated import lower price drug introduction improve version medicine partly programme agree glaxo wellcome smithkline beecham date merger item abroad glaxosmithkline play lead role discussion drive growth key product broad portfolio nature consider outside normal business expenditure glaxosmithkline expect occur regular basis government address issue fact expect able deliver earning share statutory result appear page include item cost associate restructuring activity arise outside ensure patient safety protect please eps line business performance eps specific restructuring programme treat exceptional item government pass medicare prescription drug benefit constant exchange rate return growth group multinational business operate country earn revenue incur cost currency result bring need help patient purchase represent solid achievement glaxosmithkline group report sterling affect movement exchange rate sterle overseas currency prescription drug europe situation complex pharmaceutical company face similar loss group use average exchange rate prevail year translate result overseas company sterling currency government healthcare budget come increase cost sale result generic competition see earning influence translation dollar euro japanese yen average sterling exchange rate restraint mean continual squeeze return fall significantly strong dollar japanese yen cent cent respectively weak euro great need continue demonstrate year transition glaxosmithkline end cent compare value medicine company profile transform order illustrate underlying performance group practice discuss result term constant exchange rate cer growth finally develop world ongoing challenge broadlybased product portfolio represent growth calculate exchange rate determine result overseas company sterling remain intellectual property right belief pharmaceutical industry onwards unchanged previous year cer represent growth constant exchange rate represent growth actual industry contribution persistent health crisis include low exposure patent expiry measure percentage exchange rate pricing medicine near cost glaxosmithkline lead way turnover time expect big increase pioneer availability preferentially price medicine number major new compound enter phase iii trial vaccine believe remain pharmaceutical company promise pipeline cautionary statement forwardlooke statement group report file furnish securities exchange commission sec include document write information release conduct research prevention treatment oral statement public future behalf group contain forwardlooke statement forwardlooke statement world health organization priority disease broad product portfolio drive growth group current expectation forecast future event investor identify statement fact relate strictly historical develop world hivaid tb malaria pleased glaxosmithkline ability continue deliver robust current fact use word anticipate estimate expect intend project plan believe word term similar meaning agreement reach world trade organization august pharmaceutical sale growth despite generic challenge connection discussion future operate financial performance particular include statement relate future action prospective allow country unable manufacture medicine import primarily exceptionally broad product portfolio product product approval future performance result current anticipate product sale effort expense outcome contingency generic compulsory licence give assurance fastgrowe highvalue product glaxosmithkline global legal proceeding financial result group undertake obligation update forwardlooke statement result new information future event abuse external pressure amend leader therapeutic area include respiratory antiviral trip agreement protect intellectual property remain central nervous system diabete vaccine forwardlooke statement involve inherent risk uncertainty group caution investor number important factor include strong document cause actual result differ materially contain forwardlooke statement factor include limit discuss risk factor page annual report base business performance result cer growth rate explain glaxosmithkline joint statement chairman chief executive officer glaxosmithkline description business company major product accounting time healthcare way deliver billion sale grow strong double digit include fund provoke debate corporate responsibility seretideadvair asthma chronic obstructive pulmonary report set issue face area explain disease copd grow cent year address possible performance description business discuss activity billion pharmaceutical brand measure include progress resource operating environment business world diabete treatment avandiaavandamet identify development achievement significant achievement year include progress continue perform sale billion cent follow heading make programme develop world product like valtrex herpe lamictal epilepsy grow strongly approach blockbuster status effort eliminate lymphatic filariasis lf elephantiasis business vaccine hivaid business sale debilitate disease affect million people world health history development company billion organization target eliminate lf time glaxosmithkline strategy expect donate billion treatment medicine product albendazole worth billion new product launch pharmaceutical industry large donation programme operate environment new important product introduce competition highlight include launch wellbutrin xl new reduce notforprofit price hiv treatment twice regulation improve version antidepressant levitra erectile take price combivir dysfunction approval receive lexiva hivaid advair cent day need tackle operating activity copd lamictal bipolar disorder usa enormous hivaids crisis real progress marketing distribution avandamet diabete europe responsibility share sector global society manufacture supply government international agency company plan significant product launch filing research development glaxosmithkline include solifenacin overactive bladder develop partner yamanouchi pharmaceuticals ltd proud global community investment operating resource japan avandaryl fixeddose combination treatment million cent group pretax profit intellectual property extend avandia family treatment type include million group patient assistance information technology diabete epivir plus ziagen oncedaily combination program initiative lowincome group glaxosmithkline people hivaid treatment available single tablet usa million humanitarian product donation property plant equipment building strong diverse rd pipeline governance business society provide clear evidence success create financial reporting council new combine code corporate responsibility productive rd organisation industry rd corporate governance publish board support responsibility environment health safety day december demonstrate redesign rd new code move quickly bring glaxosmithkline access healthcare develop world operation deliver product pipeline exceptional diversity governance procedure substantially line good practice access healthcare develop world quality quantity drive future growth flow code global community investment company discussion group management structure corporate acknowledgement project clinical development span governance procedure set corporate governance year number change board variety therapeutic area encompass number page board benefit direct presence dr tachi yamada pioneering approach treat patient include exciting new great knowledge experience medical practice remuneration report give detail group policy compound area oncology cardiovascular disease pharmaceutical industry new nonexecutive director remuneration amount earn director project include new chemical entity nce director join board year larry culp president senior management page product line extension ple vaccine nce danaher corporation crispin davis chief executive reed discussion group operate financial performance clinical phase ii iiiregistration expect elsevi plc sir robert wilson chairman bg group plc financial resource give operate financial record number filing year bring year experience successful track review prospect page compound potential reach blockbuster status record different industry undoubted skill strengthen board report glaxosmithkline group mean glaxosmithkline include promising compound highlight plc subsidiary undertaking company mean december kind dual kinase inhibitor sir roger hurn paul allaire leave board june dr michle glaxosmithkline plc glaxosmithkline share mean ordinary share treatment breast lung cancer cervarix vaccine barzach john mcarthur donald mchenry step glaxosmithkline plc p american depositary share ad potential prevent cent cervical cancer board agm express appreciation represent glaxosmithkline share nextgeneration antidepressant lppla inhibitor contribution company target newly identify risk factor heart disease odiparcil dedicated effective service board report figure quote market size market share market growth rate relate month end th novel antiblood clot treatment dual action conclusion behalf board corporate executive september later available glaxosmithkline cox inhibitor target inflammatory neuropathic pain team thank shareholder continue support estimate base recent datum independent external building strong heritage respiratory medicine challenging time source value sterle relevant exchange rate figure quote develop nextgeneration seretideadvair oncedaily product market share reflect sale glaxosmithkline licensee combination new longacte corticosteroid brand name appear italic report trade mark longacte selective beta agonist develop glaxosmithkline associate company exception theravance inc amaryl nicoderm trade mark aventis baycol levitra trade mark bayer bexxar trade mark corixa corporation corporate responsibility hepsera trade mark gilead service micropump trade mark corporate responsibility particular resonance flamel technologies natrecor trade mark scios navelbine trade pharmaceutical sector business create medicine treat sir christopher hogg j p garni mark pierre fabre mdicament pritor trade mark prevent disease society need value chairman chief executive officer boehringer ingelheim licence group glaxosmithkline description business description business glaxosmithkline business history development company build strong diverse rd pipeline product pharmaceutical group aim create productive discovery therapeutic area trade mark compound mechanism indication vary country glaxosmithkline plc subsidiary associated pipeline industry benefit patient consumer central nervous seroxatpaxil paroxetine selective serotonin reuptake depression panic anxiety undertaking constitute major global healthcare group society include develop focus portfolio strategy system inhibitor engage creation discovery development manufacture support pipeline manage life cycle compound wellbutrin bupropion noradrenaline reuptake inhibitor depression marketing pharmaceutical consumer healthrelated launch overthecounter product strategy imigranimitrex sumatriptan ht agonist migraine cluster headache product include selective inlicense efficient execution naramigamerge naratriptan ht agonist migraine development commercialisation supply chain process lamictal lamotrigine sodium channel modulator epilepsy bipolar disorder glaxosmithkline corporate head office london requip ropinirole dopamine dd agonist parkinson disease glaxosmithkline rd organisation measure productivity zyban bupropion sr noradrenaline reuptake inhibitor smoking addiction great west road number innovation product create brentford respiratory flixotideflovent fluticasone propionate inhale antiinflammatory asthma copd commercial value product ability middlesex tw gs serevent salmeterol xinafoate bronchodilator asthma copd address unmet need consumer include patient seretideadvair salmeterol fluticasone bronchodilatorantiinflammatory asthma copd england healthcare professional budget holder regulator propionate tel perspective constitute valuable new product flixonaseflonase fluticasone propionate intranasal antiinflammatory hayfever perennial rhinitis glaxosmithkline operational headquarters philadelphia detail give page ventolin salbutamolalbuterol bronchodilator bronchospasm research triangle park usa operation becotidebeclovent beclomethasone dipropionate inhale antiinflammatory asthma country product sell country principal product commercialisation beconase beclomethasone dipropionate intranasal antiinflammatory hayfever perennial rhinitis research development rd facility uk usa glaxosmithkline link research commercial operation closely antiviral trizivir lamivudine zidovudine reverse transcriptase inhibitor hivaids japan italy belgium product currently manufacture order maximise value portfolio compound abacavir country develop test innovative marketing campaign combivirbiovir lamivudine zidovudine reverse transcriptase inhibitor hivaid epivirtc lamivudine reverse transcriptase inhibitor hivaid powerful focus sale effort plan major market group products usa japan retrovirazt zidovudine reverse transcriptase inhibitor hivaid appropriate market group aim build strong france germany uk italy ziagen abacavir reverse transcriptase inhibitor hivaid relationship patient ultimate consumer agenerase amprenavir protease inhibitor hivaids glaxosmithkline plc public limited company incorporate medicine detail give lexiva fosamprenavir protease inhibitor hivaids th december english law th december valtrexzelitrex valaciclovir dna polymerase inhibitor shingle genital herpe company acquire glaxo wellcome plc smithkline global competitor zovirax aciclovir dna polymerase inhibitor herpe infection shingles beecham plc english public limited company way glaxosmithkline operate increasingly global environment chicken pox cold sore scheme arrangement merger company scale offer significant advantage group leverage zeffixheptavir lamivudine reverse transcriptase inhibitor chronic hepatitis b infection glaxo wellcome smithkline beecham major global scale building interdependent business share heptodinepivir hbv healthcare business successful practice business boundary geographic antibacterials augmentin amoxicillinclavulanate broad spectrum oralinjectable bacterial infection border common approach management process antimalarial antibiotic st october glaxo wellcome plc change business function internationally diverse zinnatceftin cefuroxime axetil oral antibiotic bacterial infection glaxosmithkline services plc th march talented management team order create sustain fortumfortaz ceftazidime injectable antibiotic severe life threaten infection glaxosmithkline service unlimited historical reference glaxo bactroban mupirocin topical antibiotic skin infection competitive advantage market addition glaxosmithkline wellcome plc document change amoxil amoxicillin broad spectrum oralinjectable bacterial infection continue demonstrate commitment corporate antibiotic responsibility helping improve access well medicine business segment malarone atovaquoneproguanil electron transport inhibitor treatment prophylaxis malaria develop world detail give glaxosmithkline operate principally industry segment lapdap chlorproguanil hydrochloride antifolate antimalarial treatment malaria page dapsone pharmaceutical prescription pharmaceutical vaccine metabolic avandia rosiglitazone ppargamma agonist type diabete consumer healthcare overthecounter medicine oral care consumer healthcare avandamet rosiglitazone metformin ppargamma agonist type diabete nutritional healthcare glaxosmithkline consumer healthcare recognise clear hydrochloride antihyperglycemic agent understanding need expectation consumer metformin glaxosmithkline strategy fundamental success business traditional method vaccine havrix hepatitis communicate customer television advertising engerixb hepatitis b glaxosmithkline business goal indisputable new channel internet gain twinrix hepatitis b leader pharmaceutical industry achieve goal importance whichever method choose challenge infanrix diphtheria tetanus acellular pertussis require meet key challenge face glaxosmithkline product stand competition oncology zofran ondansetron ht receptor antagonist nausea vomit cancer industry society emesis therapy new product come source importantly hycamtin topotecan topoisomerase inhibitor ovarian cancer small cell lung cancer improve productivity research development consumer healthcare partner pharmaceutical business navelbine vinorelbine cytotoxic nonsmall cell lung cancer breast ensure patient access new medicine maximise group asset opportunitie cancer reach consumer traditional healthcare pharmaceutical product overthecounter market bexxar iodine tositumomab radioimmunotherapy follicular nonhodgkin lymphoma professional cardiovascular coreg carvedilol alphabeta blocker congestive heart failure people glaxosmithkline develop strategy focus urogenital lanoxin digoxin cardiac antiarrhythmic congestive heart failure number key business driver order meet challenge single great source competitive advantage cardiac arrhythmia company people group ambition flolan epoprostenol inhibitor blood clot primary pulmonary hypertension place great people apply energy passion lacipil lacidipine calcium channel blocker hypertension difference world skill intellect key pritor telmisartan angiotensin ii antagonist hypertension component successful implementation group levitra vardenafil pde inhibitor erectile dysfunction strategy work environment support inform empower avodart dutasteride selective inhibitor type ii benign prostatic hyperplasia isoform ar resilient workforce group value draw diverse knowledge perspective experience style zantac ranitidine histamine h antagonist duodenal ulcer stomach ulcer global community detail give reflux dyspepsia copromote glaxosmithkline description business description business glaxosmithkline glaxosmithkline principal pharmaceutical product presently antiviral infanrix range paediatric vaccine combination infanrix major product necessarily sell market direct therapeutic area analysis sale combivir combination retrovir epivir consolidated provide protection diphtheria tetanus pertussis therapeutic area description principal product position reverse transcriptase inhibitor whooping cough infanrix pentapediarix provide additional category product set cornerstone multiple antihiv product regimen physician protection hepatitis b polio infanrix hexa acceptance clearly demonstrate value place add protection haemophilus influenzae type b overthecounter medicine turnover therapeutic area minimise pill burden face patient cause meningitis analgesic panadol dermatological zovirax central nervous system ziagen reverse transcriptase inhibitor product potency glaxosmithkline market priorix measle mump abreva respiratory ease use resistance profile allow play significant role rubella vaccine typherix vaccine protection typhoid gastrointestinal tum antiviral variety highly active tolerate simplified hiv fever varilrix vaccine varicella chicken pox citrucel antibacterialsantimalarial treatment regimen addition group market range vaccine prevent respiratory tract contac metabolic vaccine trizivir combination combivir ziagen combine meningitis umbrella mencevax beecham oncology emesis antihiv therapie tablet twice daily administration smoking control commit oncology emesis nicorette cardiovascular urogenital agenerase protease inhibitor treatment hiv zofran prevent nausea vomiting associate nicoderm cq medicine class bring market chemotherapy radiotherapy cancer available niquitin cq glaxosmithkline agenerase twice daily dose regiman oral injectable form approve use nicabate cq significant food drink restriction prevention treatment postoperative nausea vomit natural wellness support abtei central nervous system cns lexiva protease inhibitor treatment hiv hycamtin second line treatment ovarian cancer oral care aquafresh seroxatpaxil selective serotonin reuptake inhibitor ssri new combination tolerability convenience lexiva small cell lung cancer corega approve depression panic obsessive compulsive disorder dose daily boost ritonavir dr good navelbine approve line treatment nonsmall cell post traumatic stress disorder social anxiety disorder premenstrual macleans zeffix approve marketing usa europe china lung cancer combination cisplatin single agent dysphoric disorder general anxiety disorder paxil cr odol markets treatment chronic hepatitis b control release version launch usa bexxar treatment patient follicular nonhodgkin odol me valtrex treatment chicken pox zoster shingle cold sore lymphoma disease refractory rituximab polident wellbutrin antidepressant available usa normal episodic genital herpe long term suppression relapse follow chemotherapy poligrip sustainedrelease sr tablet formulation oncedaily genital herpe valtrex supersede zovirax widely sensodyne version wellbutrin xl launch usa september treat herpe infection cardiovascular urogenital nutritional healthcare horlick coreg alphabeta blocker prove lucozade imigranimitrex ht receptor agonist treatment antibacterial antimalarial effective treat hypertension heart attack patient ribena severe frequent migraine cluster headache augmentin broadspectrum antibiotic suitable mild moderate severe heart failure glaxosmithkline sole reference product sector naramigamerge treatment wide range common bacterial infection marketing right usa canada generic version new migraine product particularly effective respiratory tract infection augmentin product available canada overthecounter medicine es extra strength suspension specifically design treat lead product panadol widely available lamictal establish treatment epilepsy levitra pde inhibitor indicate male erectile dysfunction child recurrent persistent middle ear infection paracetamolacetominophen analgesic nicorette gum indicate bipolar disorder glaxosmithkline copromotion right worldwide nicoderm niquitin cq nicabate range smoking control augmentin xr extra strength tablet form adult combat japan levitra launch usa requip specific dopamine dd receptor agonist indicate product tum calcium base antacid citrucel laxative contac grow problem bacterial resistance community european market treatment parkinson disease treatment cold influenza abtei natural medicine zinnat oral antibiotic primarily communityacquire avodart ari inhibitor currently indicate benign prostatic vitamin range zovirax abreva treatment zyban nicotinefree prescription medicine available infection lower respiratory tract fortum hypertrophy large clinical outcome study underway examine cold sore sustainedrelease tablet treating problem hospitalbase injectable antibiotic market efficacy prevention prostate cancer smoking addiction flixonase allergy nasal spray airborne allergy malarone oral antimalarial treatment launch uk product glaxosmithkline respiratory prophylaxis malaria cause plasmodium falciparum programme appropriate switching prescription category include group principal dermatological seretideadvair combination serevent flixotide offer medicine overthecounter product betnovate high potency dermovate new longacting bronchodilator antiinflammatory single metabolic cutivate antiinflammatory steroid product treat skin inhaler seretide approve treatment chronic avandia potent insulin sensitise agent act oral care disease eczema psoriasis relafen nonsteroidal obstructive pulmonary disease copd eu underlie pathophysiology type diabetes avandamet lead oral care product toothpaste mouthwashe antiinflammatory drug treatment arthritis zantac combination avandia metformin hci medicine aquafresh sensodyne macleans odol brand serevent longacting bronchodilator treat asthma treatment peptic ulcer disease range gastric acid target insulin resistance decrease glucose production name range toothbrush sell aquafresh copd ventolin selective shortacting bronchodilator related disorder continue play major role number convenient pill dr good name addition denture care product available treat bronchospasm market patent protection lose principally polident poligrip corega brand name flixotideflovent becotidebeclovent inhale steroid vaccine product consumer healthcare treatment inflammation associated asthma copd glaxosmithkline market range hepatitis vaccine havrix nutritional healthcare protect hepatitis engerixb hepatitis b glaxosmithkline principal consumer healthcare product lead product category lucozade glucose energy flixonaseflonase beconase intranasal preparation twinrix combine hepatitis b vaccine protect major area analysis sale area set sport drink ribena blackcurrantbase juice drink rich treatment perennial seasonal rhinitis disease vaccine available adult vitamin c horlick range milkbase malt food paediatric strength chocolate drink overthecounter medicine oral care nutritional healthcare glaxosmithkline description business description business glaxosmithkline operating environment competition pharmaceutical major respiratory competitor singulair merck especially competition consumer healthcare grant marketing authorisation affords group protection usa europe symbicort astrazeneca spiriva period competitor rely confidential data pharmaceutical industry highly competitive main competitor group consumer healthcare market pfizerboehringer ingelheim regulatory file basis marketing authorisation glaxosmithkline principal competitor large international include major international company colgatepalmolive datum protection period begin date authorisation pharmaceutical company substantial resource johnson johnson pfizer procter gamble unilever wyeth antiviral grant european union expire year company major product mention addition company compete major competitor hiv market bristol myers squibb authorisation grant centralised procedure glaxosmithkline select market pharmaceutical subject competition merck pfizer year authorisation grant mutual recognition product period patent protection major competitor product overthecounter otc procedure depend country concern glaxosmithkline pioneer role hiv market patent generic version manufacturers generic medicine retrovir epivir act cornerstone combination european union expand product typically bear significant research development therapy available combivir single tablet launches usa metamucil laxative clearasil acne treatment member state anticipation enlargement european cost consequently able offer product ziagen agenerase trizivir lexiva broaden pepcid indigestion private label smoking control regulatory legislation currently undergo review impact considerably low price brand competitor research group portfolio hiv product valtrex help product change regulatory procedure datum protection period development base pharmaceutical company normally strengthen group position antiherpe area uk lemsip cold remedy nurofen anadin remain see seek achieve sufficiently high profit margin sale volume zovirax face competition generic aciclovir valtrex analgesic nicorette nicotinell smoking control period patent protection repay original usa drug price competition patent term zovirax compete novartis famvir zeffix antiviral remedy investment generally substantial fund research restoration act hatchwaxman establish current market treat hepatitis b gilead hepsera second future competition generic product generally occur oral healthcare major competitor colgatepalmolive framework approval generic drug include related patent approve food drug administration fda patents major market expire increasingly patent challenge colgate procter gamble crest datum protection provision hatchwaxman sponsor september prior patent expiry claim innovator patent abbreviate new drug application anda receive nutritional healthcare major competitor horlick valid andor infringe generic product marketing approval submit safety efficacy data antibacterial antimalarial ovaltine milo malt food chocolate drink follow loss patent protection generic product rapidly rely pioneer company extensive preclinical generic version augmentin ceftinzinnat competitor ribena primarily local fruit juice product capture large share market particularly usa clinical development datum provide propose generic drug introduce usa follow successful legal challenge lucozade compete energy drink demonstrate bioequivalent pioneer product glaxosmithkline undertake range activity maximise generic manufacturer note financial statement glaxosmithkline hold lead global position key generic drug approval subject datum protection value intellectual property include introduce innovative legal proceeding augmentin lose patent protection consumer product area worldwide second large period year new chemical entity year product market possible accelerate process country europe augmentin xr augmentin es oral care large otc medicine nutritional modification support new clinical study bring new product market develop improve patent compete broad range brand generic healthcare hold lead position uk india provision hatchwaxman filing anda protect version old product increase brand antibiotic malarone safety profile convenient dose ireland trigger procedure allow patent holder initiate patent recognition customer regiman helped product strong position versus infringement litigation significant procedural advantage mefloquine follow recent launch malaria prophylaxis glaxosmithkline believe competitive position dependent regulation pharmaceutical assure fdas approval propose generic discovery development new product product stay month pende resolution metabolic international pharmaceutical industry highly regulate effective marketing exist product litigation procedure generate litigation major competitor avandia takeda chemical acto national regulatory authority administer panoply law pharmaceutical industry introduction new product controversy particularly currently apply copromote eli lilly usa regulations govern testing approval manufacturing process competitor affect pricing level result result multiple nonconcurrent month stay label marketing drug review safety product replacement assurance product propose generic product june fda issue new vaccine efficacy pharmaceutical product regulatory outmoded notwithstanding patent trade mark regulation clarify certain aspect procedure glaxosmithkline major competitor vaccine market include requirement major factor determine protection addition increase government pressure generate controversy addition november new law aventis pasteur ap merck wyeth engerixb havrix substance develop marketable product physician patient use generic pharmaceutical enact congress modify hatch compete vaccine produce ap merck comvax time expense associate development brandname medicine increase competition waxman law modification eliminate grant recombivax hb hepatitis b vaqta avaxim hepatitis product long protect patent particular importance requirement country additional month stay patent issue anda infanrixs major competitor aps range dtpabase product authorise register prior marketing file limited grant month stay anda combination vaccine cns disorders authorisation registration maintain subsequently applicant circumstance major competitor usa paxil generic form oncology emesis national regulatory authority jurisdiction include usa second reauthorisation prescription drug launch september fluoxetine generic form zofran presently provide glaxosmithkline leadership position usa european union japan australia high user fee act come effect st october pdufa iii eli lillys prozac zoloft pfizer forest laboratory celexa antiemetic market competition include standard technical appraisal consequently introduction remains see substantial additional resource fund lexapro principal competitor usa wellbutrin rochechugai aventis recently merck major competitor new pharmaceutical product generally entail lengthy pdufa iii result reduction overall approval times ssris effexor xr wyeth product limit generic diverse cytotoxic market include bristol myers squibb approval process drug biological requirement competition wellbutrin begin usa january aventis pfizer novartis glaxosmithkline cytotoxic portfolio pdufa iii call fda initiate review action european union currently procedure success seroxatpaxil wellbutrin lead hycamtin navelbine hold relatively small market approval compare approvable nonapprovable decision obtain marketing authorisation medicinal product target generic manufacturers glaxosmithkline position report finding review continue respond appropriately note financial centralised procedure application direct fda complete previously announce statement legal proceeding recent launch paxil cr cardiovascular urogenital european medicine evaluation agency lead consolidation review activity certain biological oncedaily wellbutrin xl expect help retain glaxosmithkline market coreg usa major authorisation valid member state compulsory vaccine center drug evaluation research strong presence antidepressant market give recent competitor toprol xl generic betablocker product derive biotechnology optional new cder consolidation entail shift resource entry generic paroxetine usa generic competition group launch urogenital product levitra avodart active substance innovative medicinal product center biologic evaluation research cber commence uk number market avodart compete directly merck proscar bph mutual recognition procedure applicable cder impact shift resource remains see market levitra market male erectile dysfunction face majority conventional medicinal product operate respiratory competition pfizer viagra lillys cialis mutual recognition national marketing authorisation glaxosmithkline respiratory franchise drive growth agreement reach resolve seretideadvair gain patient competitor product procedure bind arbitration cannibalisation serevent flixotide ventolin becotide face generic competition year maintain significant sale glaxosmithkline description business description business glaxosmithkline operating activity pdufa iii action review consolidation value money marketing distribution pharmaceutical stakeholder initiative cber review activity cder fda increasingly necessary demonstrate value company launch initiative improve announce sponsorship commissioner money new product particular impact drug budget analysis total pharmaceutical turnover geographic region ability deliver important information physician renew focus innovation drug development hopefully expenditure burden disease treat set patient disease therapy treat allow rapid development need medicine market need satisfy healthcare purchaser initiative investigate use pharmacogenomic turnover geographic region sale force excellence value money additional hurdle product surrogate marker efficacy thing tool acceptance regulatory test safety efficacy usa worldwide sales force excellence initiative focuses rapidly develop safe effective drug unmet medical quality delay bring effective improve europe increase glaxosmithkline sale representative skill provide need medicine market reduce effective patent international value healthcare professional globe centrepiece project global framework training raise international market country outside usa protection time asia pacific standard representative knowledge disease europe regulatory environment continue extremely japan varied challenging glaxosmithkline anticipate market increasingly difficult latin america role glaxosmithkline medicine treat training introduction new product continue require substantial significantly improve therapy obtain premium price middle east africa address answer central question effort time expense comply regulatory requirement exist medication valuebase pricing difficult follow canada physician face decide patient treatment circumstance usa possible use glaxosmithkline medicine use price product reflect value use price control country price pharmaceutical product possible predict extent glaxosmithkline sell prescription medicine primarily initiative aim build good reputation control law government influence price group business affect future legislative wholesale drug distributor independent chain retail glaxosmithkline sale force enjoy physician control national healthcare organisation bear regulatory development relate specific pharmaceutical pharmacy physician hospital clinic government entity worldwide survey physician major world market large cost supply product consumer product price institution product ordinarily dispense recently rate glaxosmithkline sale representative public pharmacy prescription write doctor industry uk germany france spain recent government healthcare reform country france regulation consumer healthcare hospital doctor surgerie pulmonologist allergistsimmunologist paediatricians spain germany restrict pricing reimbursement neurologist ear nose throat specialist infectious disease consumer healthcare industry subject national regulation usa world large pharmaceutical market usa recent legislation healthcare reform crossborder specialist test approval manufacturing labelling marketing pressure contain healthcare cost encourage growth trade acceleration generic market increase patient product country high standard technical manage care organisation pharmacy benefit manager source ranking taylor nelson sofres healthcare europe contribution increase focus pricing currently appraisal entail lengthy approval process new product intermediary use range method low cost verispan usa government price control private sector launch include substitution generic product cheap purchase federal legislation require pharmaceutical therapy brand product prescribe doctor result marketing excellence manufacturer pay prescribe rebate certain drug order national regulatory authorisation require approve increase importance supplier healthcare goal global marketing excellence initiative eligible reimbursement medicaid federal switch product prescription otc requirement community glaxosmithkline contract manage care help undiagnosed patient seek physician help second healthcare programme include longterm experience quality safety efficacy sector small number wholesaler ensure receive appropriate treatment example product wide patient population datum confirm uk official estimate million people suffer type medicare relevant condition selflimite easily market glaxosmithkline deploy sale force diabete cent remain undiagnosed medicare prescription drug improvement diagnose consumer representative support medical staff promote diagnose cent remain untreated modernization act provide limited immediate benefit prescription product medical prescriber healthcare treat significant number undertreated medicare patient form government sponsor discount purchaser personal visit way patient achieve level health card replace comprehensive outpatient drug promotion glaxosmithkline product supplement treatment provide optimal circumstance benefit benefit intend administer scientific seminar advertising medical journal glaxosmithkline marketing initiative explore barrier proper number private organisation construct benefit television advertising provision sample direct mailing diagnosis treatment implement programme structure consistent federal law market benefit information contain group website overcome programme begin effect medicare patient societal cost disease decrease extent physician directtoconsumer dtc advertise major component law provide strong incentive manufacturer choose glaxosmithkline product patient treatment product marketing usa dtc advertisement negotiate price plan sponsor bill provide company benefit primary source information patient request specific explicit government price control senior brand product physicians usa sort outpatient drug coverage increase demand patient advocacy limit drug require low income senior outside usa dtc prohibit limited worldwide initiative seek achieve high level past able arrange private coverage low role inform patient european union dtc intimacy glaxosmithkline ultimate consumer income senior receive large subsidy deductible prescriptiononly product currently prohibit australia product patient glaxosmithkline copayment associate comprehensive benefit government allow dtc advertising pharmacyonly product host patient advocacy leader summit subject certain safeguard new zealand dtc allow bring leader patient group law change way drug administer physician selfregulate industry collaboration advertising seek area common interest office clinic hospital outpatient department standard agency market allow dtc date glaxosmithkline plan action working reimburse instead reimbursement base price publish impact limit group strive continue open access independent pricing service new law provide appropriate medicine constituency increase reimbursement base actual market price addition direct marketing product subsidiary challenge time tighten budget champion report manufacturer audit government glaxosmithkline enter agreement continue investment development new medicine addition begin physician option pharmaceutical company comarkete copromotion choosing purchase claim reimbursement product product market example levitra bayer similar approach launch europe patient instead allow drug distributor provide drug doctor advocacy group increasingly organise office submit claim medicare patient contribution distributor earn ability provide product service competitive bidding process glaxosmithkline description business description business glaxosmithkline marketing distribution consumer healthcare secondary supply chain consumer healthcare supply chain rd process discovery commercialisation delivery european region consumer healthcare manufacturing site spread principal market consumer healthcare otc medicine site european region spread country consumer healthcare supply chain diagram show relationship usa uk germany australia argentina italy mexico countries european site manufacture nearly diverse include manufacture supply otc stage rd japan canada france principal market oral care major pharmaceutical product market globally medicine oral care nutritional healthcare smoking control products usa germany uk nutritional drink glaxosmithkline wide variety finish dosage form product internal facility contract supplier business particularly strong uk ireland india worldwide research development commercialisation range product available market north america region otc oral care product primarily distribute pharmaceutical manufacturing site north research development pharmaceutical pharmacy mass market outlet directly america region locate puerto rico canada usa global biological pharmaceutical research wholesaler nutritional healthcare product distribute development rd function glaxosmithkline responsible genetic preclinical similar extensive retail wholesale network international region discover develop registering commercialise research development international region comprise manufacture site support effective marketing innovative prescription project future country spread distinct area site medicine vaccine delivery system treatment discovery worldwide fundamental review undertake consumer middle eastafrica site spread asia pacific prevention human disease research development healthcare business model product innovation marketing australia area site china japan latin aim increase competitiveness sale growth america fundamental goal thorough understanding review term project future transition glaxosmithkline disease investigation facilitate pioneer work consumer healthcare geographically base structure glaxosmithkline integration genetic range technology traditional global strategic support brand develop longterm integrate change programme implement research discipline addition work create new rd process appropriate place result responsibility time merger call global supply network gsn medicine vaccine extensive effort gain clear line glaxosmithkline strategic intent take centrally develop global brand autonomy structured deliver benefit major stream understand unmet need patient healthcare indisputable leader industry rd set goal afford local market manage local brand activity provider payer guide overall direction rd industry productive rd organisation entrepreneurial skill reduction abovesite infrastructure cost glaxosmithkline invest nearly billion fundamental prerequisite approach crucial procurement initiative pharmaceutical rd rd organisation benefit rd focus need patient benefit manufacture supply continue network rationalisation insight scientist world employ derive new medicine innovative glaxosmithkline large portfolio product range logistic improvement staff biological pharmaceutical rd activity formulation exist medicine available need tablet toothpaste inhaler complex capsule operational excellence leansigma improvement site worldwide include recover health quality life different pack size presentation network rationalisation plan production cease uk beckenham brentford cambridge dartford rd measure productivity number innovation manufacture medicine begin development site country include uk india greenford harlow stevenage tonbridge ware product create commercial value therapeutic active ingredient bulk active select formulation romania usa programme meet merger welwyn product ability address unmet need customer global manufacture supply gms develop manufacturing commitment year ahead plan usa bristol tennessee philadelphia upper merion include patient healthcare professional budget holder process scale volume production active compound upper providence pennsylvania research triangle regulator perspective constitute primary manufacturing site convert active compound external supplier park north carolina valuable new product rd position ensure finish dosage formulation responsibility procurement global function support function belgium rixensart generate right safety efficacy quality information secondary manufacture site area glaxosmithkline business manufacture canada mississauga respond different perspective data large area billion spend external france le ulis evreux demonstrate overall social benefit new medicine gms operate single global network site supplier year include purchase active ingredient italy verona increase length quality life increase workplace country year gms produce tonne bulk chemical intermediate partfinishe finished product gm japan tsukuba science city takasaki productivity active billion pack package take appropriate step protect supply chain spain tre cantos madrid deliver sale country world historical contradiction pharmaceutical industry support approximately new product line extension disruption result interrupt external supply rd deliver wide range product need lever advantage large organisation launch year appropriate stock level contract alternative register market achieve significant success bring lose creative spirit research environment supplier new compound early stage research past glaxosmithkline rd structure balance area gms focus deliver critical proof concept poc decision point extensive benefit large scale advantage secure source supply high quality product vaccine supply chain inlicense programme slow small enhance productivity c e b l peo x e ra opm cte ip unc inl rt gi eaa c mtn ei lo ac ee sn g ns e tw c apoit nrsh cr e inig c eu osl ta hat eo n rr g p lr oe e bq rf au li rr fme um na cne tn c ioets n sa n td sc itu es st m n er v bn un pa pc p sb ec p oi dlln w yg e oi ccou nhhm j ao fta ooi n n nw r u et bi ni cf evta avh e c not tt blu svh lu e er r fi r n e eg os n ii mn tih c e hl co e e ephrc ds n flt iit ae fn ue f g c es rnp ui en dr n tm f tr ir r ok mua ner n asi tsl c ry ne ia k n e e e tg dm sd er e ami rx n nm ae aa dnn ng ds n fidina rur g tsa h tna n oh en g sd e h v e w u rfl scn ra e ec fgv x rnar obe r e mly e p p e vh anr r iso e ls uc g uo p eu r rv oe ac nes rt nr gtsi e fv oi ti n hl eno l e vr f eret nh c rv da oee nll lo ep iy n wp po vm ops e mt r u e tm n en c sd tte ii itcr c sg n nle r ea er p sn sro oe io tr v un og r e rc clt por ee ap si aas mt isa ei oi ot n e ni ng ts n n h hnh u ia eda v e b e lt tsa r hn r eo b e gf ed ec pe mot tno m anp u f oou c fn u ss c h cca hh igrp ae e hi et nk la yn e l r oy ni en g ta gt hr e u e etn la h ras ai ev rt e eh e smt hr flb ah oe ii ngn ur lehe ryq fi st au ht h r rf ter oho u em tg c hh l eb rp ice reu e r btn e eg k n sc tl lt da l av r og fe n atsa hd n r e te tu h gt c oh eh eso v ea ies f se l hc ht paoh emtma st ea tp nr ra eo utr ue ct n ud r al health authority mas vaccination campaign unit remain small unit respond quickly change organisation december rd presentation uk environment opportunity scientist interact optimise bulk filling packaging carefully balanced stock glaxosmithkline pipeline future product need return investment focus primary supply chain vaccine help manage shortterm increase demand unveil analyst feature promise compound select foster entrepreneurial accountable culture global organisation site spread increase prompt disease outbreak increase demand novelty impact disease commercial potential country broad range active ingredient antibiotic public owe disease awareness campaign include nextgeneration noradrenalinedopamine nonantibiotic product manufacture package reuptake inhibitor depression cyclooxygenase inhibitor site locate australia ireland singapore uk pain lipoproteinassociate phospholipase usa majority active ingredient manufacture inhibitor atherosclerosis dual kinase inhibitor primary supply chain supply secondary pharmaceutical cancer thirdgeneration inhale corticosteroid site europe north america international offering oncedaily treatment great efficacy compare current compound glaxosmithkline description business description business glaxosmithkline addition establish centre excellence drug disease arise complex interaction product development pipeline discovery cedd discuss number partnership number gene variant environmental factor product development pipeline set show considerable breadth depth february glaxosmithkline forge company extend glaxosmithkline challenge involve significant identify gene pharmaceutical vaccine project development clinic include new chemical entity nce capability screen compound generate research predispose patient particular disease understanding phase iii registration phase ii phase product line extension vaccine competitive reason new function effectively extend cedd concept ensure role progression lead find new way intervene project preclinical development disclose project type identify efficient rapid validation maximum number lead disease key candidate preclinical testing clinical study programme initiated identify tractable target proof concept criterion hand v vaccine phase evaluation clinical pharmacology usually conduct genetically associate human disease interest p pharmaccine volunteer compound worldwide development organisation large identify genetic association major compound shionogiglaxosmithkline pharmaceutical scale clinical trial disease clinical study start investigate inl l lic ce j si en v tt hu ere r alliance relationship party phase ii efe fit ce ar cm yin ot nio dn u co tf e ne sn md nia ul e bva el ru oa ft io pn io ef n ts worldwide development wwd function integrate presence genetic marker efficacy susceptibility adverse date submission clinical regulatory activity necessary bring new medicine event enhance ability focus development date regulatory approval maa phase iii large comparative study compound versus placebo marketplace past year clinical development new medicine patient likely benefit eu approval letter andor establish treatment patient al approvable letter establish clinical benefit safety process significantly shorten improvement ultimately provide reassurance prescriber maa marketing authorisation application europe associated process enable seamless transition datum patient nda new drug application usa estimate filing date clinical testing final report implementation compoundproduct type indication phase maa nda integrate document management system reduce discovery research cardiovascular metabolic urogenital time require collate thousand page data necessary discovery research dr produce lead compound form submission regulatory agency world basis drug discovery effort cedd dr peroxisome proliferatoractivator receptor ppar dyslipidaemia provide cedd high quality new lead compound alpha agonist beginning accommodate unprecedented lppla inhibitor atherosclerosis activity define target investment dr focus number compound move pipeline group p kinase inhibitor atherosclerosis rheumatoid arthritis copd increase quality quantity lead compound angiotensin convert enzyme neutral hypertension transform change scale structure latestage available central theme investment focus peptidase acenep dual inhibitor development enable strong focus patient coreg cr beta blocker hypertension congestive heart failure daily na delivery product create therapeutically align medicine automation odiparcil indirect thrombin inhibitor prevention thrombotic complications ii cardiovascular disease development centre mdc reside wwd centre rd open new automation facility high lppla inhibitor atherosclerosis ii discuss detail accountable throughput screen tre canto spain high throughput adenosine aa agonist dyslipidaemia neuropathic pain generation life cycle management market medicine chemistry harlow uk construction new combine facility ppar delta agonist dyslipidaemia ii compound reach proof concept poc cedd start upper providence usa ppar alpha agonist dyslipidaemia ii piboserod ht antagonist atrial fibrillation new product supply organisation bridge traditional divide focus high throughput biology technique talnetant nk antagonist overactive bladder irritable bowel syndrome ii ibs schizophrenia development manufacturing ensure robust develop rapid screening new compound avodart alpha reductase inhibitor benign prostatic hyperplasia combination iii manufacturing process develop global commercial cell base animal model system case alpha blocker strategy gcs organisation provide integrate global effort support sophisticated imaging avodart alpha reductase inhibitor reduction risk prostate cancer lll noratak nesiritide recombinant type natriuretic peptide acute heart failure submit ssep na commercialisation strategic direction rd maximise system enhance understanding disease solifenacin ym muscarinic antagonist overactive bladder approvable na aloct portfolio value product life cycle crucial model levitra pde inhibitor erectile dysfunction approve amar aaug success rd capacity embrace develop new metabolic project technology streamline drug discovery process resource available exploit opportunity group beta adrenergic agonist type diabete overactive bladder limit overall productivity enhance dipeptidyl peptidase dpp iv inhibitor type diabete technology development organisation keep abreast emerge attrition reduce well value money achieve dpp iv inhibitor type diabetes technology advance creation new medicine sodium dependent glucose transport type diabetes follow annual portfolio prioritisation review cedd evaluate provide investment knowledge sglt antagonist able select programme fund internally excess asset avandamet xr ppar gamma agonist plus metformin type diabete extend release require ensure glaxosmithkline access appropriate develop novel partnership scheme know ccka agonist obesity ii technology rd generate modifie technologies ppar pan agonist type diabete ii alternative drug discovery initiative adi key philosophy focus group internal goal avandaryl ppar gamma agonist plus sulphonylurea type diabetes fix dose combination submit soct adi concept share risk reward avandia amaryl maximise return rd asset sale spinout partner consequently different business avandamet ppar gamma agonist plus metformin type diabetes fix dose combination approve aoct aoct outlicense arrangement adi partnership establish avandia ppar gamma agonist type diabete combination insulin approve na afeb academic institution supplement target validation provide infectious disease early research role genetic early stage find new medicine require essentially well access tissue sample patient population clinical augmentin daily beta lactam antibiotic respiratory tract infection study rd form adi partnership biotechnology phospholipid antiendotoxin emulsion sepsis ii component target show affect mechanism company pharmaceutical company explore topical pleuromutilin bacterial skin infection important pathological process human disease chlorproguanil dapsone antifolate artemisinin treatment uncomplicated malaria na compound typically small molecule include different approach drug discovery artesunate cda augmentin es beta lactam antibiotic acute otitis medium incl penicillinresistant pneumoniae iii na macromolecule protein therapeutic vaccine able chewable highdose chewable tablet modulate behaviour specific target target sitamaquine aminoquinoline treatment visceral leishmaniasis iii na validation process glaxosmithkline aim identify gene etaquine tafenoquine aminoquinoline malaria prophylaxis adult iii relevant common disease large unmet medical lapdap antifolate treatment uncomplicated malaria approve ajul na antiviral need major patient burden asthma noninsulin miv nucleoside reverse transcriptase inhibitor hiv infection dependent diabetes osteoarthritis copd early onset heart aspartyl protease inhibitor hiv infection disease alzheimer disease nonnucleoside reverse transcriptase inhibitor hiv infection valtrex xr nucleoside analogue management genital herpe modify release l ono ccr antagonist hiv infections ii ziagenepivir reverse transcriptase inhibitor hiv infection combination tablet submit snov soct lexiva protease inhibitor hiv infection approve sdec aoct valtrex nucleoside analogue herpe simplex virus hsv suppression approve na aapr immunocompromise patient valtrexzelitrex nucleoside analogue prevention hsv transmission approve aaug aaug glaxosmithkline description business description business glaxosmithkline estimate filing date estimate filing date compoundproduct type indication phase maa nda compoundproduct type indication phase maa nda neurology gastrointestinal psychiatry endothelin antagonist stroke dual acting cox inhibitor schizophrenia acute chronic pain condition endothelial cell adhesion molecule inhibitor inflammatory bowel disease include neuropathic pain selective ino inhibitor acute migraine nk antagonist depression anxiety selective ino inhibitor migraine asthma copd allergic rhinitis ht antagonist schizophrenia alzheimer disease noradrenalinedopamine reuptake inhibitor restless leg syndrome rls neuropathic pain mixed htdopaminergic antagonist schizophrenia depression nk antagonist depression anxiety gap junction blocker migraine epilepsy noradrenalinedopamine reuptake inhibitor depression rls neuropathic pain ii gap junction blocker migraine epilepsy n triple htnoradrenalinedopamine depression attention deficit hyperactivity ii dual acting cox inhibitor acute chronic pain condition include reuptake inhibitor disorder neuropathic pain schizophrenia glycine antagonist smoke cessation ii dual alpha integrin antagonist vla multiple sclerosis inflammatory bowel disease nk antagonist depression anxiety functional dyspepsia ii endothelin antagonist stroke chemotherapy induce nausea vomit benzodiazepine partial inverse agonist alzheimer disease vascular dementia talnetant nk antagonist schizophrenia ib overactive bladder ii ht antagonist alzheimer disease schizophrenia lamictal sodium channel inhibitor bipolar disorder acute treatment iii na alvimopan peripheral muopioid antagonist irritable bowel syndrome l wellbutrin xl noradrenalinedopamine reuptake inhibitor seasonal affective disorder iii lamictal xr sodium channel inhibitor neuropathic pain epilepsy daily l paxil cr selective serotonin reuptake inhibitor ssri premenstrual dysphoric disorder intermittent treatment approve ajan dual acting cox inhibitor acute chronic pain condition include ii lamictal sodium channel inhibitor bipolar disorder longterm prophylaxis approve amar ajun neuropathic pain migraine paxil cr ssri premenstrual dysphoric disorder continuous treatment approve aaug adenosine aa agonist neuropathic pain dyslipidaemia ii paxil cr ssri social anxiety disorder approve aoct nk antagonist functional dyspepsia chemotherapy induce ii wellbutrin xl noradrenalinedopamine reuptake inhibitor depression approve aaug nausea vomit depression anxiety alvimopan peripheral muopioid antagonist chronic opiate induce bowel dysfunction ii respiratory constipation chemokine il receptor antagonist oral chronic obstructive pulmonary disease copd avandia ppar gamma agonist alzheimer disease ii long act beta agonist copd copd asthma combination talnetant nk antagonist ibs schizophrenia overactive bladder ii glucocorticoid agonist sumatriptan mt ht agonist naproxen migraine fix dose combination ii na p kinase inhibitor oral copd rheumatoid arthritis atherosclerosis alvimopan peripheral muopioid antagonist post operative ileus iii glucocorticoid agonist allergic rhinitis asthma asthma copd lamictal sodium channel inhibitor neuropathic pain iii na combination long act beta agonist requip cr nonergot dopamine agonist parkinson disease control release formulation iii long act beta agonist copd copd asthma combination requip nonergot dopamine agonist restless leg syndrome submit sjul aldec glucocorticoid agonist imigranimitrex ht agonist adolescent migraine nasal formulation approve aapr aldec selective ino inhibitor oral asthma copd allergic rhinitis migraine imigranimitrex ht agonist migraine fast disintegratingrapid release formulation approve ajul ajun long act beta agonist copd copd asthma combination oncology musculoskeletal inflammation glucocorticoid agonist glucocorticoid agonist allergic rhinitis ii grot cxc chemokine prevention chemotherapyinduce cytopaenias glucocorticoid agonist asthma asthma copd combination calcium antagonist osteoporosis long act beta agonist cathepsin k inhibitor osteoporosis osteoarthritis chemokine ccr antagonist oral asthma allergic rhinitis ii recombinant human il immunologicallysensitive cancer pde iv inhibitor inhale asthma copd ii immunomodulator melanoma renal cell mepolizumab antiil monoclonal antibody asthma hypereosinophillic syndrome ii thrombopoietin agonist thrombocytopenia serevent beta agonist asthma copd noncfc inhaler iii na p kinase inhibitor rheumatoid arthritis atherosclerosis copd seretide beta agonistinhale corticosteroid asthma initial maintenance therapy iii na vascular endothelial growth factor solid tumour seretideadvair beta agonistinhale corticosteroid copd mortality claim iii tyrosine kinase inhibitor ariflo pde iv inhibitor oral copd approvable aloct elacridar oral bioenhancer cancer flixotideflovent inhale corticosteroid asthma noncfc inhaler approve aapr aldec nk antagonist chemotherapy induce nausea vomit ii seretideadvair beta agonistinhale corticosteroid asthma noncfc inhaler approve ajun aloct functional dyspepsia depression anxiety oct kinesin spindle protein ksp inhibitor nonsmall cell lung cancer solid tumours ii seretideadvair beta agonistinhale corticosteroid copd approve amay anov ethynylcytidine selective rna polymerase inhibitor solid tumours ii hepatitis vaccine mepolizumab antiil monoclonal antibody hypereosinophillic syndrome asthma ii erbb egfr dual kinase inhibitor breast cancer lung bladder gastric head iil hepatitis e recombinant hepatitis e prophylaxis ii neck cancer fendrix extra strength recombinant extra strength hepatitis b prophylaxis submit smay hycamtin topoisomerase inhibitor small cell lung cancer line therapy ill hepatitis b prehaemodialysis haemodialysis patient hycamtin topoisomerase inhibitor nonsmall cell lung cancer second line therapy iii na hycamtin topoisomerase inhibitor small cell lung cancer second line therapy iii paediatric vaccine oral formulation n meningitidi conjugate meningitis prophylaxis ii hycamtin topoisomerase inhibitor ovarian cancer line therapy iii combination bonivabonviva bisphosphonate treatment prevention postmenopausal iii ibandronate osteoporosis monthly oral dose priorixtetra mmrvaricella live attenuate measle mump rubella varicella prophylaxis iii rotarix live attenuate oral rotavirus prophylaxis iii bonivabonviva bisphosphonate treatment prevention postmenopausal iii ibandronate osteoporosis intermittent iv dosing streptorix conjugate pneumoniae disease prophylaxis child iii navelbine vinca alkaloid advanced tumour iii na vaccine breast cancer oral formulation nelarabine u guanine arabinoside prodrug acute lymphoblastic leukaemia lymphomas iii dengue fever attenuate tetravalent vaccine prophylactic use avandia ppar gamma agonist psoriasis iii hiv recombinant hiv prophylaxis bexxar radiolabelle antib monoclonal nonhodgkin lymphoma approve na ajun new influenza subunit influenza prophylaxis new delivery antibody pneumoniae elderly recombinant pneumoniae disease prophylaxis bonivabonviva bisphosphonate treatment prevention postmenopausal approve sjun amay varicella zoster recombinant varicella zoster prevention ibandronate osteoporosis daily oral regimen cervarix recombinant prophylaxis human papillomavirus hpv infections ii hycamtin topoisomerase inhibitor small cell lung cancer second line therapy approve anov epsteinbarr virus ebv recombinant ebv prophylaxis ii mosquirix recombinant malaria prophylaxis ii staphylococcal antibody monoclonal antibody prevention staphylococcal infection ii simplirix recombinant genital herpe prophylaxis iii boostrix polio subunit adolescentadult booster diphtheria tetanus submit sjul pertussis polio boostrix subunit adolescentadult booster diphtheria tetanus approve aoct pertussis pharmaccine breast cancer therapeutic recombinant treatment breast cancer l neu mage recombinant treatment lung cancermelanoma ii glaxosmithkline description business description business glaxosmithkline product approval approval receive number new product include significant new indication formulation exist compound progress phase clinical development product summarise table number discovery project list table progress nonclinical safety testing early phase countryregion clinical development compound continue rigorous nonclinical clinical commercial assessment lead proof product approval date description concept decision month augmentin usa convenient tablet formulation breakline amoxicillin betalactam antibiotic clavulanate betalactamase inhibitor bacterial infection compoundproduct mechanism indication avandamet eu october fix dose combination avandia metformin type diabete endothelial cell adhesion molecule inhibitor inflammatory bowel disease avandiainsulin combination usa march combine use avandia insulin type diabete selective ino inhibitor acute migraine bexxar usa june radiolabelle antib monoclonal antibody inlicense corixa aa topical pleuromutilin bacterial skin infection treatment nonhodgkin lymphoma chemokine il receptor antagonist oral copd boniva usa ibandronate bisphosphonate oral daily treatment osteoporosis inlicense gap junction blocker migraine epilepsy roche gap junction blocker migraine epilepsy imigranimitrex eu july fast dissolve tablet formulation sumatriptan ht antagonist calcium receptor antagonist osteoporosis usa june nk antagonist depression anxiety lamictal eu march lamotrigine sodium channel blocker longterm prophylaxisprevention bipolar ppar alpha agonist dyslipidaemia usa june disorder cox inhibitor nd generation pain lamictal usa january lamotrigine addon therapy paediatric epilepsy lppla inhibitor atherosclerosis lapdap eu july combination chlorproguanil dapsone treatment malaria longacting beta agonist copd levitra eu march pde v inhibitor treatment male erectile dysfunction inlicense nk antagonist chemotherapyinduce nausea vomit usa august bayer ag ht antagonist alzheimer disease schizophrenia lexiva usa october fosamprenavir protease inhibitor hiv mix htdopaminergic antagonist schizophrenia paxil cr usa august control release formulation paroxetine selective serotonin reuptake inhibitor acenep dual inhibitor hypertension continuous treatment premenstrual dysphoric disorder glucocorticoid agonist asthmacopd inhale allergic rhinitis intranasal paxil cr usa october paroxetine control release social anxiety disorder dipeptidyl peptidase iv inhibitor type diabetes requip usa ropinirole nonergot dopamine agonist restless leg syndrome dipeptidyl peptidase iv inhibitor type diabete seretideadvair diskus eu combination salmeterol longacte betablocker fluticasone nk antagonist depression anxiety usa november corticosteroid dry powder diskus device treatment copd dipeptidyl peptidase iv inhibitor type diabete valtrex usa april valaciclovir dna polymerase inhibitor suppression herpe simplex virus sodiumdependent glucose transporter type diabete immunocompromise patient sglt inhibitor valtrex eu usa august valaciclovir suppression transmission herpe simplex virus ccr antagonist hiv wellbutrin xl usa august extend release formulation bupropion treatment depression augmentin daily formulation amoxicillin clavulanate respiratory tract infection approvable letter january avandamet xr extend release fix dose combination avandia type diabete metformin centre excellence drug discovery cedd responsible identify optimal drug phase start january essential step create drug candidate candidate desire biological effect assess optimise lead compound potency efficacy safety safety development characteristic preclinical screen submission intrinsic characteristics molecule ii demonstrating achieve cedd responsible proving number significant dossier submit regulatory authority major region summarise validity therapeutic hypothesis early clinical compound safe efficacious patient smallscale table trial result candidate cedd focus specific clinical trial proof concept decision point disease area design nimble entrepreneurial product countryregion description decision information available range skill resource require drive midstage abacavirlamivudine eu usa fixed dose combination reverse transcriptase inhibitor treatment development project lead optimisation key date justifie compound progression latestage drug hiv infection decisionpoint demonstration proof concept major development necessary largescale clinical trial advair diskus usa label paediatric twicedaily dose combination salmeterol investment fund largescale clinical trial conduct register commercialise product longacting betablocker fluticasone corticosteroid dry powder device cedd accelerate progress new new biopharmaceutical cedd form avandaryl usa combination rosiglitazone sulphonylurea type diabetes compound dose human table extend rds current effort discover develop recombinant augmentin usa convenient tablet formulation breakline amoxicillin clavulanate compound progress phase initial therapeutic protein monoclonal antibodie certain bacterial infection evaluation efficacy patient addition adjustment therapeutic vaccine imigranimitrex eu usa fast dissolve tablet formulation sumatriptan ht antagonist process involve stage development enable paxil cr usa controlled release formulation paroxetine selective serotonin reuptake seven cedd base usa europe reduction development times inhibitor intermittent treatment premenstrual dysphoric disorder paxil japan paroxetine obsessive compulsive disorder biopharmaceutical centre stevenage uk result substantial number new compound achieve requip eu usa ropinirole nonergot dopamine agonist restless leg syndrome cardiovascular urogenital disease centre upper merion critical milestone proof concept potential new seretide mdi eu dose counter pressurised aerosol contain salmeterol fluticasone usa medicine show sufficient effect target seretide eu use pressurised aerosol contain salmeterol fluticasone metabolic viral disease centre research triangle park patient group justify transition later stage paediatric asthma usa development microbial musculoskeletal proliferative disease include serevent diskus eu salmeterol longacting betablocker dry powder diskus device major partnership announce imperial cancer centre upper providence usa treatment copd college london develop major clinical imaging centre neurology gastrointestinal disease centre harlow uk glaxosmithkline imperial hammersmith hospital site psychiatry centre verona italy respiratory inflammation centre stevenage uk glaxosmithkline description business description business glaxosmithkline partnership world highly describe tast replace beginning group form december sign latestage project terminate interactive relationship clinical service ongoe mdc responsible creating value major external collaboration product clinical development oxibendazole helminth intestinal infection biomedical chemical research worldclass academic delivery product development plan include manage development product preclinical stage phase iii phase ii asthma centre medical school imaging centre provide unique daytoday operational activity postpoc portfolio compound subject inlicense copromotion treatment hiv new capability require drive clinical portfolio forward delivery medicine patient maximise global commercial deal potential product ensure strong partnership vaccine rd glaxosmithkline major response challenge pulsatile drug delivery system advancis use cedd global commercial strategy gcs project vaccine rd conduct glaxosmithkline biological disease affect develop world microbial control delivery antimicrobial management function integrate mdc centre rixensart belgium include related activity musculoskeletal proliferative disease cedd responsibility control release micropump technology flamel framework order provide direct expertise planning clinical development regulatory strategy commercial strategy drug discovery unit base tre canto dedicated technology use develop new formulation execution development activity mdc therapeutically scale production packaging support function find new medicine disease research project nucleoside reverse transcriptase inhibitor medivir align follow research scientist employ devoted tre canto focus malaria tb work treatment hiv infection discover new vaccine develop costeffective group hivaid vaccine address cardiovascularmetabolic fixeddose combination tablet contain combination convenient combination product prevent infection cause prevention treatment world health infectious disease include ddw long act nonsteroidal antiinflammatory drug medical problem worldwide discovery work identify organization priority disease group work musculoskeletalinflammationgastrointestinalurology pozen glaxosmithkline range antimigraine therapie new vaccine candidate express yeast numerous external partner worldwide search new neuroscience psychiatryneurology imigranimitrex naramigamerge improve patient bacteria mammalian cell purify high level treatment disease develop world ddw oncology benefit migraine respiratory solifenacin muscarinic antagonist copromotion follow formulation vaccine involve preclinical development yamanouchi treatment overactive bladder mixing antigen select adjuvant ultimately matrix team responsible maximise worldwide preclinical development pcd participate wide range atriple monoamine reuptake inhibitor attentiondeficit stimulate good immune response human step development opportunitie product remit activity drug development process optimise hyperactivity disorder ns broad evaluate safety efficacy candidate vaccine invivo information need support registration safety selection compound potential development alliance cover number research programme central model preclinical proof concept establish programme price formulary negotiation available launch marketplace enhancement exist product nervous system disease neurosearch candidate vaccine test clinical trial healthy require commercial input gcs ensure early devise convenient formulation early individual evaluate safety effective vaccine stage regional marketing need fully integrate current collaborative adi partnerships cytokinetics inc development process metabolic rate safety compound induce immune response protect body disease development plan careful prioritisation phase oncology mitotic kinesin inhibitor shionogi co hiv evaluate laboratory animal prior testing human encounter later natural set largescale field trial development ensure high potential integrate portfolio neurology programme potential broad base discovery healthy individual follow establish safety efficacy testing require animal human mandate achieve collaboration antimicrobial oncology metabolic cross section population result obtain clinical highly regulate government agency neurology tanabe seiyaku co ltd broad base neurology mdc collaborate early stage cedd define trial development quality production process gastrointestinal urology diabete respiratory exelixis inc pcd researcher investigate dosage form eg tablet inhale target product profile new molecule integrate facility combine regulatory file oncology inflammation theravance inc asthma ranbaxy develop formulation enhance drug effectiveness technical development manufacturing function ensure submit authority country laboratory ltd broad base pcd responsible development drug formulation rapid effective launch delivery product innovative vaccine available clinical trial process support analytical method clinical programme lead molecule cedds glaxosmithkline academic adi partner uk drug synthesis product formulation delivery scale develop crossfunctional project team usa long term collaborative relationship animal research meet increase supply requirement ultimately lead group commit fund year ethical regulatory scientific reason research animal crossfunctional input extend focused life cycle management technical transfer process method option renew additional year addition remain vital research development new product deliver new indication new presentation manufacturing glaxosmithkline enter number agreement medicine vaccine animal initial regulatory approval commercial launch example party codevelop comarket certain alternative available glaxosmithkline constantly aim new product supply process partnership rd life cycle management include extend release formulation compound arrangement range milestone payment reduce number group strive exceed industry global manufacturing supply ensure robust product wellbutrin xl development programme design deliver party acquire right intellectual property standard care welfare animal use laboratory develop large scale commercial manufacturing launch new indication use lamictal bipolar disorder joint venture develop commercialise specify compound animal usually breed specifically research care key technology area provide way improve rds product gold pass initiative start agreement group obligation life qualified train staff productivity include drug delivery system predictive technology levitra wellbutrin xl launch payment future specify milestone achieve animal research unnecessary pain suffer particle engineering process innovation use particle designation agree rd regional market financial commitment summarise note scrupulously avoid glaxosmithkline actively engage engineering process innovation enhance ability manufacture key component portfolio resource financial statement commitments research develop validate experimental method manufacture consistently highquality product efficiently prioritisation management process ensure provide well alternative use animal resource place key emerge asset yield optimum discontinuation research worldwide development commercial benefit maximum medical benefit research development carry risk failure provide focus development process major patient gold pass asset high value strategic commensurate extension scientific knowledge glaxosmithkline acknowledge use animal research functional component clinical medical biomedical datum importance glaxosmithkline require specific organisational compound effect lead compound purpose subject rightly command high level public regulatory safety integrate single visibility urgency meet patient need consequently identify possess positive activity validate target interest glaxosmithkline public policy position care management organisation worldwide development small number asset receive gold pass status time prove safe introduce human feasible ethical use animal research available website crossfunctional therapeutic area strategy team enable focus organisation align manufacture commercial scale glaxosmithkline rd wwwgskcom secretariat tast cover follow group disease product depression cancer endeavour ensure far possible risk receive gold pass designation year ameliorate extensive predictive testing early possible research development consumer healthcare cardiovascular urogenital metabolic disease development process despite effort ultimate test infectious disease include ddw principal centre consumer healthcare rd uk inlicense research collaboration product remain point administer neurology gastrointestinal disease usa focus rd identification glaxosmithkline continue identify compound large number patient disease oncology musculoskeletal disease inflammation rapid development novel product bring benefit enhance portfolio create innovative collaboration glaxosmithkline merck kgaa review progress psychiatry consumer otc oral care nutritional healthcare ensure group regard partner choice development programme ssri hta receptor partial respiratory market consumer healthcare liaise closely pharmaceutical large small company agonist vilazodone result company agree maximise group asset find application development programme terminate prescription product otc marketplace glaxosmithkline description business description business glaxosmithkline operating resource intellectual property levitrad group copromotion right patent trade mark significant cost saving achieve consolidation active ingredient vardenafil expire glaxosmithkline pharmaceutical product protect simplification standardisation basic infrastructure glaxosmithkline regard intellectual property key business usa pfizer initiate legal action usa register trade mark major market general mark network email business application host number asset effective legal protection intellectual property certain country bayer glaxosmithkline product market world new central infrastructure service introduce include critical ensure reasonable return investment rd allege infringement patent broad method local variation example usa trade mark host web base application information storage intellectual property protect patent trade mark treatment claim e paxil instead seroxat advair instead document management register design copyright domain registration seretide patent trade mark right regard particularly valuable lexiva glaxosmithkline exclusive licensee patent proactive attention management computer virus threat active ingredient fosamprenavir expire trade mark protection generally extend long result minimal impact continuity business operation patent usa europe trade mark renew necessary risk mitigation plan establish important glaxosmithkline policy obtain patent protection glaxosmithkline trade mark pharmaceutical product compute risk area include externally face system datum paxilseroxat patent active ingredient paroxetine significant product discover develop rd generally assume increase importance patent privacy business continuity plan outsource business application expire usa europe litigation activity patent protection new active ingredient available product expire particular country generic compliance concern validity infringement patent protect significant market protection obtain new version product available product ongoing usa e generic competition pharmaceutical formulation manufacturing process transform extend business activity commence usa uk certain market consumer healthcare business trade mark particularly new medical use special device administer insight gain genomic proteomic transform important business brand orientate product retrovir patent active ingredient zidovudine way disease target identify validate product patent protection patent cover pharmaceutical formulation contain information obtain external source integrate basic patent position respect significant product zidovudine medical use expire internally generate information rapid flexible follow information technology usa europe manner subject analysis provide insight augmentin basic patent key active ingredient information technology play strategic role support decisionmake advantage take advance seretideadvair patent specific combination active potassium clavulanate expire market italy glaxosmithkline computer technology increase processing power ingredient salmeterol fluticasone propionate c generic competition exist market litigation expire usa b europe challenge support key business process local regional access information regulatory agency clinical opinion concern clavulanic acid production strain ongoing patent uk e functional global level leader healthcare professional patient public usa e enable transformation extension key business enhance step take reduce reliance paper serevent patents active ingredient salmeterol xinafoate avandia avandamet basic patent active ingredient activity base process clinical trial registration new medicine expire b europe b france rosiglitazone expire usa b facilitate collaboration access information use wireless handheld technology internet c italy usa europe patent commercial form active ingredient global basis administrative process include human resource rosiglitazone maleate expire usa trizivir patent specific combination lamivudine addition computer infrastructure hardware software procurement technology support streamline b europe litigation concern validity zidovudine abacavir expire organisation responsible voice video technology move selfservice model enable employee infringement patent protect product ongoing usa b europe monitor business technology trend selfsufficient reduce time effort require usa e valtrex patent active ingredient valaciclovir impact glaxosmithkline prepare group risk complete basic transaction major elearne programme avodart patent active ingredient dutasteride expire usa b europe associate late information technology allow employee choose learn new skill normal expiry usa europe request litigation concern validity infringement patent reduce training cost significantly introduce focused deliver increase value group extension term patent pende expect protect product ongoing usa e sale force technology training basic service improve quality whilst extend date usa b europe wellbutrin sr zyban patent basic active ingredient time cost service reduce return introduction extranet capability enable secure combivir patent specific combination lamivudine expire formulation patent protect currently investment increase introduction new interaction partner supplier increase zidovudine expire usa market sr sustain release formulation late rapid low cost methodology improve business process effectiveness supply chain collaboration rd b europe expire usa europe regulatory require major technology investment establish alliance partner prescriber datum exclusivity provide protection process ensure business application project pay coreg glaxosmithkline exclusive licensee patent country litigation concern validity year collaborate assess information active ingredient carvedilol expire infringement patent protect product ongoing enable glaxosmithkline staff productive remain usa e generic competition dosage form support key business process high priority adoption standard global tool support epivir patents active ingredient lamivudine commence usa expect shortly develop web base tool provide scientist collaboration information access critical enabler expire usa b europe dosage form information need candidate medicine way early achieve phase rd team draw shortlist molecule flixotideflovent flixonaseflonase usa patent ziagen basic patent active ingredient abacavir standard intranet portal adopt consideration possible treatment specific disease fast active ingredient fluticasone propionate initial expiry expire usa b europe primary communication channel employee retrieval confidence quality shortlist area date extend virtue paediatric important information easy fast zofran basic patent active ingredient ondansetron rd play important role highthroughput exclusivity european country protection provision standard intranet searching capability expire usa b europe biology laboratory automation image electronic datum capture expire b c france c italy patent use treat emesis document management clinical datum management uptake group standard collaboration product suite imigranimitrex patents active ingredient sumatriptan expire litigation concern validity infringement enable employee work collaboratively multiple implementation group enterprise resource plan expire usa b europe patent protect product ongoing usa e geographic time zone increase significantly include strategy continue common application use c italy litigation concern validity infringement product suite highquality videoconferencing facility manufacturing plant commercial unit patent protect product ongoing usa e instant message online meeting service implement number site standard transaction lamictal patent active ingredient lamotrigine middleware enable efficient movement progress global implementation standard expire usa b country include extension term supply chain whilst allow independent optimisation desktop provide employee improve access b include extension term supplementary protection certificate europe litigation concern validity infringement commercial unit regional functional level information business application low cost lightweight c include extension term national supplementary protection certificate patent protect product ongoing usa e notify follow recent change italian law subject legal challenge manufacturing web base desktop development register trademark bayer ag e note financial statement glaxosmithkline description business description business glaxosmithkline business society glaxosmithkline people year mark annual multicultural marketing corporate responsibility ehs management diversity award entrant country event glaxosmithkline take systematic approach manage ehs glaxosmithkline people fundamental success glaxosmithkline commit connect business decision highlight activity serve diverse employee customer risk impact framework information programme business skill intellect key component ethical social environmental concern solid financial stakeholder glaxosmithkline global community base global ehs standard guide management successful implementation sound business strategy performance closely connect ethical business practice key aspect impact risk organisation human capital maximise potential group group commit employment policy free group understand profit scientific commercial financial asset outcome effective discrimination potential exist staff ground make matter stakeholder want know profit ehs assurance improvement human resource policy glaxosmithkline solid reputation age race ethnic national origin gender sexual orientation reassured sound ethical basis governance responsibility glaxosmithkline conduct international employer choice faith disability particular glaxosmithkline commit business glaxosmithkline identify broad issue eh audits site key contract manufacturer supplier offer people disability access range generate interest stakeholder report achieve group initiate candidate care process base assess performance recruitment career opportunity effort retain year corporate responsibility report available commitment seek acquire good employment ehs standard include quantitative performance measurement support staff disabled secretariat website wwwgskcom candidate reflect diversity background experience site audit followup review perspective contribute success glaxosmithkline corporate responsibility committee perform continuous improvement process talent management leadership development glaxosmithkline nonexecutive director oversight corporate progress monitor action arise issue raise development planning key element performance planning responsibility matter advise board social ethical audits employee year review conduct performance reward environmental issue potential impact seriously business function ensure diverse talent pool fully pilot exercise conduct global manufacturing importance people translate employment glaxosmithkline business reputation corporate develop meet future business need successor supply investigate obtain group wide party practice demonstrate value individual executive team direct group corporate responsibility identify key position certification international standard environmental compensation benefit package glaxosmithkline total activity general counsel responsible manage health safety management system iso ohsa reward aim competitive innovative comprehensive leadership development opportunity available overall programme site achieve certification standard global local orientation depend good drive manager level opportunity target help corporate responsibility issue dialogue stakeholder process addition site business performance reward individual contribution leader meet challenge face complex global manage appropriate function glaxosmithkline previously individually certify iso pilot organisation ensure leader motivate team individual compensation philosophy programme development central department ensure confirm feasibility approach programme good work underscore glaxosmithkline commitment performance remain integrated everyday operation continue voluntary basis global certification culture performance base pay base variable share business facilitate policy development implementation achieve year human resource service information system award share option performance development planning communication crossfunctional team establish glaxosmithkline human resource delivery strategy design commitment corporate social responsibility evaluation contribute retention key talent superior beginning ensure coordinated technology human resource services proactive management glaxosmithkline manufacturing performance accomplishment business target comprehensive approach team representative information deliver low cost highly effective supply base key contract manufacturer key business area ensure policy place commitment flexible working flexitime channel easy job candidate employee supplier assess process evaluate mechanism exist implementation monitoring teleconference remote working flexible work schedule retire access information employment compensation management ehs risk impact base group eh recognise employee work good environment benefit policy programme include intuitive crossfunctional team develop set requirement contract manufacturer generally good help integrate work personal life personalise web base tool available employee corporate responsibility principle glaxosmithkline set performance identify recommendation location approach area standard ethical conduct improvement need communication involvement leadership advocacy research innovation product stimulate employee engagement daily news service property plant equipment customer access medicine employment practice human objective target place business unit intranet site include daily group right community investment care environment objective focus theme reduce key risk glaxosmithkline invest billion property news announcement online news magazine service engagement stakeholder risk identify significant base past performance carry value financial statement billion chief executive officer home qa online driver safety ergonomic chemical exposure process safety billion carrying value invest plant instance care environment access information resource encourage employee serve company resilience emergency response equipment asset construction glaxosmithkline medicine performance measure place ambassador appropriate publication medium invest million new renewal property plant support demonstration progress principle progress issue work continue clipping accompany group position statement equipment mainly relate large number project potential develop performance indicator support objective centre emerge issue ensure employee access key message important issue improvement expansion facility worldwide effective management communication explore pharmaceutical environment chemical policy climate employee survey undertaken determine site property mainly hold freehold new investment finance aim strike balance desire change theme respond external ehs challenge employee satisfaction communication channel content group liquid resources st december group stakeholder great transparency operation numerical target ehs improvement set cent employee express satisfaction capital contractual commitment future expenditure glaxosmithkline reality cost run accomplished year health safety target employee broadcast host ceo million operating lease commitment business reduction lose time injury illness rate cent chairman pharmaceutical rd hold december million information issue find corporate year environmental target include reduction energy usage recognise performance remind employee rd pipeline glaxosmithkline business sciencebase technologyintensive responsibility report overview key associate greenhouse gas emission reduction solvent information reiterate global strategy share highly regulate governmental authority allocate corporate area environment health safety access emission waste wastewater dispose ownership scheme encourage participation owner significant financial resource renewal maintenance healthcare community investment follow progress meeting target track year business increase awareness short long term business property plant equipment minimise risk interruption publish wwwgskcom date significant progress objective global local employee opinion survey allow production achieve compliance regulatory responsibility environment health safety achieve ehs target employee opportunity express view perspective standard research development manufacture important group issue environment health safety ehs key element corporate pharmaceutical use chemical hazardous material performance improvement measure responsibility group high priority responsibility group observe stringent procedure use specialist skill glaxosmithkline measure impact health safety diversity ehs high level corporate group reporting manage environmental risk activity environmental people work site impact environment glaxosmithkline diversity initiative continue focus general counsel overall responsibility provide issue date operation modify measure impact people lose time injury illness create inclusive work environment aim enhance governance leadership ehs issue head group discontinue reference responsibility environment rate result lose time hour work employee innovation productivity measurably improve make regular report corporate executive team cet health safety note financial impact air water land measure metric tonne employee attraction development retention audit committee operation line manager statement legal proceeding glaxosmithkline believe material emit waste dispose impact natural responsible ehs support sitebased ehs facility adequate current need resource measure cubic metre water gigajoule occupational health professional energy consume glaxosmithkline description business description business glaxosmithkline glaxosmithkline select measure performance improvement access healthcare develop world preferential pricing improve access group global community investment base risk risk determine evaluation arrangement cover world poor country access healthcare develop country remain unique glaxosmithkline global community investment activity impact impact consider potential supply arvs preferential price customer include government challenge global community problem root value million include million adverse impact people environment business nongovernmental organisation ngo hospital academic poverty demand significant mobilisation resource group patient assistance program medicine donation continuity business reputation measure select institution private employer true spirit partnership tackle share low income group usa million similar report company responsibility sector global society group offer notforprofit price require sustainable framework humanitarian product donation total equivalent recommend global reporting initiative longterm mandate expertise resource address underlie combine group commitment preferential pricing cent group profit tax include million multistakeholder international undertaking develop problem exist glaxosmithkline continue play commitment government avoid price referencing cost manage deliver community programme disseminate globally applicable sustainability report guideline vital role commitment rd disease preferentially price medicine help prevent product country particularly prevalent develop world diversion glaxosmithkline take step minimise threat product stewardship programme long term commitment help programme preferential pricing antiretroviral arvs diversion able supply country combivir glaxosmithkline global standard product stewardship bring sustainable change underserved community antimalarial vaccine community investment special access pack similar effort underway secure establishe requirement responsible ethical group community investment activity mainly focus activity partnership widespread regulatory approval trizivir epivir access pack management ehs aspect product life health education include colour differentiate product packaging cycle product stewardship provide systematic way identify rd disease develop world product process risk early mitigate fully deter illegal trader public health programme grow antiinfective resistance current treatment inadequate manage ultimately eliminate integrate product expert repackage medicine glaxosmithkline global alliance eliminate lymphatic filariasis healthcare infrastructure poor patient compliance complex stewardship business activity protect people welcome political commitment prevent diversion arise glaxosmithkline flagship community programme aim treatment regimen continue drive need investment environment enhance compliance local regulatory g summit june european union eliminate disfigure mosquitoborne disease world rd new drug vaccine disease affect requirement avoid interruption product supply antidiversion regulation country company commit provide develop world encourage similar step ensure introduction antiparasitic drug albendazole require estimate billion environmental sustainability glaxosmithkline believe industry extensive strict enforcement measure counter trade main preventative treatment treat billion people risk concept sustainable development central group portfolio product rd project disease beneficiarie illegal importer country environmental programme work start eventual develop world undertake rd prevention october glaxosmithkline extend voluntary licence glaxosmithkline founder global alliance environmental sustainability mitigate environmental impact treatment world health organization grant aspen pharmacare subsaharan africa large generic eliminate lymphatic filariasis lf unique partnership look way improve production efficiency use priority disease develop world hivaid tuberculosis company manufacture sale combivir epivir include ministry health endemic country non renewable resource overall balance consumption tb malaria retrovir licence previously limited public sector governmental organisation communitybase organisation resource generation waste investigate addition rd hivaid glaxosmithkline rd south africa zimbabwe group extend academic institution international organisation private future group standard sustainable development team base spain uk dedicate treatment licence cover public private sector sector define approach discovery manufacturing disease develop world project prioritise primarily subsaharan africa sale environmental sustainability start rd fifth year programme million tablet socioeconomic public health benefit support rd toolkit develop assist worth million wholesale acquisition cost commercial return group currently rd success partnership selection green chemistry process donate country ongoing preventative project programme relevance develop world glaxosmithkline continue build history community programme glaxosmithkline ship million albendazole aim produce vaccine medicine investment programme support well healthcare delivery access healthcare develop world tablet sri lanka ministry health mobilise disease disproportionally affect develop country education underserve community develop healthcare worker volunteer treat million people glaxosmithkline play active improve healthcare world group active engagement group increasingly involve publicprivate partnership single day july large community treatment people limit access medicine orange card external stakeholder consulted work enable wide range project undertake see programme type place develop world scheme help senior american citizen government develop develop world tangible output partnership launch addition group give grant million staff low income save medicine buy un ngos investment community antimalarial lapdap result collaboration expertise support activity global alliance group reinforce commitment programme uk government university liverpool achieve specifically hivaid funding eliminate lf include advocacy research community mobilisation london school hygiene tropical medicine support thank initiative global fund president bushs educational initiative bring companysponsore saving programme single initial grant wellcome trust lapdap emergency plan aid relief significant increase card extend possible saving pharmacy counter launch number african country resource need important maintain glaxosmithkline positive action hivaid widely prescribe medicine easy use incentive rd protection intellectual property mark th year positive action glaxosmithkline card rx participant able save cent preferential pricing arrangement example cure vaccine hivaid pioneer global programme hiv education care usual pay prescription end glaxosmithkline offer vaccine public health community support positive action support glaxosmithkline continue vital contribution approximately million people join programme programme significant discount year group programme countrie partner positive action improve healthcare develop world real set single sustainable notforprofit price focus subsaharan africa magnitude progress occur significant barrier stand arvs antimalarial wide range customer hivaid pandemic programme support way well access healthcare tackle share develop country subsaharan africa project affect community country world responsibility sector global society government fullyfunde global fund fight aid tb malaria international agency charity academic institution support include grant movement man mean notforprofit price offer total pharmaceutical industry aid kenya mmaak encourage men engagement country glaxosmithkline commit contribute involvement aspect hivaid crisis man health improvement sustainable manner commonly decisionmakers workplace government preferential price glaxosmithkline arvs antimalarial religious institution example support set level profit direct vulnerable community grant uk cost cover allow supply sustain long base ngo develop lowcost health education resource require group undertake reduce price hiv hepatitis sexual health use uk prison possible able meet commitment twice glaxosmithkline description business description business glaxosmithkline help address grow hivaids problem china education programme include science group effort improve public education include grant employee involvement group provide british red cross australian world international education programme use science summer free librarybase glaxosmithkline employee encourage contribute red cross threeyear programme prevent spread web base resource promote discussion science issue science education programme philadelphia area teach local community employee volunteer scheme hiv train young people drug user hiv school country seventh year basic scientific concept child th year support vary world include employee time prevention life skill group sponsor royal institution christmas lecture child participate programme cash donation charity employee complete broadcast channel television young people voluntary work matching gift programme russia ukraine rapidly increase incidence university north carolina chapel hill receive opportunity inspire eminent scientist country glaxosmithkline offer taxefficient option employee hivaid glaxosmithkline provide funding establish overall million grant travel science give accordance local taxation guideline support national network positive people help glaxosmithkline commitment environment laboratory help improve science teaching encourage advocate hiv education prevention care treatment group sponsor gowild oneoff living festival royal underserved student pursue career science usa group matched services addition group grant million botanic garden kew receive visitor employee gift value million pharmaceuticals group launch glaxosmithkline healthy year support work hivaid clinic malawi september communities health education outreach group match million employee donation uganda programme advance healthy live african americans federal united way campaign usa give combine europe congressional black caucus foundation date receive contribution million addition glaxosmithkline glaxosmithkline african malaria partnership corporate programme europe focus improve grant year period investment volunteer excellence programme provide glaxosmithkline african malaria partnership support children health total funding million support help support high school graduate college student interested grant charitable organisation usa behavioural development programme work seven african range longterm programme addition glaxosmithkline pursue career science medicine employee partner volunteer hour country group disburse grant company europe provide million regional year million commitment partner freedom hunger community activity international amref plan international programme expect glaxosmithkline make difference programme uk european forum family child live hivaids group corporate public health programme benefit nearly million people focus particularly young provide grant nonprofit organisation receive year programme work young develop country corporate programme child pregnant woman encourage effective prevention register charity base employee involvement people italy portugal romania russia spain alleviate international region address health education mobilisation measure prompt treatment antenatal malaria management hivassociate stigma discrimination provide funding million foundation regional community initiative barretstown ireland lenvol france support group provide phase initiative personal glaxosmithkline operate single charitable foundation united kingdom european child cancer lifethreatening illness hygiene sanitation education kenya zambia nicaragua community investment programme number glaxosmithkline contribute million continue rediscover inner strength selfesteem receive peru year phase provide education countrybase foundations canada czech republic france corporate programme charitable activity uk respectively school child reduce diarrhoearelate disease italy romania spain usa support project area health medical death glaxosmithkline continue support charity healthprom year glaxosmithkline france foundation research science education arts environment azerbaijan health ministry invest ethiopia group provide integrate support programme african country improve addition glaxosmithkline company uk provide fourth year safe childbirth initiative benefit management childhood illness imci partnership hivaids prevention education training care million community purpose give combined total refugee unicef enable family improve key household people expect benefit million support project uk practice behaviour significant impact foundation provide fund zippys friend school programme run partnership medical research total provide child survival rate growth development ongoing initiative year commitment child teach cope skill young child denmark epilepsy research foundation international spinal research trust lithuania continue receive funding extend pakistan national commission human development north carolina glaxosmithkline foundation usa national osteoporosis society tommys baby charity reach uk india nchd receive focus improve maternal health endow selffunde organisation operate separate glaxosmithkline annual uk impact award recognise excellence rural area entity foundation publish annual report work voluntary community health organisation north america available request use asset base support uk uk charity receive unrestricted corporate programme north america focus improve product donation mathematic science health education north carolina award work deal issue diverse public education access well healthcare child glaxosmithkline donate essential product antibiotic foundation donation total sexual abuse mental health elderly day care disability senior fund million million humanitarian relief effort donation request million include group total community donate group base business regional government major charitable organisation investment figure donation charity beat community activity manufacture specifically meet requirement bowel cancer national awareness campaign bowel glaxosmithkline work partnership charitable organisation cancer uks second deadly cancer aim highlight example glaxosmithkline contribution improve deliver relief include americare interchurch medical symptom promote early diagnosis save live healthcare include threeyear grant million assistance map international project hope ensure help expand children health fund referral glaxosmithkline hope encourage generation right product reach right person right time management initiative rmi seven state ensure scientist support science education programme example group donate vital medicine airlift continuity specialist medical care highrisk child science context enhance science teaching group iraq april aid flight kosovo organise homeless commit million year support phase americare glaxosmithkline provide relief follow new darwin centre natural history museum glaxosmithkline share recognition award recognise earthquake india flood nicaragua london glaxosmithkline continue support inspire work small communitybase organisation aim total value group international humanitarian innovative scheme postdoc research education improve health old people diverse culture product donation million exclude albendazole scheme develop partnership imperial college london organisation receive total provide extra donate group commitment lymphatic specialist schools trust million donation support launch new programme strengthen ongoing filariasis elimination programme product donation value year inspire aim raise achievement science place initiative wholesale acquisition cost wholesale list price postdoctoral researcher specialist science school assist annual usa impact award acknowledge reward include discount standard industry method science teaching study teaching qualification excellence nonprofit healthcare sector great philadelphia area charity receive unrestricted award work deal issue diverse child abuse breast cancer sexual reproductive health glaxosmithkline glaxosmithkline corporate governance section discuss glaxosmithkline management structure governance procedure contain company report disclosure corporate governance require combined code corporate governance uk list authority code include require statement compliance give detail principle provision new combine code corporate governance financial reporting council code glaxosmithkline require comply st january report annual report measure implement achieve describe section company report compliance relevant law regulation apply board corporate executive team governance policy dialogue shareholder annual general meeting internal control framework committee report combine code law regulation glaxosmithkline corporate governance corporate governance glaxosmithkline board john mcarthur age corporate executive team cet david pulman appoint rd president sir christopher hogg aged jp garni nonexecutive director mr mcarthur nonexecutive global manufacturing supply appoint rd chief executive officer director glaxo wellcome plc nonexecutive director dr pulman responsible global manufacturing supply nonexecutive chairman sir christopher chief executive officer dr garnier responsible bce inc bce emergis inc cabot corporation hca corporation chain network join glaxo responsible nonexecutive director smithkline beecham plc management group oversee operational aspect koc holdings rohm haas company telsat canada north american supply network manufacturing strategy nonexecutive chairman reuters group plc member include establish policy objective initiative ae corporation senior advisor president logistics current appointment supervisory board air liquide sa chairman direct longterm strategy chief executive officer world bank royal national theatre smithkline beecham join group david stout donald mchenry age president dr jeanpierre garnier age rupert bondy appoint rd pharmaceutical operation appoint rd senior vice president general counsel nonexecutive director mr mchenry nonexecutive mr stout responsible global pharmaceutical vaccine chief executive officer dr garnier appoint executive mr bondy responsible legal matter group director smithkline beecham plc nonexecutive business join smithkline beecham head director smithkline beecham plc chief environmental health safety issue insurance directorship include cocacola company fleetboston sale marketing president pharmaceuticals executive officer april nonexecutive director security lawyer private practice join financial corporation international paper company att current appointment january united technologies corporation member board smithkline beecham corporation trustees eisenhower exchange fellowship hold chris viehbacher ford calhoun phd pharmacology university louis pasteur sir ian prosser aged president chief information officer france mba stanford university usa appoint rd pharmaceutical dr calhoun responsible information technology global nonexecutive director sir ian nonexecutive mr viehbacher responsible pharmaceutical john coombe aged function enable key business process part director smithkline beecham plc chairman january join wellcome director appoint rd group doctoral postdoctoral training microbiology continent plc world travel tourism council continental europe glaxo wellcome chief financial officer mr coombe executive genetic biomathematic computer science join smith nonexecutive deputy chairman bp plc member responsible glaxosmithkline european pharmaceutical director glaxo wellcome plc responsible kline french cbi presidents committee business current appointment finance investor relation member supervisory john coombe board siemens ag code committee uk dr ronaldo schmitz age andrew witty chief financial officer takeover panel appoint rd president head finance function mr coombe responsible nonexecutive director dr schmitz nonexecutive pharmaceuticals europe dr michle barzach aged activity financial reporting control tax treasury director glaxo wellcome plc nonexecutive director mr witty responsible group pharmaceutical appoint rd investor relation finance system internal audit real estate legal general group plc member board director operations europe january join glaxo nonexecutive director dr barzach nonexecutive join glaxo group financial controller rohm haas company cabot corporation glaxosmithkline senior vice president asia pacific director glaxo wellcome plc member appoint group finance director current appointment international cooperation high council chairman board dr lucy shapiro age marc dunoyer equilibre et population director board project appoint rd tachi yamada president hope international consultant health strategy nonexecutive director dr shapiro nonexecutive chairman pharmaceutical japan french minister health family director smithkline beecham plc ludwig professor research development mr dunoyer appoint president pharmaceutical japan cancer research department developmental biology dr yamada lead group complex business drug discovery lawrence culp aged march join group senior vice director beckman center molecular genetic development create new medicine research appoint st july president regional director japan current medicine stanford university school medicine join smithkline beecham nonexecutive member nonexecutive director mr culp president chief executive appointment nonexecutive director anacor pharmaceuticals inc hold board chairman rd pharmaceutical officer danaher corporation prior join danaher hold phd molecular biology albert einstein college russell greig appoint board director st january position accenture previously andersen consult medicine president jennie young crispin davis aged pharmaceuticals international sir robert wilson age senior vice president appoint st july dr greig lead pharmaceutical operation outside usa appoint st november corporate communication community partnership nonexecutive director mr davis chief executive reed elsevi europe cover country join nonexecutive director sir robert nonexecutive chairman mrs young responsible group internal external plc prior chief executive aegis group plc group senior vice president worldwide bg group plc economist group previously communication image partnership global join guinness plc group business development rd prior current appointment executive chairman rio tinto plc community join glaxo wellcome director manage director united distillers member main march investor relation board guinness plc spend early career procter dr tachi yamada aged dan phelan gamble appoint st january jack ziegler senior vice president chairman research development dr yamada president sir peter job age human resource nonexecutive director subsequently executive director consumer healthcare appoint rd mr phelan responsible benefit compensation recruitment smithkline beecham plc prior join smithkline beecham mr ziegler head global consumer healthcare business nonexecutive director sir peter nonexecutive organisation development leadership development succession chairman department internal medicine produce oral healthcare overthecounter medicine director glaxo wellcome plc nonexecutive director plan human resource information system employee university michigan medical school physicianinchief nutritional healthcare product join smithkline beecham schroders plc shell transport trading company plc tibco health management lawyer private practice university michigan medical center member appoint president consumer software inc instinet group inc member join smith kline french appoint board director diadexus inc trustee healthcare business supervisory board deutsche bank ag bertelsmann ag senior vice president director human resource smithkline rockefeller brothers fund beecham member director mr pien leave group st march pursue role sir roger hurn nonexecutive deputy chairman mr paul pharmaceutical industry mr ingram continue work allaire nonexecutive director retired board time vice chairman pharmaceutical act special th june advisor group attend cet meeting capacity detail membership board committee find glaxosmithkline corporate governance corporate governance glaxosmithkline governance policy board review companys internal control risk audit committee evaluation board board committee director management policy approve governance structure audit committee review financial internal reporting board initiate systematic approach evaluation board executive code ethic board review approve major process system internal control management risk performance evaluation board committee director list board finance investment contractual decision excess external internal audit process committee director undertake chairman implement define threshold addition item board evaluate propose shareholder appointment external auditor collaboration committee chairman support board responsible group system corporate monitor performance group directly responsible remuneration oversight company secretary governance ultimately accountable group activity include work committee consist entirely independent strategy financial performance evaluation conduct way private discussion nonexecutive director meet time year engage board meeting ceo executive chairman director chairman board comprise executive nonexecutive report audit committee give director member cet appropriate assist prepare conduct evaluation director whilst board consider nonexecutive director financial operating performance glaxosmithkline external adviser conduct separate interview independent character judgement accordance remuneration committee external issue material group prospect director enable director perspectives code determine nonexecutive remuneration committee determine term service chairman performance feed chairman directors chairman dr barzach mr mchenry dr shapiro evaluate progress achievement group remuneration executive director member cet board performance evaluation board committee consider independent code financial business objective annual plan assistance external independent advisor conduct behalf chairman chairman case chairman mr mchenry evaluate make recommendation board overall monitoring report receive directly respective board committee length service glaxosmithkline predecessor executive remuneration policy committee consist entirely committee key significant risk face group company case drs barzach shapiro independent nonexecutive director meet time corporate executive team remuneration receive group board overall responsibility succession planning year necessary information remuneration cet assist ceo executive management capacitie nonexecutive director resign ceo position board give ceo broad authority director give remuneration report page group cet meet time year member position board committee independence operate business group ceo accountable responsibility list corporate executive team require code report board business performance nominations committee board consider mr mcarthur dr schmitz mr culp board meet time director attend nomination committee review structure size mr davis sir peter job sir ian prosser sir robert wilson meeting hold tenure dialogue shareholder composition board appointment member independent code board note board recognise occasion board cet make recommendation board dr schmitz mr mcarthur associated nonexecutive financial result announce quarterly director feel necessary independent legal appropriate committee monitor plan director public company rohm haas company andor financial advice company expense succession board senior management committee company report formally shareholder twice year cabot corporation consider association agree procedure enable consist entirely nonexecutive director majority halfyear fullyear result announce ceo cfo sufficient economic significance compromise independent meet year consider succession presentation final year end result institutional independence company secretary responsible board available planning necessary report investor analyst medium london new york individual director respect board procedure date publication majority board member nomination committee give addition teleconference release company secretary simon bicknell appoint exclude chairman independent nonexecutive second quarter result institutional investor analyst barrister join group director accordance recommendation financial result committee medium presentation access secretary board committees code financial result committee review approve behalf company website board annual report form f annual dr barzach mr mcarthur mr mchenry retire board committee agm take place london formal notification send review convene annual general meeting board conclusion annual general meeting agm shareholder month advance meeting preliminary quarterly statement trade th follow retirement assume board establish number committee provide business presentation shareholder director able result director member committee director seek election reelection agm sufficient resource enable undertake duty attend available formally meet informally quorum meet member quorate elect reelect board comprise executive current membership committee give table question detail agm set meeting include chairman chairman audit director nonexecutive director majority pb eolfo bwoar committees indicate follow table section annual general meeting committee ceo cfo committee meet board exclude chairman independent nonexecutive director ggoh reinrag ebmooc hcazrab pluc sivad boj ruhtracm yrnehcm ressorp ztimhcs oripahs nosliw adamay necessary ensure nonexecutive director aware understand view major shareholder company sir christopher hogg nonexecutive chairman dr garni corporate responsibility committee board place process focus sector specific issue audit c chief executive officer ceo chairman lead board corporate administration corporate responsibility committee corporate general shareholder preference respect transaction represent board ceo cet member social responsibility committee consist entirely nonexecutive general perspective shareholder year nonexecutive corporate responsibility c necessary board meeting ceo manage group financial result director provide board level forum regular review director receive external review shareholder opinion implement strategy policy adopt board nomination c external issue potential impact present october board chairman chairmen board committees remuneration c group business reputation committee receive presentation lead financial analyst specialise communicate regularly ceo cet member key c chairman member responsible annual governance oversight group pharmaceutical sector division responsibilitie role chairman worldwide donation community support committee ceo cfo maintain dialogue institutional ceo set writing agree board meet formally twice year meeting follow summary role term reference shareholder performance plan objective appear company website sir ian prosser consultations require committee term reference committee programme regular meeting speak regularly appoint senior independent director effect obtain company secretary corporate external conference presentation st january sir roger hurn senior independent director corporate administration transaction committee governance section company website st january th june corporate administration transaction committee review group investor relation department office london approve matter connection administration philadelphia act focal point contact investor board process group business certain corporate transaction year board authority accountable shareholder committee consist director corporate executive team company website give access current financial ensure company appropriately manage member company secretary committee meet business information group achieve strategic objective agree board board necessary discharge responsibility supervise overall budgetary planning treasury planning business strategy glaxosmithkline corporate governance corporate governance glaxosmithkline share buyback programme biographical detail director give number risk area specific standard meet exceed legal intellectual property october follow completion billion share board requirement applicable law establish specialist product liability intellectual property antitrust litigation buyback programme announce company audit compliance group example corporate environment government investigation relate private litigation dr barzach mr mcarthur mr mchenry retire announce plan billion share buyback health safety worldwide regulatory compliance assist significant potential risk glaxosmithkline group board conclusion agm programme programme cover purchase company dissemination implementation audit standard involve legal administrative proceeding share cancellation hold treasury share area outcome proceeding predict reappointment auditor internal control framework rely risk oversight accordance authority give shareholder level certainty resolution propose reappoint compliance council rocc report cet company annual general meeting total million pricewaterhousecooper llp auditor authorise audit committee business unit risk potential risk party allege spend audit committee determine remuneration management compliance board rmcb help identify risk marketing group product infringe intellectual company authorise purchase provide guidance risk management compliance property right party maximum million share million share special business initiative corporate business unit level rocc million share purchase cancellation company seek renew authority chair corporate compliance officer cco meet finance note financial statement share capital share regularly review assess significant risk mitigation plan potential risk uncertainty surround group donation eu political organisation incur premium account exact time future direct risk rocc oversight ability forecast future meet financial target eu political expenditure purchase determine company dependent risk deem significant group rmcb oversee risk group invest new product venture base director authority disapply preemption right market condition factor important business function increase active assumption success prove inaccurate allot new share connection right issue management risk group corporate ethic potential risk group treasury maximum cent donation political organisation eu political compliance department cec responsible support operation include tax liability transfer pricing current issue share capital expenditure development implementation practice facilitate possibility trading loss counterparty fraud compliance obtain authority purchase ordinary share agm shareholder employee compliance law group policy cco evolve financial disclosure legal reporting maximum cent current issue authorise company donation eu political manage cec assist coordination risk requirement constitute risk include appropriateness share capital organisation incur eu political expenditure management activity compliance audit effectiveness control place support financial statement provision political party election referendum act function group report group pension liability represent area internal control framework year company potential risk discuss note financial detail risk affect group note intend donation political party statement employee cost board recognise responsibility present balanced financial statement legal proceeding risk factor normal meaning expression definition understandable assessment group position prospect page area potentially significant risk subject legislation eu political organisation extend body manufacturing structure accountability audit operate regular reporting rocc include follow include concerned policy review law reform maintain supply key glaxosmithkline product potentially glaxosmithkline follow representation business community special interest significant risk group policy reasonable measure human resource group concern environment board accountability review approve ensure uninterrupted supply product include legal requirement discrimination harassment company subsidiary wish support adequacy effectiveness internal control operate manufacturing accordance applicable law regulation integrity workforce include preemployment group donation noneu political organisation total company include financial operational compliance control corporate standard exceed screen control use contractor temporary donation eu political risk management board delegate responsibility requirement group take effort minimise single staff risk inherent group employee organisation review audit committee receive report source key product rationalise supply chain individual identify committee report balance manufacturing capacity present risk research development annual general meeting responsibility management cet potentially disrupt supply important product safety market product potentially significant risk implement board policy risk control cet matter great concern glaxosmithkline conduct agm hold pm monday th responsible identify approve enforce key policy information technology laboratory practice clinical practice trial rd queen elizabeth ii conference centre broad sanctuary heart group conduct business protect information technology asset increase risk accordance applicable law regulation westminster london swp ee business transact internal control framework include central direction resource business extend network system datum party corporate standard exceed requirement meeting include allocation risk management key activity research dependency internet communication increase pharmaceutical product bring benefit risk development manufacturing marketing sale legal ensure proper system validation electronic record include potential effect preclinical clinical trial receive adopt glaxosmithkline annual human resource information system financial practice signature key regulatory issue matter potential risk conduct development potential product report framework comprehensive planning group web system accessible public comply determine safety efficacy product use human system annual budget approve board result legal regulatory requirement represent potential follow approval regulatory body spite effort approve remuneration report operating unit report monthly compare risk potential risk include use personally identifiable drug introduce marketplace unanticipated remuneration report page set budget forecast prepare regularly year information electronic record retention outsource business effect evident group view use remuneration policy operate glaxosmithkline application susceptibility viruse outside incursion extensive financial control procedure selfassessment exercise animal human tissue testing require develop new disclosure director remuneration include require group business dependent electronic risk mitigation activity review group internal product risk company act director remuneration mean disaster recovery pose potential risk auditor commercial financial responsibility report regulation resolution propose clearly delegate local business unit support regional marketing sale approve remuneration report security environment safety management structure principle design provide group operate globally complex legal regulatory threat security group employee environment central leadership couple local operating environment vary jurisdiction group retirement election reelection director property environment present significant risk autonomy framework exercise accountability policy conduct marketing accordance applicable law mr lawrence culp mr crispin davis sir robert wilson appropriate safeguard precaution continually review control group regulation corporate standard dr tachi yamada appoint director upgrade employee injury ill health occupational exceed requirement failure observe applicable agm offer election board group attach importance clear principle condition plant management potential impact marketing code rule government pricing management procedure design achieve appropriate accountability plant environment potential risk group address sir christopher hogg retire offer reelection sample legal restriction sale marketing practice control corporate policy risk management legal process set target provide guidance board article company article create significant risk commercial sector compliance mandate business unit establish process result achieve association group failure comply result legal proceeding manage risk significant business group glaxosmithkline corporate governance corporate governance glaxosmithkline effectiveness control dr schmitz member executive board committee primary responsibility make committee meet session audit committee receive regular report area director deutsche bank ag retired board recommendation shareholder appointment quorate basis member present meeting significant risk group relate internal control charge investment banking dr schmitz reappointment removal external auditor annually follow consideration report committee report member executive board director assess qualification expertise resource independence remuneration report annually board effectiveness control basf include cfo external auditor effectiveness audit process remuneration report find page control mitigate eliminate risk addition hold mba insead sir peter job ceo reuters plc make assessment committee consider paper area group business necessary bring considerable industrial experience combine code detail relevant regulatory requirement require external risk achieve satisfactory return shareholder role member committee sir ian prosser auditor evaluate report external auditor investment acquire new product business cfo later ceo continent plc member company comply code provision state compliance requirement external case company objective apply expertise institute charter accountant england wale combine code follow auditor provide nonaudit services committee ensure prudent management elimination risk director sir robert wilson begin professional career economist auditor objectivity independence safeguard policy board appoint independent review relate company subsidiary hold senior management position rio tinto plc culminate require preapproval audit committee service nonexecutive director senior independent director extend material associate undertaking joint ventures appointment executive chairman expenditure audit nonaudit services set sir roger hurn senior independent director investment committee support company secretary st january th june remainder consider audit committee report effectiveness attend committee meeting available year nonexecutive director remain available guideline set company policy engage control board believe system internal control financial resource independent professional advice shareholder raise concern address external auditor provide nonaudit service include ascertain provide reasonable absolute assurance consider necessary meeting committee attend chairman ceo cfo december skill experience external auditor material misstatement loss process accord chairman ceo cfo general counsel head global following nominations committee review board suitable supplier nonaudit service adequate safeguard guidance internal control issue turnbull committee internal audit gia cco external auditor structure composition board announce place objectivity independence audit appointment sir ian prosser senior independent director committee work structured programme compromise fee level relative annual audit effect st january activity agenda matter focus coincide key event fee limit set committee criterion committee report annual financial reporting cycle stand govern compensation individual perform b scheme performance relate remuneration item committee require consider meet annual audit appropriate annual bonus benefit kind audit committee report pensionable pension contribution solely determine audit committee role flow directly board external auditor report committee critical company wellestablishe policy include code basis basic salary company position describe oversight function authorise board investigate accounting policy practice company ethic available website helpline facility remuneration report page activity term reference committee alternative accounting treatment discuss report investigation unlawful conduct write term reference approve management resultant conclusion external b notice contract period service contract committee meet session time board committee report regularly board auditor material write communication management year company position describe time quorate basis session attend performance activity assign restriction access information remuneration report page member committee main responsibility include review corporate cfo report financial performance company b compensation commitment event early account financial reporting process monitor technical financial accounting matter nomination committee report termination director contract company position integrity company financial statement evaluate nomination committee term reference include respect mr coombe previous contract describe system internal control management risk general counsel report material litigation responsibility propose appointment board remuneration report page oversee compliance law regulations ethical code company secretary report corporate governance committee member new nonexecutive practice committee oversight role require address company require comply combine director executive director appoint regularly relationship management internal head gia report effectiveness system code st january report compliance external auditor understand monitor report internal control step take improve company case nonexecutive director committee annual report issue regard relationship tier accountability party risk management framework consider particular skill knowledge experience measure describe implement benefit board significantly appointment committee entirely compose independent nonexecutive cco report activity undertake rocc annual report contain statement broad selection criterion focus achieve balance director sir christopher hogg resign member board operate decision take company secretary chairman disclosure representation uk markets committee effect st january sir robert delegated management manner committee report matter affect quality individual ceo experience skill develop wilson appoint place date performance board committee timely disclosure financial material information sector board engage professional search agency individual director evaluate committee member bring considerable financial accounting board public market shareholder specialise recruitment high calibre nonexecutive experience committee work member past enable committee review clarity completeness director dossier potential nonexecutive appointee board record division employment experience finance accounting role disclosure publish annual financial statement provide committee candidate shortlist responsibility chairman ceo comparable experience corporate activity interim report quarterly preliminary result interview consider relevant qualification new company determine independence announcement formal announcement relate nonexecutive director select appoint offer board determine combine qualification nonexecutive director state reason financial performance prior release board election company agm experience committee member take independence notwithstanding existence relationship appointment announce publicly modus operandi give committee collectively financial audit committee management internal audit circumstance likely affect appear expertise necessary discharge responsibility accordingly board work ensure quality company customise induction process conduct affect independence board choose nominate committee member corporate accounting financial reporting committee new nonexecutive director focus particular board appoint effect st january recent relevant financial experience serve primary link board external experience take account different background independent nonexecutive director senior internal auditor facilitate necessary independence process include meet key member cet arrive conclusion board consider follow independent director management encourage external internal key executive case visit particular point dr ronaldo schmitz chairman auditor communicate freely regularly committee operational facility group b c annual report contain committee april prior appointment committee meet collectively separately require statement work nomination nonexecutive director company nonexecutive committee recommend board consider external auditor head gia remuneration audit committee director glaxo wellcome plc serve audit appoint dr tachi yamada executive responsible committee pharmaceutical rd group executive director new director receive formal tailor dr yamada subsequently appoint board customise induction join board effect st january glaxosmithkline corporate governance glaxosmithkline remuneration report b c composition position hold accounting period end th april sarbane member remuneration audit oxley require company annual report contain report nomination committee comply combined state responsibility management establish code committee amend term maintain adequate internal control financial reporting reference comply requirement assess effectiveness company internal control combined code available shareholder financial reporting company require remuneration report set remuneration policy company website report compliance annual report management operate glaxosmithkline respect director undertake process ensure position c c c audit committee comply corporate executive team cet member report compliance date requirement review arrangement disclosure director remuneration include require staff company raise confidence concern sarbanesoxley introduce requirement ceo director remuneration report regulation impropriety matter financial report cfo complete formal certification confirm regulation accordance regulation follow monitor review effectiveness internal audit section remuneration report subject audit annual review annual report form f activity provision nonaudit service remuneration nonexecutive director remuneration share company external auditor contain material misstatement omission option incentive plan pension remain section subject audit page refer financial statement financial information fairly law regulation auditable section present material aspect financial condition result operation cash flow period cover report submit shareholder board approval number provision law regulation apply annual report annual general meeting reference chairmans glaxosmithkline company share quote letter notice annual general meeting send new york stock exchange nyse form adss responsible establish maintain disclosure shareholder control procedure ensure material information nyse rule known evaluate effectiveness remuneration report executive director nyse rules permit company follow home country uk control procedure yearend result cet member refer executive corporate governance practice instead apply evaluation contain annual report disclose reference glaxosmithkline share adss mean respectively usa provide company explain significant variation annual report change control ordinary share glaxosmithkline plc p american explanation provide company website reasonably likely material effect control depositary share glaxosmithkline plc ad represents disclose external auditor audit glaxosmithkline share sarbanesoxley act committee significant deficiency material weakness follow number corporate accounting scandal design operation internal control financial introduction usa congress pass sarbanesoxley act sarbane report fraud regardless materiality involve remuneration policy oxley sarbanesoxley establish new enhance standard person significant role company internal executive director term condition remuneration corporate accountability usa company control financial reporting nonexecutive director term condition fee corporate governance structure believe robust director senior management remuneration line good practice certain change necessary ensure indicate annual report annual remuneration compliance sarbanesoxley significant change internal control nonexecutive director remuneration financial reporting recommend security exchange commission director interest sec glaxosmithkline establish disclosure committee ceo cfo complete certification share option committee report ceo cfo audit file sec group form f incentive plans committee chair company secretary pension member consist senior manager finance legal evaluation disclosure control procedure director senior management compliance corporate communication investor relation group carry evaluation supervision director interest contract participation group management include external legal counsel external auditor invite ceo cfo effectiveness design operation attend meeting responsibility consider group disclosure control procedure inherent materiality information timely basis determine limitation effectiveness system disclosure control disclosure treatment information procedure include possibility human error responsibility timely filing report sec circumvention override control procedure formal review annual report form f accordingly effective disclosure control procedure committee meet time provide reasonable assurance achieve control sarbanesoxley require annual report contain objective base group evaluation ceo cfo statement member company audit conclude st december disclosure committee audit committee financial expert control procedure effective provide reasonable asurance information require disclose report board review qualification background group file submit securities exchange act member audit committee determine amend record process summarise member company audit committee audit report require committee financial expert combine qualification experience audit committee member take significant change internal control financial modus operandi audit committee report collectively financial expertise necessary discharge change group internal control responsibility explanation basis board financial reporting year materially affected judgement refer reasonably likely affect materially group internal control financial reporting glaxosmithkline remuneration report remuneration report glaxosmithkline remuneration report introduction committee meet time member remuneration policy pay performance comparator attend follow follow table set company pay remuneration committee committee responsible principle performance comparison make recommendation board company number meeting number meeting committee consider finding establish core market cap hold whilst attend remuneration policy term agree policy committee member committee member principle underpin new remuneration policy company country determine total individual remuneration package mr j mcarthur glaxosmithkline abbott laboratories usa executives chairman th june pay performance performance astrazeneca uk committee review develop mr p allaire robust transparent governance structure aventis france remuneration policy align executive remuneration chairman th june commitment leader good remuneration practice bristolmyers squibb usa interest shareholder whilst meet imperative recruit dr barzach pharmaceutical industry eli lilly usa retain executive talent essential leadership mr c davis glaxosmithkline uk company sir roger hurn formulate policy committee decide johnson johnson usa sir peter job remuneration structure support business merck usa remuneration policy set report finalise mr mchenry secure retain motivating key talent novartis switzerland undertake extensive consultation process shareholder pfizer usa competitive market place institutional body course quorate meeting hold effect formal grant roche holding switzerland uk shareholder guideline follow maximum year chairman glaxosmithkline chairman share option performance share award effect sanofisynthelabo france extent consistent need business committee meet shareholder represent nearly half committee decision scheringplough usa company maintain regular dialogue shareholder glaxosmithkline share capital ensure committee takeda chemical industry japan exception company secretary employee global pharmaceutical company primary pay obtain clear understanding shareholder expectation wyeth usa company involve conduct committee comparator group communicate competitive issue face company meeting dr garni ceo senior vice president human performance condition base measurable benchmarking committee derive considerable benefit resource invite attend meeting delivery strong financial performance delivery benchmarking purpose total remuneration incorporate base process consultation result instigate major shift committee require superior return shareholder compare salary annual bonus longterm incentive set pay way glaxosmithkline set remuneration pharmaceutical company tower perrin lead firm remuneration benefit committee regard executive pension senior executive high proportion total remuneration opportunity consultant provide strategic advice glaxosmithkline arrangement base performancerelate remuneration revise remuneration policy design establish general remuneration benefit planning provide deliver medium longterm global pharmaceutical industry continue framework remuneration consistent market datum tower perrin appoint committee remuneration determined project value primary pay comparator executive appropriate company scale scope operation meet separate mandate advise remuneration method explanation marketplace company senior executive talent recruitment need business closely align uk senior executive management remuneration structure executive director instance pay benchmarke publicly available shareholder guideline st december company cet particular performance condition apply remuneration datum company second large pharmaceutical company world independent review executive remuneration equally longterm incentive award revenue operation continent cover indicate remuneration report committee provide context information reference exgratia payment country cent sale generate appoint deloitte touche llp deloitte conduct tower perrin annual global pharmaceutical pay survey pay structure simple consistent usa comprehensive review remuneration executive pharmaceutical human resources association phra business need glaxosmithkline deloitte report exclusively committee ensure global pharmaceutical industry benchmark remuneration committee chairman company overall policy intend provide median total remuneration subject scrutiny review committee consider composition committee change year median performance poor performance result total pay datum global business primarily consumer deloitte provide consulting service glaxosmithkline early see departure mr allaire remuneration significantly pay comparator group manufacturing sector year provide advice executive sir roger hurn mr mcarthur appoint interim chairman median opportunity earn upper quartile total remuneration matter committee prior determine annual longterm incentive opportunity committee lead committee conduct remuneration exceptional performance committee consider range vest level policy review member committee deloitte review aspects remuneration policy strong alignment performance demonstrably achieve base different assumption share price dr barzach mr davis appoint st july sir peter job element remuneration performance measure interest shareholder provide executive growth performance level etc performance line appoint th june mr mchenry pende term condition executive contract review unambiguous signal importance deliver success expectation total remuneration target median embodiment higg report combine code include consideration relevant comparator company company shareholder comparator group longterm incentive opportunity set board deem members committee performance measurement pay benchmarking way provide position total remuneration independent nonexecutive director senior role commitment median consequence revise definition independence set deloitte independent review produce follow key finding committee apply policy consistent ensure stable benchmark develop reduce combined code dr barzach mr mchenry transparent basis significant change measure link pay performance need strengthen impact shortterm fluctuation incentive policy global retired committee st january implication assess performance discuss shareholder potential payment failure need address pharmaceutical company assess number year combine code set corporate use comparator pay benchmarke committee strong alignment uk good practice shareholder governance section use discretion ensure remuneration level reasonable guideline need valuation method believe change cause concern sir robert wilson mr culp appoint member global pharmaceutical company primary market project value method benchmark total shareholder position discuss shareholder committee st january mr mcarthur retire talent remuneration method project future value prior implementation board conclusion annual general meeting longterm incentive opportunity uncompetitive remuneration package different performance scenario th role chairman committee represent major change method hitherto apply assume sir robert wilson date pay comparison base solely estimate present value mathematical model committee believe new approach moderate impact market fluctuation short term greatly strengthen focus performance glaxosmithkline remuneration report remuneration report glaxosmithkline individual element remuneration longterm incentive tsr measure sterling performance period setting eps target committee consider balance fix base salary variable annual executive eligible performance share award share change value share value company internal projection analyst forecast bonus longterm incentive element remuneration change option remuneration policy provide annual longterm reinveste dividend pay order remove impact glaxosmithkline eps performance analyst forecast performance chart show normal range incentive award normally performance share vary tax treatment dividend different jurisdiction pharmaceutical industry variability ceo dr garnier cfo mr coombe award share option award new remuneration policy dividend reinveste gross committee agree follow key principle govern increase emphasis use performance share glaxosmithkline rank median performance use eps performance measure ceo cfo committee consider performance share provide comparator group cent share vest adjustment consider major item strong alignment shareholder value new glaxosmithkline company adjustment judgement committee remuneration policy increase emphasis use share vest determine vest level committee purpose adjustment ensure performance share longterm incentive award determine regard company underlie financial performance performance measurement fair reasonable target performance half participant shareholder base salary annual bonus longterm incentive longterm incentive reward derive performance share tsr rank company percentage discretion exercise committee disclose glaxosmithkline award vest grant annual award plan consistent shareholder annual report base salary practice pay comparator group leading committee set basis decision consider base salary set reference median relevant uk company longterm incentive cet appropriate adjustment market executive pharmaceutical pay comparator basis executive director group actual salary level review annually vary departure previous policy share option grant cet prior share option grant executive depend executive experience responsibility market member subject performance condition director subject performanc e condition order value change usually effect st april increase apply share option grant executive director option vest business formance eps growth arise independent review provide close alignment uk good practice represent exclude currency exceptional ite ms average major step change global pharmaceutical pay practice median percentage point annum increase annual bonus typically apply performance condition median uk retail price index threeyear performance bonus determine basis formal review vest option period tsr measure prorata basis glaxosmithkline annual performance stretch financial target base review process committee consider performance fall comparator level vest grant vest increase straight line basis business performance profit interest tax subject performance condition apply longterm determine actual relative level tsr simple eps performance hurdle set table detailed assessment individual business unit group incentive committee conclude appropriate ranking achievement objective bonus payable financial annualise percentage measure performance combination absolute financial performance cent target performance provide close link shareholder return payment growth ep award vest result base earning share ep delivery bonus subject upper limit executives superior value shareholder base total shareholder executive notional dividend reinveste rpi ceo range cent cent return tsr pay proportion vest award receipt rpi base salary ceo limit cent dividend incorporate benchmarke rpi annual bonus pay basis target business committee conclude eps key measure award level addition performance share earn rpi performance business fully reflect executive sell meet relate tax performance base salary provide annual cash business measure extend group ensure liability year follow end vest performance condition substantially consistent uk line median pay comparator group organisational alignment period committee believe align interest shareholder guideline expectation considerably case ceo bonus target set executive longterm interest shareholder demand operate global comparative performance previously measure reference committee follow end financial year committee pharmaceutical company change consistent ftse committee conclude prior performance share award part half review ceos performance determine bonus payable new policy provide pay performance measurement performance performance comparator earn reference glaxosmithkline tsr ceo make recommendation committee performance group pharmaceutical company provide performance compare ftse company performance level achieve objective well assessment company performance tsr choose constituent half award deliverable executive onwards performance executive recommendation consider appropriate comparative measure focus company business performance ep growth exclude measure financial year follow grant committee determine resultant bonus return shareholder understand test currency exceptional item average option committee decide grant executive choose invest bonus glaxosmithkline mechanism measure performance allow comparison percentage point annum increase uk performance condition meet year share minimum year annual investment company operate different country retail price index threeyear performance period period performance measure financial plan end threeyear hold period executive year follow date grant option extent performance share award share option deliver pre awards glaxosmithkline deliver return entitle matching award cent defer option performance condition met end resident executive form adss award deliver rank ftse base tsr shareholding match subject performance year option lapse form ordinary share executive resident uk performance share award condition plan open approximately senior country award plan vest th position ftse cent committee consider remeasurement important executive term committee believe incorporate dilution limit consistent guideline provide share vest glaxosmithkline rank th position feature grant light imposition arrangement encourage shareholde senior executive association british insurers national association share subject award vest performance condition industry major consider appropriate executive participate pension fund shareholder representative body th th position vest occur competitor apply option committee term current estimate dilution exist award slide scale consider prior annual grant option bonus award reflect committee belief merger approximately cent company share remeasurement permit company produce superior result year take capital st december b share option account factor outside control management notably pension share option allow holder buy share future date exchange rate change launch generic competition performance share executive participate glaxosmithkline senior executive share price prevail time grant share option paxil usa pension plan pension arrangement structure executive level performance share vest grant manager glaxosmithkline accordance plan operate executive country base company tsr relative performance include executive share option grant executive likely retire benefit normally comparator group threeyear measurement period executive link achievement compound annual payable age detail individual arrangement ep growth performance period executive director set glaxosmithkline remuneration report remuneration report glaxosmithkline share ownership requirement key aspect new contractual framework dr garni leave prior age receive align interest executive shareholder provision apply option subject contractually entitle aspect policy executive require maintain significant holding share performance testing circumstance option accordingly severance payment dr garni glaxosmithkline requirement important notice period calendar month performance share award month prior termination company cause resignation align interest executive shareholder ceo termination termination notice date lapse executive include year worth pension require hold share value time base salary employ company contribution mr coombe remain entitled termination cash equivalent executive director require build shareholding executive month benefit continue medical dental committee view balance new pension value time base salary member cet termination payment x annual salary insurance arrangement contractual entitlement previous require build shareholding value time base x annual target bonus contract aim provide fair replacement previous salary requirement build shareholding value nom itigation require addition dr garnier mr coombe entitle receive arrangement time base salary apply executive year worth pension contribution termination benefit govern benefit policy group result policy review executive new arrangement come effect st january include dr garniers mr coombe contract execute required continue satisfy shareholding requirement likely effect final accrue benefit rd march effect st january minimum month follow retirement healthcare medical dental transfer value dr garniers pension dr garni dr garniers contract expire st october company personal financial advice entitlement spouse pension pension increase mr coombe st march day life assurance contribution reduce initial pension order share qualify share ownership month reach th birthday vest longterm rule relevant equity incentive requirement hold personally executive mr coombe participate glaxo wellcome define benefit incentive plan termination payment respect earn defer share plan retirement age entitle receive annual notice period extend contract expiry date programme operate company unexercised share option pension base exist arrangement pension rds final salary rd widow pension include calculation st december term relevant pension plan dr yamadas appointment board pende finalisation inflation proof benefit accrue glaxo dr garnier shareholde adss mr coombe noncompete clause month termination new contract previous contractual arrangement wellcome uk pension arrangement augment share appointment board notice date supersede letter set principal term trustee plan cent reflect distribution st january dr yamada hold adss holding appointment available inspection term surplus augmentation apply element excess share ownership requirement date drga rnier target bonus cent salary mr coombe cent letter expire early execution new contract mr coombes pension earning st march salary termination month notice dr yamadas contract company terminate employment prior retirement remuneration element imposition month noncompete period executive consider available inspection shareholder final mr coombe entitle receive pension calculate vitally important company order protect group intellectual executive participate legacy glaxo wellcome detail confirm employ month age soon property light noncompete clause competitor practice smithkline beecham employee share plan uk committee believe appropriate provide mitigation usa glaxosmithkline plan replace contract review level severance payment committee pension entitlement consider investor dti guidance determined line uk plan provide pension base twothird final addition contractual provision outline sharesave plan sharereward plan inland revenue competitive practice appropriate provide payment salary salary age cash balance plan provide annual event dr garni mr coombe service agreement approve plan open uk employee term target bonus termination mr coombe previous contract specify compensation pay event redundancy event notice contribution interest sum accumulate cash terminate employ company entitled mr coombe member sharesave plan termination give case redundancy mr coombe balance plan contractual promise provide specific contribute month provide option require mitigate result loss earning special defer bonus award member level retirement income buy share end threeyear saving period line cet respect payable th february asap prove shareholder glaxosmithkline glaxo wellcome smithkline opportunity available uk employee mr coombe beecham appropriate glaxosmithkline make annual contribution cent terminate cause prior date detail contribute month buy share share reward dr garniers annual salary bonus fund increase bonus give plan company match number share buy dr garni mr coombe agree change interest rate base yield year treasury bond case awards glaxosmithkline annual month contractual term compensation come broadly line company liability make annual investment plan provide agreement terminate new contractual framework include reduction contribution executive receive benefit include healthcare cause defer income contractual notice period calendar month medical dental personal financial advice life assurance prior employee include dr garni move gain loss automatically distribute soon order honour certain aspect old contribution cash value benefit receive final salary pension arrangement current cash administratively practicable termination resign contractual term number individual feature executive director show balance structure employee cash balance plan retire termination cause defer retain contribution base combined annual salary annual distribute end minimum executive director term condition remuneration dr garnier case include entitlement bonus year deferral period reimbursement excise tax change control relate remuneration review dr garnier pension provision line policy applicable senior executive executive director contract payment life insurance benefit fund company age simplify remove entitlement receive dr garnier entitle receive continue medical dental policy executive director contract follow provision relate vest longterm year worth additional pension contribution termination insurance subject extensive review change new incentive remove entitlement receive payment policy provide framework contract executive director follow merger participant legacy share pre awards company enable dr garni purchase annuity appoint future option scheme elect exchange legacy option termination company cause treat year old new pension option glaxosmithkline share receive retirement resignation good reason ie resignation arrangement provide simple annual contribution additional cash benefit equal cent grant price elect retain director cent annual salary annual bonus original option additional benefit trigger company merge company result change pension contribution vary performance new option exercise lapse qualify control provide resignation occur new annual contribution rate represent additional cash benefit participant retain option day anniversary change control option enhancement dr garniers pension entitlement design second anniversary effective date vest remain exercisable option term consolidate previous additional contractual term single merger performance share vest end performance annual contribution rate new annual contribution percentage period subject performance timeapportione ensure long dr garnier continue employment age financial position prior consolidation contractual pension entitlement glaxosmithkline remuneration report remuneration report glaxosmithkline result remuneration review number change mr allaire receive fee annum tsr performance graph contract cet member allocation american depositary share follow graph set performance company compensate agree change nonexecutive director share arrangement relative ftse index company amendment relate follow aspect constituent performance comparator group dr michle barzach sir peter job mr john mcarthur mr merger th december graph prepare termination company poor performance donald mchenry sir ian prosser dr ronaldo schmitz accordance regulation indication notice period relate severance payment reduce dr lucy shapiro likely vest award grant company month letter appointment nonexecutive incentive plan entitlement postnotice longterm incentive grant director date th june case agree removed serve company nonexecutive director conclusion annual general meeting agm follow termination company performance share awards anniversary appointment case sir peter job month prior termination notice date lapse sir ian prosser dr schmitz dr shapiro appointment new cet member standard contractual term extend term year mutual outlined executive director apply agreement dr barzach mr mcarthur mr mchenry announce retire board conclusion nonexecutive director term condition fee agm th glaxosmithkline total return ftse total return index mr mcarthur succeed mr allaire chairman nonexecutive director glaxosmithkline service glaxosmithkline performance comparator group remuneration committee th june fee contract instead letter appointment company increase annum date mr mchenry aim provide nonexecutive director fee director senior management remuneration succeed sir christopher chairman corporate social competitive company equivalent size follow table set director glaxosmithkline responsibility committee corporate responsibility complexity nonexecutive director entitle plc remuneration earn interest share committee th february fee increase compensation appointment terminate glaxosmithkline plc interest share option incentive annum date sir ian prosser succeed plan pension benefit member cet enhance link directors shareholders sir christopher chairman nominations committee company secretary know senior management set table glaxosmithkline require nonexecutive th february sir ian step chairman participate remuneration plan executive director receive significant fee form nomination committee effect st january director aggregate remuneration interest share allocate share account offer opportunity succeed sir christopher directors senior management provide invest balance fee share account share pay director retirement fee payable share allocation nonexecutive board later date pay basis dividend director share arrangement director reinveste interim follow chairman chairmen board committee receive nonexecutive annual share allocate director fee annually high fee dr barzach ordinary share sir peter job ordinary share term condition mr j mcarthur adss mr mchenry ads sir christopher hogg sir ian prosser ordinary share sir christopher hoggs letter appointment board dr r schmitz ordinary share date th june agree serve dr l shapiro adss company nonexecutive director conclusion annual general meeting follow anniversary appointment extend term mr h lawrence culp mr crispin davis sir robert wilson years mutual agreement letter appointment nonexecutive director date th june case agree sir christophers letter appointment amend serve company nonexecutive director st september record appointment nonexecutive conclusion annual general meeting follow chairman effect th receive anniversary appointment case annum plus allocation share annum extend term year mutual agreement mr culp mr davis join board st july sir roger hurn mr paul allaire sir robert joined board effect st november sir roger hurn retire deputy chairman nonexecutive fee payable share allocation nonexecutive director mr allaire retire nonexecutive director director share arrangement director effect th june sir rogers mr allaire letter follow appointment date th june case nonexecutive annual share allocate agree serve company nonexecutive director fee annually director conclusion annual general meeting mr l culp adss follow anniversary appointment case mr c davis ordinary share extended term year sir robert wilson ordinary share mutual agreement sir roger receive fee annum allocation ordinary share nonexecutive director share arrangement glaxosmithkline remuneration report remuneration report glaxosmithkline annual remuneration nonexecutive director remuneration total cash allocate elect total cash allocate elect total total fee salary fee annual annual fee annual annual salary benefit bonus remuneration salary benefit bonus remuneration footnote current nonexecutive director sir christopher hogg executive director dr barzach dr j p garnier abc mr l culp mr j coombe bc mr c davis total sir peter job mr j h mcarthur current nonexecutive director mr f mchenry sir christopher hogg sir ian prosser dr barzach e dr r schmitz mr l culp dr l shapiro mr c davis sir robert wilson sir peter job mr j h mcarthur nonexecutive director mr f mchenry sir richard syke sir ian prosser sir roger hurn dr r schmitz sir peter walters dr l shapiro f mr p allaire sir robert wilson mr j young total nonexecutive director table set remuneration receive nonexecutive director glaxosmithkline accordingly include sir richard syke ad dr barzachs fee receive glaxosmithkline france healthcare consultancy provide dr shapiros fee receive member sir roger hurn glaxosmithkline scientific advisory board sir peter walters mr p allaire nonexecutive director require receive fee form share adss balance receive cash mr c bonham elect receive cash payment form share adss total value share mr j young adss date award cash payment form total fee include annual remuneration table fee salary table set value fee receive form cash share adss total nonexecutive director share adss notionally award nonexecutive director allocate interest account include total remuneration director interest table accumulate balance share adss notional dividend subsequently reinveste pay nonexecutive director retirement retirement nonexecutive director follow merger participant legacy share option scheme elect exchange legacy option option receive share adss cash equal value share adss date retirement glaxosmithkline share grant additional cash benefit equal cent grant price original option additional benefit know exchange offer incentive eoi payable new option exercise lapse market value qualify additional table set accumulate number share adss hold nonexecutive director st december cash benefit participant retain option second anniversary effective date merger year dr garnier movement account year receive relate option exercise sir richard syke receive result option lapse market value amount include benefit table number share adss dividend b dr garni nonexecutive director united technologies corporation respect dr garni receive form defer nonexecutive director share arrangement allocate elect reinveste pay stock unit stock option grant price mr coombe member supervisory board siemens ag respect mr coombe receive stock appreciation right grant price amount exclude table current nonexecutive director retain executive director sir christopher hogg c dr garnier mr coombe receive special defer bonus award member cet award equivalent dr barzach salary st december notionally invest glaxosmithkline share adss th february bonus pay mr l culp adss th february equivalent value share adss notionally acquire february plus dividend reinveste mr c davis period st december value share adss notionally acquire respect dr garni increase sir peter job cent year include dividend reinveste year share notionally acquire respect mr coombe mr j h mcarthur adss value st december increase cent year include dividend reinveste year mr f mchenry adss addition remuneration receive director set sir richard syke receive relate appointment senior sir ian prosser advisor st june dr r schmitz dr l shapiro shares e dr barzach receive fee subsidiary company healthcare consultancy provide include adss fee salary sir robert wilson f dr shapiro member glaxosmithkline scientific advisory board receive fee form adss include fee salary nonexecutive director sir roger hurn director receive remuneration currency sterle average rate exchange year mr p allaire adss director receive expense year require separate disclosure require regulation mr j young share adss glaxosmithkline remuneration report remuneration report glaxosmithkline th june sir roger hurn mr allaire retired board follow retirement receive value share share option adss award nonexecutive director share arrangement equivalent smithkline beecham arrangement grant th june award share adss total value date award indicate sir roger hurn weight average mr allaire th june value share adss sir roger hurn option adss date grant grant price number exercise mr allaire change value attributable dividend reinveste change share price date awards dr j p garnier th june sir roger elect receive value share th june quarterly instalment year accordingly receive mr allaire elect receive adss retirement mr young elect grant receive value share th annual instalment accordingly receive weighted average option share date grant grant price number lapse director interest mr j coombe follow beneficial interest director company show register maintain company accordance company act option outstanding st december early late vesting lapse date market price glaxosmithkline share year end give table share adss th february st december st december th february st december st december vest date lapse date footnote weight average dr j p garni grant price number early latest early late dr j p garni market price underwater year end vest option mr j coombe ab unvested option sir christopher hogg dr barzach mr l culp market price year end vest option mr c davis unvested option sir peter job mr j h mcarthur total ad option st december mr f mchenry cd sir ian prosser vest date lapse date dr r schmitz weight average dr l shapiro mr j coombe grant price number early latest early late sir robert wilson market price underwater year end vest option unvested option glaxosmithkline ad represent glaxosmithkline share include share purchase glaxosmithkline sharereward plan totalling share st december share market price year end unvested option th february total share option st december b include nonbeneficial interest trust hold nil share st december nil share th february c addition interest show mr mchenry interest defer fee plan relate period mr mchenry director glaxosmithkline grants share option executive director senior manager annual basis generally november initial smithkline beckman prior merger beecham group defer fee index total return glaxosmithkline grant follow completion merger march measurement period option grant march share payable seven year follow mr mchenrys retirement nonexecutive director glaxosmithkline total accumulate value commence st january measurement period option grant november commence defer fee st december restate reflect merger fully provide equivalent glaxosmithkline adss st january respectively director hold option share option plan refer include share adss receive fee describe nonexecutive director share arrangement dividend receive note financial statement employee share scheme director interest option share adss convert share adss st december include director interest company share interest abovementione director th february reflect change end financial year date follow merger director elect exchange outstanding option legacy share option plan option glaxosmithkline share director participant legacy scheme election receive additional benefit cash sum equal cent grant price original option additional benefit give new option exercise lapse provide exercise lapse second anniversary effective date merger case sir richard syke cessation executive employment early grant market option exercise date number price price gain gain dr j p garni average exchange rate year gain dr garni amount th february dr garnier exercise option exercise price give rise gain dr garnier receive respect exchange offer incentive benefit arise exercise option mr coombe exercise share option highest low closing price year end st december glaxosmithkline share respectively high low price glaxosmithkline adss year end st december respectively market price glaxosmithkline share st december st december glaxosmithkline ad st december share price th february glaxosmithkline share glaxosmithkline ad glaxosmithkline remuneration report remuneration report glaxosmithkline incentive plan pension grant accrue annual pension benefit transfer value executive director retirement set adss market adss performance share plan adss number price regulation require disclosure accrue benefit end year change accrue benefit year transfer dr j p garni award value begin end year change transfer value year listing rule require additional award disclosure change accrue benefit net inflation transfer value change award change award change change accrue transfer value accrue accrue accrue transfer transfer year benefit change benefit benefit benefit value value transfer year net accrue grant year value inflation benefit share market share pa pa pa pa performance share plan share number price dr j p garnier mr j coombe award mr j coombe award change transfer value show net contribution individual award award dr garni member employee cash balance pension plan glaxosmithkline make annual contribution calculate percentage employee base salary bonus fund increase interest rate set annually advance base performance share plan psp mediumterm incentive scheme introduce psp replace longterm incentive year treasury bond rate provide cash sum retirement cash sum purchase pension retirement base plan midterm incentive plan operate respectively glaxo wellcome smithkline beecham annuity rate applicable time dr garni entitlement spouse pension pension increase reduce term psp number share actually vest determined follow end relevant year measurement initial pension period dependent glaxosmithkline performance period describe page share awards normal retirement age plan year age dr garnier pension arrangement buy line term grant annually november december measurement period commence follow st january end year service agreement assume retirement age reduce effect reduce dr garniers accrue benefit annum annum exclude effect inflation cash balance available dr garnier plan st december year measurement period award end st december base performance require purchase annuity year previously assume glaxosmithkline period cent award vest february share exercise transfer value cash sum dr garnier plan increase year result phase transfer froma market average money previous scheme accumulation interest contribution pay company cent base salary plus bonus price market price value share award exercise exercise dr garniers accrue benefit transfer value translate yearend exchange rate longterm incentive plan share number change accrue benefit transfer value translate average exchange rate mr j coombe accordingly change accrue benefit transfer value state exclude exchange loss follow change accrue benefit year change accrue benefit year net inflation change year transfer value longterm incentive plan ltip share award scheme operate glaxo wellcome plan close new entrant completion merger grant award mr coombe february vested february dr garnier member retirement saving plan money purchase scheme open employee contribution completion measurement period connection merger performance condition respect grant invest range fund value accumulate fund pay retirement contribution february waive pay scheme company respect dr garni invest glaxosmithkline share stock ownership account share hold account include director interest table vest vest unvested participation unvested deferred participation dividend defer mr coombe transfer value calculate basis actuarial advice accordance actuarial guidance note gnthe participation vest participation participation vest reinveste participation midterm incentive plan adss transfer value represent present value future payment pension plan whilst mr coombes annual accrue dr j p garni benefit increase exclude effect inflation transfer value increase million year increase arise primarily result follow factor midterm incentive plan mtip share award scheme operate smithkline beecham plan close new entrant completion merger participation grant connection merger performance condition method calculate transfer value review follow completion formal valuation pension scheme respect grant waive measurement period end st december ensure assumption continue reasonable follow st december valuation assumption update include increase allowance life expectancy member retirement lead increase transfer participation vest award dr garnier th november ad price ad value pension fund member assumption continue review follow valuation adjust price time vest final award adss receipt award defer director appropriate dr garnier defer receipt amount award deferred award additional adss subsequently receive dividend reinvestment include director interest table annual increase transfer value large close individual retirement term mr coombes service technically retain mtip pay agreement retire age mr coombe approach retirement transfer value pension increase average reflect level fund require meet annual accrue benefit payment stock appreciation right sar adss grant price yield gilt underlie asset link decline lead increase market value dr l shapiro gilts require meet annual accrue benefit sar hold dr l shapiro grant price market price glaxosmithkline ad year end dr shapiro member glaxosmithkline scientific advisory board sab dr shapiro member smithkline beecham sab completion merger glaxo wellcome member sab receive annual grant smithkline beecham sars general vest year date grant expire year date grant grant sars sab member cease sar entitle holder cash sum future date base share price growth date grant date exercise provision financial statement accrue gain sar date grant connection merger previously grant sar immediately exercisable glaxosmithkline remuneration report glaxosmithkline operate financial review prospect director senior management operate financial review prospect discuss report purpose necessary provide information compensation interest director senior management operate financial performance group financial group group purpose disclosure group define director members cet company outlook financial resource group secretary respect financial year total compensation pay member group period follow heading serve capacity aggregate decrease accrue pension benefit aggregate payment financial trend ratio define contribution scheme member group grant option share adss award share adss performance share plan th february year result year st december compare thencurrent member group comprise person own share adss constitute cent year st december issue share capital company group hold date option purchase share financial position resource st december adss share adss award performance share plan include share adss vest deferred share adss legacy smithkline beecham midterm incentive plan include outlook risk factor share adss vest defer adss award legacy smithkline beecham stock appreciation right additionally accordance requirement holding issue executive share option plan described note financial statement employee share scheme year result year st december compare year st december directors interest contract select financial datum ukus gaap describe note financial statement relate party transaction end financial year result year compare primarily result director connect person material interest contract significance relation group business group precede year reference quarterly company halfyearly trend result appropriate director remuneration report approve board director sign behalf exchange group multinational business operate country earn revenue incur cost currency result group report sterling affect movement exchange rate sterle overseas currency sir christopher hogg group use average exchange rate prevail chairman period translate result cash flow overseas group rd march subsidiary associate undertaking joint venture sterling period end rate translate net asset undertaking currency influence translation dollar euro japanese yen average sterling exchange rate strong dollar japanese yen cent cent respectively weak euro cent compare give overall adverse currency impact result year business performance constant exchange rate business performance primary performance measure management present exclude merger item integration restructuring cost disposal business management believe exclusion item provide well reflection way business manage give indication performance group term element revenue expenditure local management able influence information provide addition statutory result prepare uk gaap appear page give assist shareholder gain clear understanding underlying performance business increase comparability period present order illustrate underlying performance group practice discuss result term constant exchange rate cer growth represent growth calculate exchange rate determine result overseas company sterling remain unchanged previous year cer represent growth constant exchange rate represent growth actual exchange rate glaxosmithkline operate financial review prospect operate financial review prospect glaxosmithkline financial trend ratio year statutory result growth growth world economy world market pharmaceutical cer cer fear terrorism sar war iraq include global pharmaceutical sale increase cent turnover pharmaceutical uncertainty war aftermath hold headline billion consumer healthcare rise unemployment number major world economy total collapse world trade organisation talk mexico world market value growth little underpin fragile global economic situation geographic region bn total cer cost sale optimism recovery global economy settle usa sell general administration economic climate emerge year europe research development remain little confidence significant improvement germany trading profit long term france uk profit taxation usa dominate area recovery vigorous italy earning resilient economic performance particularly consumer japan basic earning share penny p p p sector growth rate cent achieve despite asia pacific concern grow budget deficit possible impact latin america merger restructure disposal subsidiarie interest rate taxis middle east africa cost sale uk growth stronger expect canada sell general administration subdue cent effect increase uk total research development interest rate year autumn follow trading profit increase february lead prediction uk rate market buoyant maintain increase month double digit growth represent cent global profit taxation prescription pharmaceutical market compare cent earning euro zone germany economy continue weak decade ago growth country france italy improve business performance result improvement welcome general th september glaxosmithkline hold second position turnover agreement indicate longterm trend world pharmaceutical market market share cost sale european central bank express confidence zone cent pfizer market share cent sell general administration economic situation maintain interest rate glaxosmithkline seven product world research development cent middle year impact accession pharmaceutical products augmentin avandia new country european union likely imigranimitrex seretideadvair seroxatpaxil wellbutrin trading profit subsequent change labour force slow future economic zofran growth europe profit taxation world market value growth adjust earning end year industrialise nation follow therapeutic class bn total cer adjust earning share penny p p p usa reporting sign recovery china growth healthy cardiovascular cent projection cautious research development statutory central nervous system seven cent japans economy show slow alimentary tract metabolic pharmaceutical expect growth reflect continued weakness business antiinfective bacterial consumer healthcare investment despite optimism strong growth viral fungal exclude vaccine total alongside sign slow recovery global economy respiratory share price index improve halt threeyear decline interest indicate reduce risk recession deflation note datum base month th september net interest payable momentum achieve stage year pharmaceutical turnover interest cover time time time particularly economies asia usa uk growth rate include review turnover constant indicate renew strength world economy interest cover calculate statutory profit interest divide net interest payable exchange rate cer state sterling growth likely lead usa follow albeit steeply rate find table pharmaceutical turnover tax rate slowly europe therapeutic area geographic region business performance statutory result exchange total pharmaceutical turnover million currency influence group result borrowing compare million increase dollar euro japanese yen net debt cent approximately cent overall growth came gear pound hit high level dollar price increase remainder volume growth growth year climb yearend euro gain sterling term cent significantly impact gearing ratio calculate net debt percentage shareholder fund net debt minority interest cent dollar year dollar weakness dollar currency fall value euro investor weigh group portfolio turnover new product launch impact continue unrest iraq tension world major market year account concern economy cent total turnover grow cent million turnover establish franchise product amount million represent cent total turnover grow cent compare year turnover old product actively promote million decline cent represent cent total turnover glaxosmithkline operate financial review prospect operate financial review prospect glaxosmithkline global pharmaceutical turnover fourth quarter respiratory pharmaceutical turnover therapeutic area decline cent reflect turnover decline glaxosmithkline continue global leader respiratory total usa europe international cent million europe turnover grow pharmaceutical sale key product cent million international turnover seretideadvair flixotideflovent serevent amount therapeutic area growth growth growth growth major product total cer cer cer cer grow cent million turnover decline billion cent sale seretideadvair group generic competition paxil begin september large product grow cent billion cns depression contribute decline serevent flixotide constituent seroxatpaxil product seretideadvair pharmaceutical wellbutrin pharmaceutical turnover therapeutic area brand world usa sale grow cent million migraine glaxosmithkline ability continue deliver pharmaceutical imigranimitrex turnover growth despite generic competition seretide continue perform strongly europe naramigamerge product primarily exceptionally broad product cent international market cent lamictal portfolio fastgrowe highvalue product growth prospect advair strengthened requip fda approval use treatment chronic obstructive zyban include respiratory product seretideadvair billion pulmonary disease copd fourth quarter cent diabete treatment avandiaavandamet respiratory billion cent wellbutrin depression old respiratory product ventolin becotide continue flixotideflovent serevent seretideadvair billion cent emesis treatment zofran decline patient convert new product seretideadvair billion cent lamictal epilepsy billion flixotideflovent cent trizivir hiv billion cent antiviral serevent valtrex herpe billion cent coreg heart hiv medicine grow region total billion flixonaseflonase ventolin disease billion cent pediatric vaccine sale cent sale trizivir glaxosmithkline triple becotide infanrixpediarix billion cent combination therapy grow cent million lexiva hiv launch december initial sale antiviral central nervous system cns million hiv trizivir cns sale grow cent million sale global sale valtrex receive fda approval august combivir europe grow cent international sale grow reduce risk transmission genital herpe rise epivir cent retrovir cent million ziagen sale seroxatpaxil glaxosmithkline lead product agenerase depression anxiety disorder decline cent antibacterial herpe million sale decline cent million antibacterial sale decline cent worldwide valtrex follow launch generic paroxetine september cent usa augmentin sale zovirax january glaxosmithkline innovative new product paxil cent year result generic competition cr increase share total paxil prescription brand begin quarter zeffix generic generic launch cent cent usa glaxosmithkline new antibiotic augmentin es antibacterial paxil cr sale million europe paxil sale child augmentin xr adult record combine augmentin decline cent million reflect competition zinnatceftin sale million spite generic competition pricing pressure international sale grow cent fortum million lead continue strong growth japan amoxil metabolic sale wellbutrin depression grow cent worldwide sale metabolic category billion metabolic avandiaavandamet million reflect increase physician awareness cent avandia franchise avandia avandamet product outstanding efficacy favourable sideeffect profile grow cent year sale cent vaccine new oncedaily formulation wellbutrin xl launch million hepatitis september formulation account cent infanrix avandamet combination avandia metformin hci brand wellbutrin prescription early february expand avandia metabolic franchise launch oncology emesis seven cent sale fourth quarter europe avandia benefit zofran hycamtin limited generic competition wellbutrin begin usa increase physician acceptance sale million january mg dose generic competition cent franchise benefit eu cardiovascular dose form wellbutrin sr expect time approval avandamet december avandia urogenital coreg glaxosmithkline medicine epilepsy lamictal continue international market sale million levitra cent avodart grow region achieve sale million cent june fda approve lamictal long vaccine term maintenance treatment bipolar disorder sale vaccine grow cent billion support zantac infanrixpediarix franchise cent million hepatitis franchise decline cent million reflect competitive pressure usa europe usa glaxosmithklines new pediarix vaccine launch cer represent turnover growth constant exchange rate represent growth actual exchange rate analysis turnover quarter give financial record page january pediarix add protection hepatitis b poliomyelitis infanrix combination result few injection infant glaxosmithkline operate financial review prospect operate financial review prospect glaxosmithkline cardiovascular urogenital result management believe european region usa international coreg sale grow cent million benefit turnover market invoice basis present usa report cent turnover growth year cent turnover growth international region recent datum show highly significant statistical properly represent consumption product business represent cent total pharmaceutical reflect mixture good growth middle east africa difference survival coreg metopropol patient market glaxosmithkline staff base market turnover canada japan asia pacific latin america grow strongly heart failure instrumental promotion group product mexico rebound follow poor economic condition advair maintain strong growth sale million market create product sale final consumption realignment wholesaler stock level levitra vardenafil new agent treatment erectile drive overall respiratory growth cent market table give adjustment order dysfunction launch usa august adversely affect sale constituent product flovent overall international growth drive seretide seroxatpaxil restate turnover market europe turnover europe half year levitra research serevent show decline flonase indicate avandia partly offset decline zantac zovirax create basis adjustment glaxosmithkline estimate develop bayer ag copromote glaxosmithkline treatment perennial rhinitis grow strongly cent base recent datum independent external source asia pacific area grow performance seretide value sterle relevant exchange rate management believe sale growth cent central nervous system avandia strong growth number market partly oncology emesis turnover create basis report turnover market product include sale wellbutrin cent reflect offset decline cent large market australia sale zofran grow cent million drive provide well reflection performance business performance new day formulation wellbutrin xl reflect reduced sale zyban zantac old antibiotic strong performance cent million market europe paxil sale decline cent launch generic growth japan reflect strong growth paxil serevent paroxetine september january glaxosmithkline therapeutic area total turnover europe region unaffected valtrex partly offset decline zovirax zantac innovative new product paxil cr increase share total paxil sale zantac fall cent million decline restatement government price reduction prescription brand generic generic launch region parallel trade occur occasionally world cent cent paxil cr sales middle east africa area follow trend sufficiently material affect significantly turnover datum million market growth seretide avandia vaccine regional analysis market present invoice basis canada growth drive seretide avandia sale antiviral therapeutic area grow cent turnover report table represent sale invoice hiv lead strong performance trizivir cent glaxosmithkline local entity customer local consumer healthcare sale pharmaceutical turnover europe region partially draw sale constituent product valtrex market plus copromotion income market reconciliation adjustment parallel trade growth herpe grow cent drive fda approval cer pharmaceutical turnover geographic region reduce risk transmission genital herpe otc medicine invoice basis region invoice adjustment create invoice adjustment create major market sale avandia increase cent benefit analgesic r ag joio rn arket af l c eg rr ow th europe launch avandamet november antibacterial sale dermatological france decline cent result generic competition begin gastrointestinal usa uk quarter coreg sale increase cent respiratory tract europe italy reflect benefit recent datum show highly smoking control germany france spain significant statistical difference survival coreg natural wellness support uk italy central metopropol patient heart failure oral care eastern europe germany spain europe europe nutritional healthcare central turnover market europe adjust effect discussion individual market performance europe eastern europe europe parallel trade turnover basis country region turnover create basis turnover product finally consume product invoice basis growth consumer healthcare sale cent international sell glaxosmithkline million comprise otc medicine sale increase asia pacific europe region contribute cent pharmaceutical turnover cent nutritional healthcare sale increase japan overall turnover growth region cent oral care sale increase cent l din la e eae sr tic frica pharmaceutical turnover geographic region cent good growth record italy central canada turnover create basis eastern europe government healthcare reform include otc medicine region growth pricing reimbursement restriction adversely affect turnover overthecounter medicine sale billion cent major market total cer france spain germany seretide glaxosmithkline large sale smoking control gastrointestinal product cer represent turnover growth constant exchange rate represent growth usa sell product europe report notable growth france italy significantly usa primarily flat market condition actual exchange rate analysis turnover quarter give financial record uk partly offset expect decline page europe private label competition growth smoking control serevent flixotide trizivir show strong growth france product recently launch europe sale dermatological individual government determine pricing medicine uk major market region decline sale herpe product acquire early year helped offset decline country europe result wide price variation italy franchise mainly result generic competition zovirax product parallel trade occur party germany partially offset patient switch new valtrex product spain oral care exploit price differential purchasing product market central oral care sale billion cent low price enforce sell government eastern europe glaxosmithkline sensodyne brand continue grow purchaser market high price europe region agree parallel trade permit single international market rule european union glaxosmithkline asia pacific nutritional healthcare derive benefit profit resale high price japan nutritional healthcare product grow cent latin america billion lucozade sport lucozade hydroactive continue middle east africa canada drive growth category cer represent turnover growth constant exchange rate represent growth actual exchange rate analysis turnover quarter give financial record page glaxosmithkline operate financial review prospect operate financial review prospect glaxosmithkline trading profit statutory result profit taxation statutory result trade profit business performance profit taxation business performance statutory result include merger item integration analysis discussion profit taxation relate illustrate glaxosmithkline business performance analysis discussion profit taxation relate restructure cost disposal subsidiary statutory performance analysis trading profit subsequent discussion business performance exclude merger item integration restructuring cost growth cer operating incomeexpense disposal business management believe exclusion operating incomeexpense turnover royalty income item provide well reflection way royaltie income operate expense business manage accordingly information provide operate expense cost sale supplement contain consolidated statement sell general profit loss page prepare accordance administration income equity investment income equity investment uk gaap research disposal disposal development growth trading profit cer operating incomeexpense include litigation cost operating incomeexpense include litigation cost turnover provision relate legal claim withdraw product provision relate legal claim withdraw product product cost sale product withdrawal antitrust matter equity investment cost sale withdrawal antitrust matter equity investment carry cost sale reduce percentage turnover result carry value adjustment arise stock market price sell general value adjustment arise stock market price change royalty benefit arise merger manufacturing restructuring change royalty income product disposal equity administration income product disposal equity investment sale saving favourable product mix small pricing benefit investment sale research offset adverse exchange impact merger development operating expense million year compare manufacture cost incur million million operating expense million year trading profit million yearonyear movement reflect low compare million year year high provision product liability antitrust movement reflect high provision product liability claim partially offset high proceed product sell general administration antitrust claim partially offset high cost sale disposal equity investment sale sell general administration sga cost decline proceed product disposal equity investment sale cost sale reduce percentage turnover result c e ine x cn c ret e l alr ee sn efl c de e c c ein llg not gr se ad cv ou sc tge sd oim n se uir pg pe ivr oe ri sn nte ehg wera et pi rw de c ureo c tpt la ra utn l nyd c h f efp sse e r hbt ai yo r gn ea sl b thhu ee fipn nre fi l st ed ti n ts l ep mo iss epa nol ts sa rl eo gf b rdu nin ge ts hs ee sp al f f h e lm thi cll aio ren reflect b thne ne fi f fs f sva eor ti u brin yg b lef nr p r v dm eu sc er tg ee xr c x hm aaa n n gsmu ef ia mlc l ppu arr ci cn ti ng g r e bs etr nu ec fit tu r win ag mav oi rn eg u thh n ea r e se hr ao rf ek p onr fgo psfi r ots fi sl os fs ae ss cf ia j esin r iv sn pu rir ne cs ip llyd fa ross mo c ti ha et e gd r oup relate cost saving programme increase pension cost service business sell general administration hold quest diagnostic inc merger integration cost sga grow cent sell general administration sga cost grow driven selling cost increase account share profitslosse joint venture associate cent reflect increase selling cost support new product net interest payable percentage point increase charge relate operational undertaking launch charge relate operational excellence cost save interest payable excellence pension cost increase individually add share profit associate arise principally programme increase pension cost partly offset cost investment income percentage point cost saving reduce growth group hold quest diagnostic inc save initiative cost save initiative relatively small percentage point produce reduction percentage point relative expense express net interest payable restructuring activity estimate share interest payable associate operational excellence charge sga percentage turnover interest payable grow cent drive principally sell cost increase investment income pension cost increase add percentage point net interest payable increase compare largely research development offset cost save initiative produce result unwind discount provision long rd decline cent reflect reduced merger integration share interest payable associate reduction percentage point express percentage term receivables cost partly offset increase clinical trial inlicense activity turnover reinvestment merger synergy pharmaceutical rd profit ordinary activity taxation business expenditure represent cent pharmaceutical turnover net interest payable increase compare largely research development performance year result unwind discount provision research development rd increase cent reflect take account net operating incomeexpense longterm receivables increase clinical trial inlicense activity reinvestment contribution associate net interest payable business trading profit merger synergies pharmaceuticals rd expenditure represent performance profit tax million compare statutory trading profit million growth profit ordinary activity taxation statutory cent pharmaceutical turnover year million increase cent cent strong turnover growth cent result demonstrate improved trading margin percentage take account net operating incomeexpense trading profit merger item restructuring cost disposal business point principally low merger integration cost contribution associate business disposal net interest business performance trading profit million cost saving derive merger integration manufacturing merger manufacturing restructuring payable statutory profit tax million compare growth cent strong turnover growth initiative partly offset charge relate operational glaxosmithkline good progress merger million increase cent cent demonstrate improved trading margin point excellence cost save programme high pension cost manufacture restructuring plan merger programme cent compare principally cost substantially complete end combine saving derive merger integration manufacturing programme produce annual saving exceed initiative partly offset charge relate operational excellence publish target billion cost saving programme high pension cost cost million incur year respect focus operational excellence value creation merger manufacturing restructure tax relief elimination waste bureaucracy programme million net charge million cost integral way business manage include severance asset writedown professional fee site charge book business performance closure glaxosmithkline operate financial review prospect operate financial review prospect glaxosmithkline block drug company inc glaxosmithkline use good advice determine transfer critical accounting policy impairment fix asset glaxosmithkline acquire block drug january cost pricing methodology seek manage transfer pricing carry value fix asset subject depreciation consolidated financial statement prepare accordance incur integrate business million issue satisfactory conclusion basis external amortisation review impairment uk generally accept accounting principle follow include redundancy asset writedown site closure professional advice continue believe adequate indication value asset impaired accounting policy approve board describe provision liability likely arise open assessment impairment determine reference high net note financial statement accounting policy disposal business continue wide difference view realisable value value use measure reference management require estimate assumption profit disposal business million reflect group irs ultimate liability riskadjuste future cashflow discount appropriate risk affect amount asset liability revenue expense final settlement disposal healthcare matter vary significantly amount provide free interest rate future cashflow base business report financial statement actual amount result service business dependent outcome litigation proceeding forecast inherently judgemental future event differ estimate follow consider negotiation relevant tax authority cause assumption impairment review critical accounting policy adopt taxation change consequent adverse effect future result credit taxation merger restructuring item group amount million reflect actual tax rate applicable turnover business performance transaction territory arise gross turnover reduce discount allowance vary investment share merger restructure disposal product arrangement buy group arrangement subsidiarie earning growth purchase organisation dependent submission glaxosmithkline invest share employee cer share ownership trust order meet obligation arise claim time initial recognition sale total statutory earning certain company employee share option scheme provision time sale estimate discount basic earning share p p share hold cost provision recognise shortfall allowance payable base historical experience amount integrate nature group worldwide operation basic earning ad proceed receivable employee exercise subject change dependent thing involve significant investment research strategic management believe permanent impairment type buy group product sale mix level provision manufacture limited number location consequential adjust earning value relation period time relate review regularly light historical experience actual crossborder supply route numerous endmarket give rise adjust earning share p p share option exercise impairment discount allowance give change arrangement complexity delay negotiation revenue authority adjust earning ad adverse effect result group accounting future event cause assumption discount profit individual group company liable weight average number base change affect future result period follow change uk accounting tax disagreement revenue authority share million group requirement share show deduction intragroup transaction particular price good equity shareholder fund long subject transfer group company different tax adjust earning adjust earning share present potential impairment legal dispute jurisdiction produce conflict claim revenue order illustrate business performance glaxosmithkline provide anticipate settlement cost authority profit fall tax individual primary measure management adjust earning pension postretirement benefit associate expense arise asserted claim group territory resolution issue continue fact life increase cent adjust earning share increase cost provide pension postretirement benefit reasonable estimate likely outcome glaxosmithkline group open issue revenue cent reflect reduction weight average charge profit loss account accordance dispute company director take legal advice authority usa uk japan canada far number share result group share buyback ssap period benefit derive establish provision take account insurance large relate glaxo heritage product usa programme interest cost programme impact employee service cost assess accordance agreement regard relevant fact group earning advice receive independent actuary basis usa number year glaxosmithkline circumstance matter accordance accounting assumption select management assumption include significant open issue relate transfer pricing glaxosmithkline actual rate exchange adjust earning share increase requirement provision unasserted claim future earning pension increase discount rate expect attempt settle dispute direct discussion cent sterling term compare cent cer claim reasonable estimate likely long term rate return asset disclose note internal revenue service irs subsequently term adverse currency impact eps cent outcome ultimate liability pende financial statement employee cost expect long discussion usa uk authority year reflect significant weakening dollar relative unasserted claim vary amount provide term rate return asset determine base long term term double tax convention country compare cent adverse currency dependent outcome litigation proceeding government bond rate adjust risk current market glaxosmithkline understand view tax impact turnover difference principally arise investigation possible settlement negotiation expectation note give additional disclosure authority different unable reach different mix currency profit compare turnover require frs retirement benefit selection different agreement discussion terminate july intangible asset take expense taxation business assumption affect future result group intangible asset acquire glaxosmithkline group receive claim additional taxis disposal result basic eps pence compare party cost acquisition capitalise licence irs assert legacy company glaxo wellcome owe year pence dilute ep pence compare product right goodwill compound development amortise estimate statutory notice deficiency billion penny merger manufacturing restructuring addition critical accounting policy outline useful life exceed year estimate useful live billion tax principally relate allocation profit cost low result sterling accounting policy product right goodwill deem review annually impairment review undertake glaxo heritage product usa countries base growth basic eps cent significantly high important respect balance sheet prepare event occur question carry value extent irs successful claim interest cer base growth adjust ep despite overall accordance accounting principle gaap asset brand acquire business capitalise payable glaxosmithkline estimate interest negative impact currency merger glaxo wellcome smithkline beecham independently separable longterm claim date approximately billion billion account acquisition give rise product right value group brand amortise estimate net federal tax relief similar tax issue remain open dividend billion goodwill billion recognise useful life exceed year end date glaxosmithkline expect receive claim board declare fourth interim dividend penny goodwill product right determine indefinite useful economic life foresee brand irs year share make total year penny share life amortise review annually amortise subject annual impairment review compare total dividend penny share impairment impairment review assess business projection glaxosmithkline exhausted administrative remedy impairment review base riskadjusted future cash flow prepare group annual budgeting planning open company plan contest claim additional glaxosmithkline expect similar increase total discount appropriate riskfree interest rate future process determine impairment value taxis file petition tax court trial dividend declare allocation cash flow base business forecast goodwill occur business projection include expect quarterly dividend rebalance glaxosmithkline inherently judgemental future event cause value assumption future event change future event intend increase interim dividend intangible asset impair glaxosmithkline continue believe profit report cause assumption business projection change pence pence remainder total dividend adverse effect future result group subsidiary period date consequent adverse effect future result group year allocate fourth quarter dividend pay taxis usa sufficient reflect report gaap activitie operation glaxosmithkline operate financial review prospect operate financial review prospect glaxosmithkline financial position resource financial position debtor commitment contingent liability group policy provide settlement cost debtor increase reflect timing yearend financial commitment summarise note financial assert claim environmental dispute reasonable receipt higher defer tax asset insurance receivables statement commitment contingent liability estimate prior point liability record goodwill additional cash contribution uk pension plan obligation respect short longterm debt set legal environmental cost discuss risk factor intangible fix asset note financial statement contingent liability page tangible fix asset provision note financial statement net debt glaxosmithkline use good advice determine transfer investment group carry provision million st december amount provide pension postretirement benefit pricing methodology basis external professional respect estimate future liability fix asset restructure integration plan legal environmental advice continue believe adequate provision million relate legal dispute million dispute set note financial statement liability likely arise open taxation assessment equity investment relate pension postretirement benefit provision liability charge ultimate liability matter vary significantly stock employee provision tax legal amount provide dependent outcome litigation debtor dispute indemnify disposal liability cost contractual obligation commitment proceeding negotiation relevant tax authority liquid investment manufacture restructuring merger integration extent follow table set group contractual obligation discuss note financial statement cash bank balance sheet date actual constructive obligation commitment fall payment taxation exist reasonably estimate current asset loan overdraft net debt mal myr mrs mrs rs cash flow creditor group net debt st december comprise loan summary consolidated cash flow statement set creditor amount year finance lease obligation net current asset operate lease cash liquid investment commitment total asset current liability borrowing repayable year intangible fix asset net cash inflow operating activity loan borrowing repayable year tangible fix asset dividend joint venture creditor net debt commitment associate undertaking return investment servicing creditor amount year total net debt decrease million primarily finance provision liability charge low purchase share company cancellation partly group enter number research collaboration taxation pay net asset offset increase work capital develop new compound pharmaceutical company capital expenditure financial investment term arrangement include upfront fee equity acquisition disposal call share capital pension investment loan commitment fund specify level equity dividend pay share premium account group continue account pension arrangement research addition group agree net cash inflowoutflow management reserve accordance ssap transitional provision payment future milestone achieve liquid resource finance profit loss account frs disclose pension asset liability group agreement relate compound early stage management liquid resource equity shareholder fund st december net deficit allow deferred development milestone payment continue number finance taxation million million fourth year compound successfully nonequity minority interest quarter special cash contribution million development process generally close product decreaseincrease cash year equity minority interest reduce funding deficit marketing approval great possibility success capital employ company review position annually payment show represent maximum reconciliation net cash flow movement net debt contribution appropriate pay milestone achieve number commitment investment licensing agreement glaxosmithkline investment exclude share principally neurosearch ranbaxy laboratories ltd net debt begin year shareholder fund st december carry value million pozen inc pension commitment provide note decreaseincrease cash year summary movement equity shareholder fund set million market value st december financial statement employee cost cash inflowoutflow management million million investment liquid resource include associate joint venture mainly equity contingent liability net increase longterm loan share hold derive directly group follow table set contingent liability comprise net repayment shortterm loan business investment include stake company begin year discount bill performance guarantee item arise exchange movement group research collaboration provide access profit year normal course business expect net debt end year biotechnology development potential interest interest dividend expire company arise business divestment share issue exercise share option net cash inflow operating activity million total yr yrs yrs yrs share purchase cancel decrease million arise timing share exchange movement guarantee trade receipt yearend period high st december esot hold million uk tax exchange movement contingent liability payment legal provisionable item partly offset glaxosmithkline share carry value million unrealised gain reduce restructure integration payment market value million future exercise unrealise gain equity investment total capital expenditure tangible intangible fix asset share option share awards valuation shortfall end year normal course business group provide amount million million disposal consider represent permanent diminution value indemnification guarantee respect business disposal realise million million equity investment context length future period relate equity shareholder fund increase million legal dispute subsequently arisen cost million million purchase share option exercise accordingly provision st december million st december provision reasonable estimate year sale equity investment realise million increase arise retain earning positive exchange likely outcome dispute include note million movement overseas net asset partly offset share financial statement provision liability charge purchase cancel glaxosmithkline operate financial review prospect operate financial review prospect glaxosmithkline share glaxosmithkline plc purchase esot liquidity funding maturity counterparty risk group use limited number interest rate swap satisfy future exercise option award group operate globally primarily subsidiary company group invest centrally manage liquid asset government redenominate external borrowing interest rate coupon employee share incentive scheme nil total establish market group trade bond shortterm corporate debt instrument minimum require group purpose duration swap match million million receive employee nature group business patent protection shortterm credit rating ap money market fund duration principal instrument interest rate derivative exercise share option option exercise satisfied product group portfolio group product credit rating aaaaaa preference share investment fully instrument account hedge relevant asset share previously purchase esot yield million compete largely product efficacy price selling collateralise highly rate bond credit rating show liability possible million option exercise satisfied issue margin sufficient cover normal operating cost standard poor moodys investor service group manage centrally shortterm cash surplus new share yield million million group operating subsidiary substantially cash generative respectively borrowing requirement subsidiary company use forward group purchase share market cancellation operate cash flow fund investment research group manage net borrowing requirement contract hedge future repayment originate amount million million period development new product routine outflow portfolio long mediumterm borrowing include bond currency st january th february million capital expenditure tax dividend repayment mature shortterm finance dollar commercial sensitivity analysis consider sensitivity group net debt share purchase cancel cost million debt group time time additional demand paper programme billion cent coupon hypothetical change market rate assume finance share purchase acquisition bond million cent coupon bond issue variable remain constant base composition net debt future cash flow european medium term note programme glaxosmithkline operate relatively low level net debt st december percentage point basis point group expect future operate cash flow addition strong positive cash flow normal trading group mediumterm borrowing mature date increase decrease average interest rate result sufficient fund operate debt service cost satisfy activity additional liquidity readily available commercial private financing mature negligible change group annual interest expense normal level capital expenditure meet obligation paper programme longdate sterling bond mature private financing exist licensing agreement meet routine redeem glaxosmithkline time equity risk management commitment include tax dividend subject risk group uncommitte euro medium term note particular occurrence event increase equity investment classify current asset available sale factor discuss page group time programme billion million issue cost funding group group group manage disposal meet overall business time additional demand finance st december million flexible auction market prefer stock flex requirement arise group regularly monitor value acquisition group access source liquidity amp million auction rate preference stock arp equity investment enter hedge selectively bank financial institution addition treasury operation originally issue notice redeem flex amp approval board cash flow operation need objective treasury activity manage posttax net arp give february redemption expect costincome financial operation benefit group complete march april financial asset liabilitie payment policy earning corporate treasury operate profit centre analysis net debt give note financial glaxosmithkline longterm debt rating aa standard group company responsible monitoring manage glaxosmithkline use variety financial instrument include statement net debt analysis financial asset liability poor aa moodys investor service agency work capital term sale collection supplier derivative finance operation manage market risk carry value fair value reconciliation net debt shortterm rating paper issue group commercial payment reflect local commercial practice operation financial instrument comprise cash give note financial statement financial paper programme p respectively liquid resource borrowing spot foreign exchange contract instrument relate disclosure discussion uk company uk subsidiarie derivative financial instrument quantitative disclosure policy ensure supplier pay time particular number derivative financial instrument manage foreign exchange risk management market risk accordance requirement financial uk company seek market risk treasury operation derivative instrument glaxosmithkline foreign currency transaction exposure arise report standard principally comprise forward foreign currency contract interest normal trade flows respect external intragroup settle term payment supplier agree rate currency swap swap borrowing liquid trade hedge glaxosmithkline policy minimise group continue benefit strong positive cash flow term transaction asset currency require group purpose exposure overseas operating subsidiary transaction risk group net debt decrease significantly year ensure supplier aware agree term manage exposure funding risk change foreign matching local currency income local currency cost st december group purchase payment exchange rate interest rate purpose intragroup trading transaction match share market million abide term payment centrally intragroup payment term manage reduce glaxosmithkline balance use borrowing liquid asset financial asset liability st december policy include arrangement accelerate payment small risk exceptional foreign currency cash flow hedge selectively regard cash flow operating activity representative treasury policy strategy supplier management corporate treasury currency earn tax cost intragroup glaxosmithkline apply consistently year distribution currency business asset significant proportion group borrowing include significant change policy year payment performance denominate posttax cost borrowing compare commercial paper programme dollar benefit st december average number day purchase posttax return liquid asset liquidity dollar denominate capital market certain esot share purchase share purchase cancellation represent trade fix asset creditor company borrowing swap currency share hold trust satisfy future exercise option nil day nil day respect company liquid asset surplus immediate operating requirement require group purpose group seek denominate awards group share option award scheme uk subsidiary aggregate day day group company invest manage centrally borrowing currency principal overseas asset proportion share hold trust respect corporate treasury requirement group company awards rule scheme require company treasury policy operating finance meet possible central borrowing denominate swap foreign currency satisfy exercise market purchase issue resource match investment overseas group asset treat glaxosmithkline plc uk base business report sterle new share share hold trust match hedge relevant net asset pay dividend sterling profit role corporate external borrowing mainly manage centrally corporate option award grant diminish dilutive effect treasury glaxosmithkline manage monitor group treasury comprise portfolio long mediumterm base composition net debt st december new share issue shareholder capital earning external internal funding requirement financial risk instrument shortterm finance cent appreciation sterle major currency annual general meeting shareholder renew support group corporate objective treasury activity result reduction group net debt approximately glaxosmithkline hold issue derivative financial approval glaxosmithkline market purchase govern policy procedure approve board million cent weaken sterle major instrument trading purpose group treasury policy share rd october glaxosmithkline announce monitored treasury management group glaxosmithkline currency result increase group net debt specifically prohibit activity transaction financial second share repurchase programme billion exact maintain treasury control system procedure monitor approximately million instrument undertake manage risk arise time future purchase follow change foreign exchange interest rate liquidity credit financial underlie business activity speculation uk company law repurchased share hold risk interest rate risk management treasury share cancel depend glaxosmithkline policy interest rate risk management require market condition factor net borrowing fix rate increase ratio forecast net interest payable trading profit glaxosmithkline operate financial review prospect operate financial review prospect glaxosmithkline outlook risk factor outlook risk loss expiration patent marketing exclusivity risk substantial adverse outcome litigation continue consolidation pharmaceutical industry patent infringement litigation government investigation adversely affect group competitive position continue pharmaceutical sale growth exist product key driver effort generic manufacturer involve challenge note financial statement legal proceeding consolidation group customer increase pricing glaxosmithkline current business performance validity patent assertion product discussion proceeding governmental investigation pressure year transition glaxosmithkline month infringe group patent group successful group currently involve unfavourable resolution challenge group absorb erosion group product million billion patent protection period maintain exclusive right similar future proceeding investigation generic start fourth quarter expect annual global sale product market major product particularly usa material group financial result group return growth impact generic paxilseroxat augmentin respect group group high margin sale material provision relate legal proceeding diminish underlie business strength show face generic competition wellbutrin sr zofran imitrex country group revenue margin adversely investigation reduce earning group avandia respect group currently glaxosmithkline engage legal proceeding validity affect note financial statement legal material provision relate legal proceeding defend intellectual property right usa infringement group patent relate proceeding discussion patentrelate proceeding investigation future reduce earning product particular relate paxilseroxat group involve case practice plaintiff bar claim damage group major product wellbutrin discuss risk factor compensatory punitive statutory amount bear subject problem loss patent protection generic drug manufacturer seek market generic version note financial statement legal proceeding relationship underlie harm accordingly potentially unexpected effect regulatory proceeding publicity affect group important product include mislead quantify potential exposure claim doctor patient confidence pressure competitive glaxosmithkline publish earning guidance wellbutrin seretideadvair avandia imitrex valtrex lamictal proceeding investigation type describe note product new effective treatment deliver ep constant exchange rate line zofran prior expiration group patent introduce impact group revenue operate business performance eps impact generic exhibit readiness product future recent insurance loss experience include pharmaceutical result significant particular group face intense significant group look forward return generic product competitive augmentin paxil product liability exposure increase cost insurance competition manufacturer generic pharmaceutical ep growth launch usa respectively coverage pharmaceutical company generally include product major market significant adverse impact group overall sale group order contain insurance cost group net debt billion low relative earning group adjust coverage profile accept great generic product enter market expiration market capitalisation position advantage degree uninsured exposure patent datum exclusivity period group product opportunity arise build business follow patent expiry ability generic manufacturer introduction generic product typically lead dramatic loss obtain regulatory approval generic version group risk uncertaintie inherent business product liability litigation sale reduce group revenue margin product relevant example manufacturer affect future performance include expect earning group currently defendant number product liability proprietary product expiration date patent indicate expect approval generic version flonase growth discuss risk factor lawsuit include class action involve substantial claim group major product set follow patent expiry usa mid approve damage relate group pharmaceutical product generic launch adversely affect group sale risk factor governmental payer control earning litigation particularly usa inherently unpredictable pharmaceutical product subject price control pressure risk uncertaintie relevant group business excessive verdict justify evidence occur restriction market include japan germany factor list group think weakness intellectual property protection certain class action sweep person prescribe france italy government intervene directly set cause group actual result differ materially country group product inflate potential liability force price addition market major purchaser expect historical result country group operate patent number claim pain suffer punitive damage pharmaceutical product governmental agency protection significantly weak usa frequently assert product liability action allow private health care provider economic power exert risk rd deliver commercially successful new european union addition effort control public health represent potentially openende exposure substantial pressure price term access formulary product crise develop country south africa brazil continue development commercially viable new product consider plan substantial reduction scope antitrust litigation group predict exist control increase critical group ability replace sale old product patent protection pharmaceutical product particular usa increasingly common follow new control introduce reduce group decline expiration exclusive right increase overall country facilitate competition market adverse outcome prosecution patent infringement action margin affect adversely ability introduce new product sale develop new product costly lengthy uncertain generic manufacturer unable defendant direct indirect purchaser payer profitably process new product candidate fail stage introduce compete product number year loss initiate antitrust action claim direct indirect example usa group high margin process latestage product candidate fail patent protection include abrogation patent right purchaser payer typically file class action sale country pricing pressure significantly receive regulatory approval compulsory licensing likely affect adversely group relief seek include treble damage restitution claim increase implementation pharmaceutical benefit operating result national market expect new product candidate appear promise development medicare event state programme control material group overall absence adequate patent governmental investigation significant investment fail reach market cost pharmaceutical adopt medicare protection limit opportunity look market group respond federal state governmental limited commercial success result efficacy safety programme initiate outpatient pharmaceutical coverage future sale growth investigation usa pricing marketing concern inability obtain necessary regulatory approval beneficiarie government private insurer reimbursement number prescription drug product difficulty excessive cost manufacture infringement offer coverage enormous purchasing power investigation result related restitution civil false claim patent intellectual property right inability programme demand discount implicitly create act litigation behalf federal state government differentiate product adequately price control prescription drug additionally number relate proceeding initiate glaxosmithkline compete successful development group research state propose implement scheme control behalf consumer private payer development pipeline particular importance light price senior citizen drug programme include recent anticipate expiration patent datum exclusivity importation country bulk purchasing drug risk competition price control limitation sale number group large selling product growth number patient cover large party competition manage care institution usa likely group operate highly competitive business increase implementation medicare amendment pharmaceutical business face competition increase pricing pressure group product trend proprietary product large international manufacturer adversely affect group revenue margin sale producer generic pharmaceutical significant product usa term implementation medicare innovation technical advance intensification price pharmaceutical benefit finalise possible competition competitor adversely affect group quantify impact benefit group financial result operate result glaxosmithkline operate financial review prospect operate financial review prospect glaxosmithkline year regulatory control global political economic condition accordance sec disclosure requirement follow sale wellbutrin depression grow cent group comply broad range regulatory control group conduct substantial portion operation outside discussion compare result year st december million reflect increase physician awareness testing approval manufacturing marketing uk fluctuation exchange rate sterling result year st december product outstanding efficacy favourable effect profile pharmaceutical consumer healthcare product currency especially dollar euro japanese yen application approval oncedaily formulation growth rate include review turnover constant particularly usa countries european union materially affect group financial result wellbutrin xl submit fda exchange rate cer state sterling growth affect cost product development time group control change inflation interest rate find table pharmaceutical sale glaxosmithkline medicine epilepsy lamictal continue require reach market uncertainty successfully rate foreign currency exchange rate control therapeutic area grow region achieve sale million economic factor affect business possibility cent group file snda lamictal seek strict regulatory control heighten risk withdrawal political unrest legal regulatory change nationalisation exchange firstever indication longterm management depressive regulator approval previously grant reduce jurisdiction group operate factor episode bipolar disorder currency influence group result revenue result product recall product liability materially affect group future result operation dollar euro japanese yen lawsuit addition case group voluntarily respiratory cease marketing product example withdrawal accounting standard pound hit high level dollar glaxosmithkline continue global leader respiratory lotronex shortly initial launch usa face decline new revise accounting standard rule promulgate twoandahalf year climb euro gain pharmaceutical sale key product sale base concern efficacy safety time time uk international accounting standard cent dollar year seretideadvair flixotideflovent serevent amounting scientifically justify absence regulatory action setting board material adverse impact dollar fall value euro investor weigh nearly billion cent development postapproval adverse event profile group report financial result group believe impact possible war iraq tension north korea sale seretideadvair glaxosmithkline second large product product product class major impact complie appropriate regulatory requirement concern fear economy grow cent billion contribute marketing sale product financial statement disclosure company pharmaceutical sale decline serevent flixotide constituent product advair experience investigation potential noncompliance asthma market leader new prescription concentration sale wholesaler accounting disclosure requirement result total pharmaceutical sale million compare year market seretide continue usa line pharmaceutical company significant penalty million increase cent perform strongly europe cent international group sell product small number wholesaler cent overall growth come price market cent december glaxosmithkline addition hospital pharmacie physician group increase growth sterling term cent significantly file nda ariflo copd group expose concentration credit risk impact weakness dollar currency wholesaler affect financial difficulty materially group portfolio sale new product antiviral adversely affect group financial result launch major market year account hiv medicine grow region total billion cent total sale grow cent sale cent sale trizivir glaxosmithkline triple environmental liability million sale establish franchise product combination therapy grow cent million environmental law jurisdiction impose actual amount million represent cent total sale potential obligation group remediate contaminate valtrex herpe continue benefit convenient grow cent compare year sale old site group identify potentially oncedaily dose suppressive therapy achieve strong product actively promote million responsible party comprehensive environmental sale growth cent worldwide cent decline cent represent cent total sale response compensation liability act number site usa october glaxosmithkline file snda valtrex remediation cost relate group use ownership global pharmaceutical sale fourth quarter grow seek firstever indication reduce risk transmission site failure properly manage environmental risk seven cent reflect sale growth cent genital herpe december glaxosmithkline file result additional remedial cost materially million europe sale growth weak nda protease inhibitor treatment hiv adversely affect group operation note cent sale million international decline zovirax sale reflect transfer newer valtrex financial statement legal proceeding discussion sale flat million generic competition environmentalrelate proceeding group involve pharmaceutical sale therapeutic area antibacterial reliance information technology antibacterial sale decline cent worldwide group portfolio product major therapeutic group increasingly dependent information technology cent usa augmentin sale cent area experience good growth year include fast system include internet base system internal year result generic competition begin grow franchise cns billion cent respiratory communication communication customer quarter generic version augmentin billion cent antiviral billion cent supplier significant disruption system introduce usa follow decision district vaccine billion cent computer virus outside incursion court eastern virginia hold invalid glaxosmithkline materially adversely affect group operation patent augmentin expire central nervous system sale ceftin decline cent generic competition sale seroxatpaxil glaxosmithkline lead product taxation begin quarter depression anxiety disorder driver growth effective tax rate group earning benefit cns therapy area sale billion cent globally fact portion earning tax favourable cent usa international sale paxil grow rate jurisdiction outside united kingdom change cent million lead continue strong growth tax law application respect matter japan launch april paxil cr continue gain transfer pricing risk double taxation relate acceptance strong tolerability profile portion group earning tax favourable rate increase group effective tax rate adversely affect financial result group involve significant dispute internal revenue service transfer pricing matter discuss note financial statement taxation glaxosmithkline operate financial review prospect operate financial review prospect glaxosmithkline pharmaceutical sale therapeutic area metabolic sale antiviral therapeutic area grow cent lead worldwide sale metabolic category million strong performance trizivir cent partially total usa europe international avandia franchise avandia avandamet grow cent draw sale constituent product valtrex therapeutic area growth growth growth growth year sale cent million cent major product total cer cer cer cer cns avandamet combination avandia metformin hci sale avandia increase cent benefit depression expand avandia metabolic franchise launch launch avandamet november antibacterial sale seroxatpaxil fourth quarter avandamet treatment type decline augmentin start experience generic competition wellbutrin diabetes medicine target insulin resistance second half year cardiovascular franchise migraine decrease glucose production convenient pill coreg sale increase million reflect improved market imigranimitrex approval fda avandia share naramigamerge million patient worldwide europe lamictal requip vaccines europe region contribute cent pharmaceutical sale zyban sale vaccine grow cent billion support overall sale growth region cent hepatitis franchise cent million total good growth record market include spain respiratory vaccine sales europe grow cent sale grow central eastern europe government healthcare reform flixotideflovent serevent seretideadvair cent launch twinrix continue growth include pricing reimbursement restriction adversely seretideadvair havrix drive new state mandate require hepatitis affect sale italy flixotideflovent vaccination school age child infanrix glaxosmithkline serevent dtpa range combination vaccine grow cent international flixonaseflonase ventolin million cent sale growth international region reflect becotide mixture good growth middle east africa canada cardiovascular urogenital asia pacific decline sales latin america principally antiviral coreg sale grow cent million benefit poor economic condition mexico brazil hiv trizivir year new indication treatment addition mexico suffer realignment wholesaler stock combivir severe heart failure level epivir retrovir november levitra vardenafil new agent overall international growth drive seretide seroxatpaxil ziagen treatment erectile dysfunction receive positive opinion avandia vaccine partly offset decline zantac agenerase european cpmp fda issue approvable letter zovirax herpe levitra levitra research develop bayer ag asia pacific area grow performance seretide valtrex copromoted glaxosmithkline zovirax vaccine strong growth number market partly offset low growth large market australia reflect oncology emesis zeffix reduce sale zyban zantac sale zofran grow cent million drive antibacterial strong performance cent million market growth japan reflect strong growth paxil augmentin flixotideflovent partly offset decline old product zinnatceftin therapeutic area zantac government price reduction fortum amoxil sale relafen arthritis fall reflect generic competition middle east africa area follow trend usa metabolic market growth seretide avandia vaccine hiv avandia regional analysis canada growth drive seretide paxil avandia vaccine antiviral partly offset low sale antibacterial usa hepatitis infanrix usa report cent sale growth year consumer healthcare sale business currently represent cent total pharmaceutical growth oncology emesis sale sale growth central nervous system product cer zofran cent drive wellbutrin reflect increase otc medicine hycamtin prescribing primary care physician psychiatrist paxil analgesic cardiovascular follow launch cr formulation april lamictal dermatological urogenital indicate epilepsy record sale growth cent gastrointestinal coreg advair maintain strong growth sale million respiratory tract drive overall respiratory sale growth cent smoking control zantac adversely affect sale constituent product natural wellness support flovent serevent show decline flonase oral care indicate treatment perennial rhinitis grow strongly nutritional healthcare cent cer represent sale growth constant exchange rate actual exchange rate certain product reclassify different therapeutic area comparative purpose glaxosmithkline operate financial review prospect operate financial review prospect glaxosmithkline otc medicine trading profit profit ordinary activity taxation statutory result profit taxation business performance smoke control sale growth drive performance statutory trading profit million growth take account net operating expense net analysis discussion profit taxation relate nicodermniquitinnicabate usa nicoderm grow strongly cent strong sale growth seven cent operating income contribution associate business performance despite competition private label launch demonstrate improved trading margin percentage business disposal net interest payable statutory profit competitor patch niquitin lozenge commit point cent compare principally tax million compare million operating incomeexpense launch usa november clinical study cost saving derive merger integration increase cent royalty income commit help smoker try quit manufacturing initiative low cost operate expense analgesic panadol record good sale growth cent implement initiative trading profit business performance cer cent sterling partly offset decline number illustrate glaxosmithkline business performance brand abreva usa zovirax europe profit taxation statutory result income equity investment analysis trading profit subsequent discussion treatment cold sore drive dermatological sale disposal exclude merger item integration restructuring cost growth cent cer cent sterling decline operating incomeexpense disposal business management believe exclusion gastrointestinal sale citrucel rise cent cer royalty income item provide well reflection way cent sterling offset decline tum operate expense operating incomeexpense include litigation cost business manage accordingly information provide tagamet provision relate legal claim withdraw product product supplement contain consolidated statement withdrawal antitrust matter equity investment carry income equity investment profit loss page prepare accordance oral care value adjustment arise stock market price change royalty disposal uk gaap oral care sale grow marginally europe decline income product disposal equity investment sale highly competitive market overall oral care sale decline growth operating expense million year compare cent principally result reduce aquafresh sale cer million income year year movement reflect operating incomeexpense include litigation cost increase sensodyne sale partially offset sale high provision product liability claim provision relate legal claim withdraw product cost sale low proceed disposal equity investment sale product withdrawal antitrust matter equity investment nutritional healthcare sell general carry value adjustment arise stock market price nutritional healthcare lucozade ribena report strong administration profit disposal interest associate change royalty income product disposal equity growth europe drive increase availability promotion research disposals interest associate investment sale horlick sale decline primarily international market development group sell million share quest diagnostic inc operating expense million year realise gain million trading profit trading profit statutory result compare million income year year movement reflect high provision product liability share profitslosse joint venture associate analysis discussion relate statutory cost sale claim low proceed disposal undertaking performance statutory result include merger item integration cost sale reduce percentage sale result benefit equity investment sale share profit associate arise principally group restructure cost disposal subsidiary arise merger manufacturing restructuring saving hold quest diagnostic inc growth profit disposal interest associate movement stock provision favourable regional mix cer disposal interest associate net interest payable sale group sell million share quest diagnostic inc sell general administration interest payable sell general administration cost benefit cost saving cost sale realise gain million investment income arise merger integration implementation cost save sell general programme include local restructuring europe international administration share profitslosse joint venture associate share interest payable associate region research undertaking development share profit associate arise principally research development group hold quest diagnostic inc trading profit research development rd increase cent net interest payable increase compare largely reflect increase clinical trial inlicense activity result high average level net debt drive use cash cost sale disposal business reinvestment merger synergies pharmaceuticals rd fund group share buyback programme benefit cost sale reduce percentage sale result benefit profit product divestment disposal business expenditure represent cent pharmaceutical sale small number share issue reflect earning share arise merger manufacturing restructuring saving million reflect final settlement merger year movement stock provision favourable regional mix relate product disposal disposal healthcare profit ordinary activity taxation business service business trading profit performance inin gg g g ee nn ere ar la al na dn ad md inm isi tn ri tt iora not co st benefit low net interest payable b gu ros win te hs p f e r fo prm era cn ec ne r sa td roin ng g ep rr thfi nw sa l e g ro w tm h olli fo sn e vw ei nth path rte fo tp er inti tn eg sn tc io nm ae n ae sx sp oe cn iase te g et h e r rw edit uh c eth de p rois fip bsa yl merger integration cost cost save programme merger interest payable cent demonstrate improved trading margin million add million profit integration implementation initiative include local investment income percentage point cent compare take account contribution associate net interest restructuring europe international region principally cost saving derive merger integration payable business performance profit tax million share interest payable associate manufacturing initiative compare million increase cent research development research development rd increase cent reflect increase merger integration cost high clinical trial inlicense activity reinvestment merger synergies pharmaceuticals rd expenditure represent cent pharmaceutical sale year glaxosmithkline operate financial review prospect operate financial review prospect glaxosmithkline select financial datum ukus gaap merger item restructuring cost disposal business earning growth profit loss account cer merger integration item represent item earning arisen result merger glaxo wellcome smithkline amounts accordance uk gaap basic earning share p p beecham acquisition block drug restructuring cost turnover basic earning ad arise merger acquisition manufacturing operating profit restructuring programme agree glaxo adjust earning profit taxation wellcome smithkline beecham date merger adjust earning share p p earning item nature consider outside adjust earning ad basic earning share p p p p p normal business expenditure glaxosmithkline expect diluted earning share p p p p p weight average number occur regular basis share million weight average number share issue key item discuss basic adjust earning adjust earning share present diluted merger manufacturing restructuring order illustrate business performance dividend glaxosmithkline share pence glaxosmithkline good progress merger primary performance measure management adjust glaxosmithkline shareholder p p p manufacturing restructuring plan remain track deliver earning increase cent adjust earning share glaxo wellcome shareholder p p forecast total annual merger manufacturing restructuring increase cent reflect reduction weight smithkline beecham shareholder p p saving billion exclude benefit block average number share result group share drug acquisition estimate cost achieve remain buyback programme interest cost programme dividend express term glaxosmithkline share billion billion charge impact group earning amount accordance gaap st december actual rate exchange business performance eps increase turnover cost million incur year respect cent compare cent cer term net incomeloss merger manufacturing restructure tax relief adverse currency impact eps cent year basic net incomeloss share pence p p p p p million net charge million cost reflect significant weakening dollar relative diluted net incomeloss share pence p p p p p include severance asset writedown professional fee site compare cent adverse currency impact closure sale difference principally arise different mix information present gaap net incomeloss net incomeloss share result year end currency profit compare sale st december adjust reverse amortisation expense goodwill indefinitelive intangible asset block drug company inc sfas apply year take expense taxation product glaxosmithkline acquire block drug january cost divestment result eps pence compare adjust net incomeloss incur integrate business million penny diluted ep pence compare adjust basic net incomeloss share penny p p p include redundancy asset writedown site closure pence merger manufacturing restructuring adjust diluted net incomeloss share penny p p p cost low result sterle disposal business base growth eps cent significantly high balance sheet profit disposal business million reflect cer base growth business performance ep despite final settlement merger relate product disposal overall negative impact currency amount accordance uk gaap disposal healthcare service business total asset taxation dividend net asset board declare fourth interim dividend penny equity shareholder fund share make total year penny share business performance amount accordance gaap compare dividend penny share merger restructuring disposal total asset subsidiary net asset shareholder equity total exchange rate charge taxation business performance profit million represent effective tax rate cent guide holder adr follow table set period indicate information exchange rate dollar represent increase compare effective rate sterling report federal reserve bank new york noon buying rate cent restate implementation average frs defer tax credit taxation merger restructuring item average rate year calculate average noon buying rate day month year amount million reflect estimate actual tax rate feb jan dec nov oct sept applicable transaction territory arise high low noon buying rate th february glaxosmithkline glaxosmithkline financial statement section comprise director statement responsibility independent auditor report financial statement financial statement consist principal financial statement support note director statement responsibility independent auditor report financial statement consolidate statement profit loss consolidate statement total recognise gain loss consolidate statement cash flow consolidated balance sheet reconciliation movement equity shareholder fund company balance sheet note financial statement presentation financial statement accounting policy new accounting policy future requirement exchange rate merger glaxo wellcome smithkline beecham segment information merger item restructuring cost divest business operate incomeexpense operating profit joint venture associate undertaking net interest payable taxation earning share dividend goodwill intangible asset tangible fix asset fix asset investment equity investment stock debtor creditor provision liability charge contingent liability net debt commitment share capital share premium account nonequity minority interest reserve legal proceeding acquisition disposal financial instrument relate disclosure employee cost employee share scheme relate party transaction reconciliation accounting principle principal group company glaxosmithkline glaxosmithkline director statement responsibility independent auditor report members glaxosmithkline plc director statement responsibility relation internal control audit financial statement comprise basis audit opinion financial statement consolidate statement profit loss consolidate statement board audit committee review conduct audit accordance auditing standard total recognise gain loss consolidate statement director assessment risk internal control framework issue united kingdom auditing practice board audit cash flow consolidated company balance sheet operate glaxosmithkline consider effectiveness include examination test basis evidence relevant responsible ensure maintenance proper accounting relate note prepare historical cost system internal control operation group amount disclosure financial statement record disclose reasonable accuracy financial convention accounting policy set statement year cover report date approval auditable director remuneration report position group time financial accounting policy audit disclosure board director include assessment significant estimate judgement statement prepare comply company require schedule company act director preparation financial act contain director remuneration report auditable combine code statement accounting policy appropriate require law prepare financial statement company group circumstance consistently apply board consider glaxosmithkline plc apply principle financial period true fair view state adequately disclose combined code describe corporate respective responsibility director auditor affairs company group end governance page comply plan perform audit obtain financial period profit loss period director responsibility prepare annual report requirement combine code exception information explanation consider necessary director remuneration report financial statement responsible ensure operation system senior independent director company position order provide sufficient evidence reasonable accordance applicable united kingdom law account internal control take reasonable step safeguard describe corporate governance provision assurance financial statement auditable standard set statement director responsibility asset group prevent detect relate executive director service contract pension director remuneration report free material fraud irregularity arrangement company position describe responsibility audit financial statement misstatement cause fraud irregularity remuneration report auditable director remuneration report accordance error form opinion evaluate overall financial statement year end st december relevant legal regulatory requirement unite adequacy presentation information financial comprise principal statement support note set require listing rule financial service authority kingdom auditing standard issue auditing practice statement financial statement page report auditor consider director statement board report include opinion prepare compliance relation point combined director confirm suitable accounting policy companys member body accordance opinion code specify review consistently apply preparation financial statement section company act purpose opinion support reasonable prudent judgement estimate give opinion accept assume responsibility annual report necessary applicable accounting standard follow purpose person report financial statement true fair view state financial statement prepare go annual report year end st december show hand come save expressly affair company group st december concern basis comprise report director remuneration report agree prior consent write profit cash flow group financial statement additional information investor year end responsibility auditor relation financial report opinion financial approve board director sign financial statement properly prepare statement set independent auditor report statement true fair view financial behalf accordance company act opposite statement auditable director remuneration part remuneration report require report properly prepare accordance financial statement year end st december schedule company act properly company act report opinion include annual report publish prepared accordance company act report director consistent financial hardcopy print form website director statement company keep proper accounting responsible maintenance integrity annual record receive information report website accordance uk legislation governing explanation require audit information specify preparation dissemination financial statement access sir christopher hogg law director remuneration transaction website available outside uk comparable chairman disclose legislation different rd march read information contain annual report pricewaterhousecooper llp director remuneration consider implication report aware charter accountant register auditor apparent misstatement material inconsistency embankment place remuneration report page report set financial statement information comprise london england remuneration policy operate glaxosmithkline financial summary description business unauditable rd march disclosure director remuneration disclosable director remuneration report joint statement chairman information relate director officer interests chief executive officer operate financial review prepare accordance company act prospect corporate governance statement amend director remuneration report regulation review corporate governance statement reflect complie section b combine code company compliance seven provision combine code issue june specify review go concern basis listing rule financial service authority report make enquiry director reasonable require consider board expectation group company adequate resource statement internal control cover risk control continue operational existence foreseeable future form opinion effectiveness company group reason continue adopt go concern basis corporate governance procedure risk control prepare financial statement procedure glaxosmithkline consolidated statement profit loss glaxosmithkline consolidate statement profit loss year end st december merger merger merger restructuring restructuring restructure business disposal business disposal business disposal performance subsidiary statutory performance subsidiary statutory performance subsidiary statutory note turnover cost sale gross profit sell general administrative expenditure research development expenditure trading profit operating incomeexpense operate profit share profitslosse joint venture associate undertaking profit disposal interest associate product divestment profitloss disposal business profit interest net interest payable profit ordinary activity taxation taxation profit ordinary activity taxation equity minority interest preference share dividend earning profit attributable shareholder basic earning share p p p adjust earning share p p p dilute earning share p p p profit attributable shareholder dividend retain profit consolidate statement total recognise gain loss year end st december profit attributable shareholder exchange movement overseas net asset unrealise gain equity investment tax exchange movement unrealise gain total recognise gain loss glaxosmithkline consolidate statement cash flow glaxosmithkline consolidate statement cash flow year end st december reconciliation operating profit operating cash flow analysis cash flow note note operate profit return investment servicing finance depreciation interest receive impairment asset write interest pay amortisation goodwill intangible fix asset dividend pay minority shareholder loss sale tangible fix asset dividend pay preference share profit sale equity investment increasedecrease stock increase trade debtor capital expenditure financial investment decreaseincrease trade creditor purchase tangible fix asset increase provision sale tangible fix asset purchase intangible asset merger transaction cost pay sale intangible asset net cash inflow operating activity product divestment purchase share employee share option award proceed share employee share option cash flow statement purchase equity investment sale equity investment net cash inflow operating activity dividend joint venture associate undertaking return investment servicing finance acquisition disposal taxation pay purchase business capital expenditure financial investment cash acquire subsidiary acquisition disposal disposal business equity dividend pay investment joint venture associate undertaking net cash inflowoutflow management liquid resource finance disposal interest associate management liquid resource finance decreaseincrease cash year financing issue share capital reconciliation net cash flow movement net debt redemption preference share issue subsidiary share capital purchase cancellation net debt begin year finance cash flow decreaseincrease cash year increase longterm loan cash inflowoutflow management liquid resource repayment longterm loan net increase longterm loan net repayment shortterm loan net repayment shortterm loan net repayment obligation finance lease net repayment obligation finance lease net noncash fund subsidiary undertaking acquire exchange adjustment analysis change net debt cash flow exchange noncash movement movement net debt cash bank overdraft net debt end year debt year commercial paper eurobond mediumterm note debt year eurobond mediumterm note private financing management liquid resource liquid investment net debt information significant change net debt note net debt glaxosmithkline glaxosmithkline consolidate balance sheet company balance sheet st december st december note note share subsidiary company cost goodwill fix asset intangible asset amount owe group undertaking tangible asset taxation investment cash bank fix asset current asset equity investment dividend payable stock amount owe group undertaking debtor creditor amount year liquid investment net current liability cash bank net asset current asset loan overdraft capital reserve creditor call share capital creditor amount year share premium account net current asset reserve total asset current liability profit loss account loan equity shareholder fund creditor creditor amount year provision liability charge approve board net asset sir christopher hogg capital reserve chairman call share capital rd march share premium account reserve profit loss account equity shareholder fund nonequity minority interest equity minority interest capital employ approve board sir christopher hogg chairman rd march reconciliation movement equity shareholder fund year end st december note equity shareholder fund begin year total recognise gain loss year dividend share capital issue share capital purchase cancel exchange movement goodwill write reserve equity shareholder fund end year glaxosmithkline note financial statement glaxosmithkline note financial statement presentation financial statement additional information accordance requirement accounting policy foreign currency transaction generally accept accounting principle gaap include foreign currency transaction group company book description business consolidation note financial statement note statement local currency exchange rate ruling date glaxosmithkline major global healthcare group consolidated financial statement include difference reconciliation net income shareholder transaction forward rate hedge forward engage creation discovery development manufacture equity uk gaap provide asset liability result cash flow exchange contract foreign currency asset liability market pharmaceutical product include vaccine company subsidiary undertaking include employee translate local currency rate exchange rule overthecounter otc medicine healthrelate consumer presentation statement profit loss share ownership trust esot balance sheet date forward rate exchange difference product glaxosmithkline principal pharmaceutical product columnar presentation adopt statement group share net asset result joint venture include trading profit include medicine follow therapeutic area profit loss order illustrate underlie business associate undertaking central nervous system respiratory antiviral antibacterial performance primary measure management revenue vaccine oncology emesis metabolic cardiovascular financial statement undertaking consolidate purpose certain item identify separately revenue recognise profit loss account good urogenital st december exclude business performance comprise merger supply external customer order receive integration item include product divestment cost relate undertaking group material interest certain limited case customer collect good revenue financial period previously announce manufacturing restructuring account subsidiary group exercise dominant recognise title risk loss pass turnover represent financial statement cover financial year effect disposal subsidiary management believe influence joint venture group exercise joint control net invoice value deduction discount give st january st december comparative figure exclusion item provide well reflection way associate group exercise significant point sale accrual estimate future rebate financial year st january st december business manage give indication influence return methodology assumption estimate st january st december performance group term element revenue rebate return monitor regularly light interest acquire undertaking consolidated expenditure local management able influence historical information past experience turnover include composition group effective date acquisition interest sell consolidated copromotion income group records share list subsidiary associate undertaking trading profit reflect turnover cost sale comprise date disposal revenue relate cost sale value add tax opinion director principally affect profit cost manufacture external royalty sell general transaction balance subsidiary undertaking sale taxis exclude revenue net asset group give principal group administrative expenditure comprise cost sell eliminate profit take sale subsidiary company note distribution medical support currently market product undertaking sale joint venture associate undertaking expenditure cost administration cost research product sell customer outside group expenditure recognise respect good service receive composition financial statement development create future product sale supply accordance contractual term provision consolidated financial statement draw accordance goodwill arise acquisition interest subsidiary obligation exist future liability respect uk generally accept accounting principle uk gaap accounting convention undertaking joint venture associate undertaking past event obligation reliably uk accounting presentation financial statement prepare historical represent excess purchase consideration estimate advertising promotion expenditure charge cost convention group share separable net asset acquire capitalise financial statement comprise profit loss account incur shipment cost inter separate item case subsidiary undertaking company transfer charge cost sale distribution cost consolidate statement profit loss accounting standard cost investment case joint venture sale customer include sell general consolidated statement total recognise gain loss financial statement comply applicable uk accounting associate undertaking goodwill denominate currency administrative expenditure restructuring cost recognise consolidated statement cash flow standard acquisition financed case respect direct expenditure business reorganisation consolidate balance sheet acquisition prior goodwill write plan sufficiently detail advanced reconciliation movement equity shareholder fund accounting principle policy reserve subsequent disposal asset acquisition appropriate communication affect company balance sheet preparation financial statement conformity relate goodwill remove consolidated reserve undertake balance sheet date note financial statement generally accept accounting principle require management charge consolidated profit loss account estimate assumption affect report amount permit section company act group interest joint venture account research development asset liability disclosure contingent asset profit loss account company present gross equity method group interest associate research development expenditure charge profit liability date financial statement report undertaking account equity method loss account period incur tangible consolidated statement total recognise gain loss amount revenue expense report period fix asset research development depreciate include actual result differ estimate defer taxation relief unrealise intragroup profit accordance group policy account extent consider recoverable realise profit attributable shareholder reflect financial statement prepare accordance consolidate statement profit loss company accounting policy approve board asset liability overseas subsidiary associate environmental expenditure unrealise gain loss value group describe note undertaking joint venture include related goodwill environmental expenditure relate exist condition result overseas net asset relate foreign currency borrowing translate sterling rate exchange rule balance past current operation current attributable currency movement period sheet date result cash flow overseas subsidiary future benefit discernible charge profit loss tax item associate undertaking joint venture translate account group determine liability sitebysite basis sterling average rate exchange exchange adjustment record liability time probable reconciliation movement equity shareholder fund arise open net asset profit year reasonably estimate liability include group comprise item contribute increase decrease retain overseas subsidiary associate undertaking portion cost portion potentially period shareholder fund item include joint venture translate sterling exchange difference responsible party cost probable total recognise gain loss period arise relate foreign currency borrowing take directly able satisfy respective share cleanup obligation dividend pay propose reserve report statement total recognise recovery reimbursement virtually certain proceed share issue period gain loss record asset cost share purchase cancellation translate sterling asset liability result cash flow share buyback programme pension postretirement benefit overseas subsidiary associate undertaking joint change goodwill arise acquisition prior cost provide pension employee postretirement venture report currency hyperinflationary economy st january set directly reserve benefit charge consolidated profit loss account adjustment reflect current price level loss systematic rational basis base actuarial assumption net monetary asset charge consolidated profit loss period benefit derive employee service account difference charge contribution pay include asset liability consolidate balance sheet glaxosmithkline note financial statement note financial statement glaxosmithkline accounting policy continue prior acquire minor brand similar intangible accounting policy continue gain loss foreign exchange contract designate eliminate group balance sheet reserve year hedge forecast foreign exchange transaction defer legal dispute investment joint ventures associate acquisition include measurement relate foreign currency provision anticipate settlement cost legal investment joint venture associate undertaking transaction period occur gain loss balance expense associate claim receive legal carry consolidated balance sheet group share tangible fix asset sheet hedge accrue take directly reserve dispute group reasonable estimate net asset date acquisition post tangible fix asset state cost provision forward premiumdiscount recognise interest likely outcome dispute provision acquisition retain profit loss goodwill depreciation impairment cost acquire develop life contract unasserted claim obligation exist arise acquisition net amortisation computer software internal use internet site external dispute possible reasonable estimate cost interest differential interest swap agreement recognise use capitalise tangible fix asset software associate claim group party stock profit loss account adjustment interest expense site support significant business system expenditure charge profit loss account incur stock include financial statement low cost life agreement lead creation durable asset include manufacturing overhead appropriate net employee share plans depreciation calculate write cost tangible fix realisable value cost generally determine debt instrument incentive form share provide employee asset exclude freehold land equal annual instalment basis debt instrument state net proceed share option share award scheme respect award expect useful life normal expect useful life adjust amortise issue cost debt evenly term scheme certain share option grant company provide major category tangible fix asset review annually taxation debt finance esot purchase company share open market group account taxation defer accelerate meet company obligation provide share reason timing difference originate new accounting policy future requirement employee exercise option award excess freehold building year reverse balance sheet date defer tax asset december urgent issue task force issue abstract purchase price share exercise price option leasehold land short lease term recognise extent consider recoverable amend abstract relate accounting award charge profit loss account building year future taxable profit defer tax retain presentation esot requirement mandatory period service respect option award plant machinery year earning overseas subsidiary provide report require share hold esot grant respect share option grant share option fixture equipment year bind commitment distribute past earning future period show deduction arrive shareholder fund exercise account share issue exercise price erp system software year defer tax measure average tax rate expect charge profit loss account employee share option additional employer cost respect option award computer software year apply period time difference restrict intrinsic loss difference charge profit loss account period service erp system software generally involve significant customisation expect reverse defer tax liability asset market price exercise price date grant asset liability esot include group prior implementation expect useful economic discount june council european union adopt balance sheet cost run esot charge profit life seven year maximum year regulation require list company member state loss account share hold esot account computer software disposal tangible fix asset cost current asset investment prepare consolidated financial statement accordance fix asset investment hold cost provision recognise relate accumulate depreciation remove current asset investment state low cost net international financial reporting standard ifrs shortfall proceed receivable employee exercise financial statement net proceed realisable value glaxosmithkline annual report prepare ifrs deem permanent impairment value take consolidated profit loss account case security acquire significant premium year end st december financial discount maturity value intend hold redemption result announcement prepare accordance ifrs goodwill lease cost adjusted amortise premium discount life quarter goodwill state cost provision amortisation leasing agreement transfer group substantially maturity security float rate bond state cost amortisation calculate write cost equal annual benefit risks ownership asset treat group project convert financial report uk interest income take profit loss account instalment expect useful life useful life finance lease asset purchase outright gaap ifrs progressing train programme receivable basis normally expect exceed year asset include tangible fix asset capital element roll finance staff worldwide preparation leasing commitment show obligation finance equity investment include current asset regard collection historical datum provide comparative intangible fix asset lease asset hold finance lease depreciate available sale information ifrs advanced intangible asset state cost provision amortisation short lease term useful live asset interest element lease rental charge profit derivative financial instrument exchange rate acquire licence patent knowhow marketing right lease operating lease annual rental group hold issue derivative financial instrument amortise estimate useful life equal instalment group use average exchange rate prevail charge profit straightline basis lease term trading purpose long year item capitalise restricted period translate result cash flow overseas relate specific compound product derivative financial instrument manage exposure subsidiary joint venture associate undertaking impairment fix asset develop commercial application estimate useful life market risk treasury operation principal derivative sterling period end rate translate net asset carry value fix asset review impairment determine amortisation charge review annually instrument currency swap forward exchange contract undertaking currency influence indication asset impair account estimate time takes bring interest rate swap derivative contract treat translation relevant exchange rate provision impairment charge profit year compound product market marketable product inception economic hedge underlie financial concern year impairment review conduct development cost incur group instrument matching accounting treatment cash flow acquire goodwill intangible asset certain intangible associate acquire licence patent knowhow derivative contract high correlation specific average rate consider indefinite life marketing right write profit loss account financial instrument hedge inception amortise intangible subject annual impairment test incur hedge period derivative instrument long euro impairment determine reference high net designate hedge restate market value future yen brand value independently fair value realisable value value use measure reference change value take directly profit loss account period end rate business acquire party brand discount future cash flow value share hold value substantial longterm brand esot review quarterly determine permanent currency swap forward exchange contract fix euro sell separately rest business acquire impairment value relate asset liability contract currency yen brand amortise estimate useful life long contract rate accrue profit loss account year end useful economic life life contract brand foresee glaxosmithkline note financial statement note financial statement glaxosmithkline merger glaxo wellcome smithkline beecham segment information continue combination glaxo wellcome plc smithkline beecham plc treat merger th december uk gaap merger accounting share issue glaxosmithkline plc acquire glaxo wellcome smithkline beecham account turnover location subsidiary undertake par share premium arise share acquire glaxosmithkline glaxo wellcome smithkline beecham similarly usa account nominal value share issue consolidated financial statement glaxosmithkline result net europe assets glaxo wellcome smithkline beecham combine book amount subject alignment adjustment international turnover include intersegment turnover segment information usa analysis turnover profit taxation total asset net asset tangible fix asset business geographical sector set europe business sector consist pharmaceutical prescription pharmaceutical vaccine consumer healthcare oral care international otc medicine nutritional healthcare geographical sector reflect group significant regional market intersegment turnover consistent group regional market management reporting structure business sector datum include allocation corporate cost sector sale business sectors usa europe group activity organise global basis geographical sector figure influence location international group operate resource particular manufacturing research variation time intragroup trading fund external turnover arrangement group copromote product party record sale group record share revenue copromotion statutory profit tax location subsidiary undertaking income turnover nature copromotion activity group record cost sale pharmaceutical turnover usa include copromotion income million nil nil europe international operating profit turnover business sector share profit joint venture associate undertakings pharmaceutical profit disposal interest associate consumer healthcare profit disposal businesse external turnover product divestment net interest payable statutory profit tax business sector profit taxation pharmaceutical profit taxation consumer healthcare taxation operate profit minority interest share profit joint venture associate undertaking preference share dividend profit disposal interest associate statutory earning profit disposal business product divestment total asset location subsidiary undertake net interest payable usa profit taxation europe profit taxation international taxation total operating asset minority interest cash bank liquid investment preference share dividend total asset statutory earning net asset location subsidiary undertake total asset business sector usa pharmaceuticals europe consumer healthcare international total asset net operating asset net debt net asset business sector net asset pharmaceutical consumer healthcare net assets glaxosmithkline note financial statement note financial statement glaxosmithkline segment information continue merger item restructuring cost divest business continue plant disposal land equipment computer asset merger restructuring block drug subsidiary total tangible fix asset location subsidiary undertaking buildin g ms vehic le ms softw mre construct io mn mal mal manufacturing restructuring usa merger integration cost europe block drug integration cost international total effect operate profit profit disposal business effect profit tax turnover location customer usa effect taxation operating item europe effect taxation nonoperate item international effect taxation external turnover effect earning uk segment disposal merger restructuring block drug subsidiary total information give separately respect uk include group europe market region consider group home segment purpose segmental reporting manufacturing restructuring merger integration cost block drug integration cost turnover location customer effect operate profit product divestment turnover include intersegment turnover profit disposal business intersegment turnover effect profit tax turnover location subsidiary effect taxation operate item operate profit effect taxation nonoperate item total asset effect taxation net operating asset effect earning disposal merger item restructuring cost divest business merger restructuring block drug subsidiary total manufacturing restructuring cost incur glaxosmithkline implementation manufacturing restructuring previously announce plan restructure manufacturing activity merger integration cost merger integration cost relate integration glaxo wellcome smithkline beecham unify glaxosmithkline business block drug integration cost cost include consultancy fee respect integration planning severance cost asset writeoff cost relate early vest effect operating profit lapse performance condition share option share incentive award cost programme encourage staff convert loss disposal business glaxo wellcome smithkline beecham share option glaxosmithkline share option integration cost incur effect profit tax relate integration block drug business cost include professional fee severance cost asset writeoff product divestment income arise relate finalisation disposal famvir kytril product require effect taxation operate item order obtain regulatory approval merger effect taxation nonoperate item effect taxation disposal business relate finalisation disposal clinical laboratory healthcare service disposal business primarily arise sale affymax include million write goodwill effect earning previously eliminate group reserve operating incomeexpense royalty income operate expense income equity investment disposal royalty income principally core recur income form royalty outlicense intellectual property operating expense include litigation cost provision relate legal claim withdraw product product withdrawal antitrust matter income equity investment disposal include equity investment carry value adjustment arise stock market change product disposal equity investment sale glaxosmithkline note financial statement note financial statement glaxosmithkline operating profit net interest payable follow item charge operating profit interest payable employee cost note bank loan overdraft advertising loan distribution cost respect finance lease depreciation tangible fix asset unwind discount provision own asset lease asset share interest payable associate amortisation goodwill amortisation intangible fix asset exchange loss foreign currency depositsloans investment income operating lease rental interest income plant realise gain land building unwind discount asset audit fee fee auditor work auditor uk firm auditor overseas firm analysis fee auditor work taxation assurance auditrelated service tax service taxation charge base profit period merger glaxo wellcome smithkline beecham uk corporation tax uk statutory rate service double taxation relief include audit fee fee relate company audit overseas taxation glaxosmithkline plc include assurance service amount related group preparation adoption defer taxation international financial reporting standard preparation section sarbanesoxley act tax service relate fee pay corporate tax compliance tax planning advice service include human resource advisory compliance treasury relate service include fee auditor work million pay auditor management share taxation charge associate consulting practice sell group start apply discount certain longterm asset liability riskfree rate return reconciliation current taxation rate group profit joint venture associate undertakings uk statutory rate taxation overseas taxis associate undertaking average group tax rate share profit quest diagnostic inc effect special tax status manufacturing location share loss associate undertaking share option deduction usa amortisation goodwill merger restructuring cost rd credit share loss joint venture permanent difference capital allowance excess depreciation intragroup profit reverse time difference tax loss share turnover joint venture time difference sale joint venture associate undertaking prior year item current tax rate ordinary activity capital allowance excess depreciation intragroup profit reverse time difference tax loss time difference share taxation charge associate prior year item tax rate ordinary activity group operate country tax rate differ uk tax rate average group tax rate determine aggregate local standard tax rate weight proportion accounting profit profit arise manufacturing operation singapore puerto rico ireland tax reduce rate effect reduction taxation charge increase earning share p p p glaxosmithkline note financial statement note financial statement glaxosmithkline taxation continue earning share integrate nature group worldwide operation involve significant investment research strategic manufacture p p p limited number location consequential crossborder supply route numerous endmarket give rise complexity delay negotiation revenue authority profit individual group company liable tax disagreement basic earning share revenue authority intragroup transaction particular price good transfer group adjustment merger item restructuring cost disposal subsidiary company different tax jurisdiction produce conflict claim revenue authority profit fall tax merger integration transaction cost individual territory resolution issue continue fact life glaxosmithkline group open issue revenue restructuring cost authority usa uk japan canada far large relate glaxo heritage product usa block drug integration cost disposal business glaxosmithkline attempt settle dispute direct discussion internal revenue service irs adjust earning share subsequently discussion uk authority term double tax convention country glaxosmithkline understand view tax authority different unable reach diluted earning share agreement discussion terminate july basic adjust earning share calculate divide profit attributable shareholder weight average group receive claim additional taxis irs assert legacy company glaxo wellcome owe year number share issue period number calculate basic diluted earning share reconcile statutory notice deficiency billion billion tax principally relate allocation profit glaxo heritage product usa country extent irs successful claim interest payable adjusted earning share calculate business performance earning business performance primary performance glaxosmithkline estimate interest claim date approximately billion billion net federal tax relief measure management present exclude merger item integration restructuring cost disposal business similar tax issue remain open date glaxosmithkline expect receive claim irs year management believe exclusion item provide well reflection way business manage give indication performance group term element revenue expenditure local management able glaxosmithkline exhaust administrative remedy open group plan contest claim additional taxis influence information provide addition statutory result prepare uk gaap give assist shareholder file petition tax court trial expect gain clear understanding underlying performance business increase comparability period present glaxosmithkline continue believe profit report subsidiary period date pay taxis usa sufficient reflect activity operation net profit period attributable shareholder earning basic diluted glaxosmithkline use good advice determine transfer pricing methodology seek manage transfer pricing issue adjustment merger item restructuring cost disposal subsidiary satisfactory conclusion basis external professional advice continue believe adequate provision liability likely arise open assessment continue wide difference view group irs adjust earning ultimate liability matter vary amount provide dependent outcome litigation proceeding negotiation relevant tax authority weight average number share issue million million million show financial statement provision taxation arise distribution profit basic adjust retain overseas subsidiary associate undertaking ground remittance profit retain st december dilution share option require way incremental tax arise dilute st december group income tax loss approximately million million capital loss estimate excess billion excess billion recognise defer tax asset insufficient share hold employee share ownership trust esot exclude trustee waive right dividend share evidence loss held esot current defer defer tax creditor tax debtor tax provision dividend tax balance st january interim exchange adjustment second interim charge profit loss account interim cash pay fourth interim movement st december dividend share p p p defer taxation assetliability interim accelerate capital allowance second interim stock valuation adjustment interim intragroup profit fourth interim product business disposal pension postretirement benefit tax loss legal dispute merger integration manufacturing restructure net timing difference defer taxation provide stock valuation adjustment intragroup profit timing difference show current defer taxation movement arise origination reversal timing difference net timing difference include accrue expense provision glaxosmithkline note financial statement note financial statement glaxosmithkline plant land equipment computer asset goodwill total tangible fix asset building vehicle software construction total cost st january cost st january exchange adjustment exchange adjustment addition note addition disposal cost st december reclassification amortisation st january cost st december exchange adjustment provision year depreciation st january exchange adjustment amortisation st december provision year net book value st january disposal reclassification net book value st december depreciation st december impairment st january licences exchange intangible asset patent etc brand total impairment loss cost st january disposal exchange adjustment impairment st december addition asset write total depreciation impairment st december cost st december net book value st january net book value st december amortisation st january exchange adjustment net book value st december group land building comprise freehold property million provision year st january million property lease year million st january million asset write property lease year million st january million include plant equipment vehicle amortisation st december st december lease asset cost million st january million accumulate depreciation million st january million net book value million st january million impairment st january impairment loss principally arise decision rationalise facility calculate base net realisable value value exchange adjustment use typically record sga discount rate cent impairment loss asset write joint associate equity fix asset investment venture undertaking investment share total impairment st december total amortisation impairment st december st january exchange adjustment net book value st january addition charge year net book value st december impairment licence patent acquire year relate acquisition compound right research base agreement transfer note disposal retain profit year brand largely comprise portfolio product acquire acquisition sterling winthrop inc panadol solpadeine goodwill amortisation hedex product acquire acquisition block drug company sensodyne polident poligrip st december consider indefinite life give strength durability brand level marketing support accordingly amortise valuation sterling brand review annually year cash flow forecast investment joint venture comprise million share gross asset million million share gross liability million basis original independent assessment acquire posttax discount rate cent valuation block drug brand review annually year cash flow forecast posttax discount rate principal associate undertaking quest diagnostic inc clinical laboratory business list new york stock exchange cent investment book value st december million million market value million million st december group own cent quest cent book value include goodwill amortise year amortisation charge million goodwill st december amount million million goodwill million relate continue group interest clinical laboratory asset attribute quest remain eliminate group reserve equity investment comprise list investment million million unlisted investment million million market value list investment st december million million investment share consist share hold employee share ownership trust note market value share st december million million valuation shortfall consider represent permanent diminution value context length future period relate share option exercise accordingly provision glaxosmithkline note financial statement note financial statement glaxosmithkline equity investment provision pension legal postretirement manufacturing merger defer total liability charge benefit restructure integration dispute taxation provision total st january st january exchange adjustment exchange adjustment addition charge year impairment unwind discount disposal apply st december reclassification movement st december equity investment include list investment million million market value list investment million million group special cash contribution total million uk pension scheme contribution relate pension scheme include amount apply provision contribution relate uk pension scheme increase pension prepayment show debtor note stock group recognise cost respect plan manufacture restructuring initiate raw material consumable follow merger glaxo wellcome smithkline beecham acquisition block drug plan largely complete cost work progress recognise provision principally respect identify severance site announce manufacturing activity finish good cease expect incur mainly cost asset writedown recognise impairment fix asset group recognise cost respect plan integration glaxo wellcome smithkline beecham business implementation integration follow merger substantially complete cost recognise provision respect identify severance expect incur respect programme encourage staff convert glaxo wellcome smithkline beecham share option glaxosmithkline share option employee exercise option debtor provision discount million riskfree rate return provision legal dispute matter include amount relate antitrust product liability contract termination amount year selfinsurance environmental cleanup property rental company director take legal advice establish provision trade debtor take account insurance agreement regard relevant fact circumstance matter debtor accordance accounting requirement provision discount million riskfree rate return prepaid pension contribution reclassification include amount receivable insurance contract show debtor note prepayment accrue income provision unasserted claim ultimate liability matter vary amount provide amount year dependent outcome litigation proceeding investigation possible settlement negotiation debtor prepayment accrue income glaxosmithkline involve number legal dispute include notification possible claim early defer taxation note stage matter reliable estimate outcome accordingly provision record matter unasserted claim nature group business number matter subject negotiation litigation debtor include trading balance million nil joint venture associate undertaking debtor year large individual amount provide expect settle year year include insurance recovery receivable discount riskfree rate return discussion legal issue refer note legal proceeding creditor contingent liability st december contingent liability comprise guarantee discount bill item arise normal course amount year business amount million million discussion tax issue refer note taxation legal issue trade creditor refer note legal proceeding taxation note social security creditor accrual defer income dividend payable amount year creditor accrual defer income accrual include obligation wage salarie million million glaxosmithkline note financial statement note financial statement glaxosmithkline net debt net debt continue secure loan liquid investment loan amount million million secure charge fix current asset cash bank finance lease obligation loan overdraft year rental payment year bank loan overdraft rental payment year commercial paper rental payment year eurobond mediumterm notes rental payment year obligation finance lease rental payment year loan rental payment year total finance lease obligation loan year bank loan financial instrument eurobond mediumterm note private financing information give note loan stock obligation finance lease commitment loan capital commitment contract provide financial statement net debt intangible fix asset tangible fix asset balance sheet date group liquid investment aggregate market value million million liquid investment include redeemable preference share fully collateralise highly rate bond billion nil group enter number research collaboration develop new compound pharmaceutical company loan overdraft year term arrangement include upfront fee equity investment loan commitment fund specify level research commercial paper comprise billion programme million issue st december future addition group agree payment future milestone achieve st december million back committed facility day duration million million agreement relate compound early stage development milestone payment continue number year million renewable annually liquid investment million million million compound successfully development process generally close product marketing approval great possibility success weight average interest rate commercial paper borrowing st december cent cent group commitment million million relate revenue payment licence loan year alliance principally exelixis inc bond issue european medium term note programme billion cent coupon bond number commitment licensing agreement principally neurosearch ranbaxy million cent coupon bond laboratory ltd pozen inc loan year repayable period follow commitment operating lease pay rental year operating lease land building expire year year year year year year year year operating lease plant equipment vehicle expire year loan repayable year carry interest effective rate cent cent repayment date range year year commitment operating lease pay rental future year glaxosmithkline note financial statement note financial statement glaxosmithkline profit share reserve reserve loss account total share capital share premium account ordinary share p p ccm oi uu nm number st december goodwill write share capital authorise exchange movement st december share purchase cancellation st december profit attributable shareholder share capital issue fully pay dividend st january revaluation goodwill exchange share capital issue share option scheme st december share capital purchase cancel exchange movement st december uk tax exchange movement share capital issue share option scheme share purchase cancellation share capital purchase cancel profit attributable shareholder dividend st december unrealise gain equity investment st december number exchange movement number share issuable outstanding option note tax exchange movement unrealise gain st december share purchase cancellation st december profit attributable shareholder dividend number unissue share option unrealise gain equity investment st december revaluation goodwill exchange st december st december october glaxosmithkline commence new billion share buyback programme follow completion billion buyback programme announce total million spend new share buyback programme goodwill arise acquisition st january write reserve amount million million spend exact time future purchase repurchase share hold include goodwill million previously hold goodwill reserve offset reserve goodwill treasury share cancel determine company dependent market condition factor write relate primarily disposal affymax group hold quest diagnostic inc goodwill period st january th february million share purchase cancel cost denominate local currency subject revaluation amount million st december million goodwill acquisition st january capitalise accordance accounting policy set note detail substantial shareholding refer substantial shareholding exchange movement take reserve include loss million loss million loss million foreign currency loan deposit gain million gain million loss million nonequity minority interest retranslation net asset million nil loss million goodwill eliminate reserve smithkline beecham holdings corporation sbh corp subsidiary incorporate delaware usa issue million flexible tax exchange movement unrealise gain year million million nil relate taxable auction market prefer stock flex amp comprise share issue series dividend share element foreign currency loan deposit unrealise gain take reserve fix issuance sevenyear period end july half share year period end half dividend share vary predominately prevail interest rate exchange adjustment debit reserve cumulatively million million million set seven week auction share trade reserve include merger reserve create merger glaxo wellcome smithkline beecham amounting million sbh corp issue million auction rate preference stock arp comprise share issue st december million million reserve include capital redemption reserve create series dividend vary condition similar flex amp describe result share buyback programme amount million st december million million arp flex amp constitute preference share represent nonequity minority interest notice total reserve amount million st december million million million redeem series give february redemption expect complete march april million million relate company million million million relate joint venture associate undertakings smithkline beecham plc certain circumstance guarantee payment dividend declare preference share smithkline beecham plc agree sbh corp certain circumstance provide support sbh corp relation principal profit glaxosmithkline plc year million million million dividend guarantee support limit circumstance holder preference share favourable million million million give retain loss million profit million position holder preference share smithkline beecham plc preference share represent longterm profit million cost share purchase cancellation million million nonequity minority interest group balance sheet accordance frs capital instrument uitf obligation capital million unrealise profit capital reduction subsidiary nil million nil profit instrument loss account reserve st december stand million million million million unrealise million nil glaxosmithkline note financial statement note financial statement glaxosmithkline legal proceeding group continue pursue patent infringement claim legal proceeding continue case discovery phase june group litigation eastern district pennsylvania apotex commence action district court district group involve numerous legal administrative action file watson pharmaceuticals geneva alphapharm andrx teva pharmaceuticals zenith new jersey faulding pharmaceutical company allege proceeding principally product liability intellectual property district court southern district ohio eon labs bulk supplier basf sumika fine chemical apotex infringement method use patent ondansetron antitrust governmental investigation relate private manufacture district court southern district alphapharm basf sumika file counterclaim faulding challenge compound patent case litigation significant matter describe new york impax laboratorie district court action allege group violate antitrust unfair date report stay pende decision northern district california excel pharmaceutical competition law teva reddy kali case district court district new jersey intellectual property february cafc hear apotexs appeal decision district court eastern district virginia watson case lamictal usa district court district columbia deny settle term involve supply agreement refer august group commence action district apotexs request fda require delist certain court district new jersey teva pharmaceuticals paxil group patent paxil orange book october usa inc allege infringement group compound patent usa number distributor generic drug file judge grant summary judgement noninfringement cafc affirm district court decision dismiss lamotrigine active ingredient lamictal oral tablet application fda market generic version impax excel case group appeal case patent expire july defendant file anda paxilseroxat paroxetine hydrochloride prior expiration decision cafc january cafc rule favour fda certification invalidity group patent group patent paroxetine hydrochloride march glaxosmithkline file action pentech impax affirm district court ruling impax fda approval anda stay early january hemihydrate apotex launch generic version paxil pharmaceutical district court northern district generic version infringe group patent fda resolution patent infringement litigation trial september distributor looking bring illinois infringement group patent paroxetine early grant tentative approval impax generic version date set case market anhydrate version paroxetine hydrochloride hydrochloride pentech file anda capsule version cafc rule group appeal summary case paroxetine mesylate response group file paxil assert compound presentation infringe judgement noninfringement excel case eons motion levitra action distributor infringement group patent patent invalid april summary judgement noninfringement deny district october pfizer inc file action bayer ag group patent case complex group believe group reach settlement pentech par court trial eon case conclude december glaxosmithkline district court district generic anhydrate version infringe pharmaceutical pentech grant right date report decision announce delaware allege manufacture sale levitra contain andor convert hemihydrate form andor pentechs anda paroxetine hydrochloride capsule vardenafil infringe patent newly issue pfizer january cafc grant eons motion stay infringe group patent settlement allow par distribute puerto rico substitutable ask bayer glaxosmithkline permanently enjoin preliminary injunction launch eons mg generic generic paroxetine hydrochloride immediate release tablet september patent trademark office initiate july glaxosmithkline file action apotex version enter trial court conclusion supply licensed group royalty payable reexamination pfizer patent base question district court northern district illinois trial term supply agreement group par entitle distribute product patentability light prior art pfizer action include infringement group patent paroxetine hydrochloride glaxosmithkline watson pharmaceutical begin ship market apotexs generic version paxil available additional suit file court follow launch hemihydrate apotex file abbreviate new drug second mg generic version day eon begin september settlement par pentech levitra usa predicate validity patent application anda fda seek approval introduce shipment generic version january acknowledge glaxosmithkline patent covering stay pende outcome reexamination generic form paxil follow trial february judge hemihydrate form paroxetine hydrochloride valid zofran rule glaxosmithkline patent valid infringe imitrex enforceable infringe pentechs propose capsule august group commence action district apotexs product glaxosmithkline appeal rule non december group commence action product bureau competition federal trade court district new jersey reddycheminor infringement court appeal federal circuit district court southern district new york commission review settlement review voluntary dr reddys laboratories dr reddy certify invalidity cafc hear appeal district court dr reddys laboratory allege infringement conduct request group par pentech patent ondansetron active ingredient zofran tablets intellectual property matter cafc hear appeal primary compound patent sumatriptan active ingredient pentechs supplier asahi glass co file claim alleging include compound patent expire july january date report decision imitrex patent expire defendant file settlement violate antitrust law district court method use patent later expire december announce anda fda certification invalidity northern district illinois dismiss claim instance take account expect extension compound patent certify invalidity noninfringement june glaxosmithkline file action geneva october asahi appeal decision cafc paediatric exclusivity reddy case schedule trial second compound patent expire december pharmaceutical subsidiary novartis pharmaceutical similar claim bring apotex sumika pende july group file action dr case early stage district court eastern district pennsylvania district court eastern district pennsylvania reddys laboratories district court infringement infringement group patent paroxetine hydrochloride group patent relate orally disintegrate tablet valtrex october glaxosmithkline file action synthon follow notice genevas anda filing case presentation zofran october group file action group commence action district pharmaceutical district court middle district consolidate similar infringement action westward pharmaceuticals inc district court court district new jersey ranbaxy laboratories north carolina infringement group patent generic company subsequently file anda additional infringement group patent relate injectable allege infringement group compound patent paroxetine hydrochloride paroxetine mesylate synthon infringement action bring base patent issue presentation zofran dr reddy disintegrate tablet valaciclovir active ingredient valtrex patent expire file b application paper nda fda subsequent original filing apotex northern case westward case consolidate defendant file anda fda paroxetine mesylate different salt form paroxetine district illinois group file action apotex early dr reddy case schedule trial certification invalidity group compound patent market form paxil december relate new patent eastern district noninfringement patent expire glaxosmithkline synthon reach settlement pursuant march group file similar action teva pennsylvania december judge grant list orange book fda approval anda stay group grant synthon royaltybearing license pharmaceuticals usa inc district court district deny summary judgement motion file apotex early october resolution patent market paroxetine mesylate product usa delaware allege infringement method use patent result issue validity infringement infringement litigation discovery underway case ondansetron teva certify invalidity noninfringement new patent trial group petitioned wellbutrin method use patent teva challenge avandia district court permit interim appeal cafc june distributor generic pharmaceutical product file compound patent trial teva case conclude january august group file action district court group request food drug administration anda sustain release bupropion hydrochloride tablet date report decision district new jersey teva pharmaceuticals usa inc fda remove patent relate paxil register wellbutrin sr zyban accompanied case announce september november january infringement group patent relate maleate salt pharmaceutical patent maintain fda orange book certification invalidity andor infringement group group file action teva court form rosiglitazone active ingredient avandia delisting affect validity patent patent group bring suit patent infringement infringement group patent relate injectable expire september group file comparable relate patent litigation follow fda approval anda filing party group file suit orally disintegrate tablet presentation zofran action court dr reddys laboratory allege apotex subsequently launch generic version paxil andrx pharmaceutical file anda district infringement patent maleate salt form september early ondansetron case involve orally disintegrate zofran court southern district florida february tablets commence group january kali district court judge grant andrxs summary judgement motion laboratorie district court district new jersey rule product infringe group patent september cafc reverse decision remand case district court trial glaxosmithkline note financial statement note financial statement glaxosmithkline legal proceeding continue uk europe legal proceeding continue baycol august bayer ag withdraw baycol cerivastatin sodium dr reddys laboratory teva file andas fda seroxat patent set expire include supplementary worldwide light report adverse event include death certification invalidity group maleate salt patent follow expiration datum exclusivity period europe protection certificate protection relate combination involve rhabdomyolosis glaxosmithkline participate fda approval andas stay early marketing authorisation issue synthon bvgenthon active ingredient salmeterol fluticasone propionate marketing baycol usa pursuant copromotion november resolution respective patent infringement october regulatory authority denmark paroxetine separate patent exist challenge provide agreement bayer license holder action teva subsequently file additional certification mesylate different salt form paroxetine patent protection uk late manufacturer product challenge validity group basic compound patent market form seroxatpaxil marketing authorisation subsequently generic uk ivax arrow generic file rosiglitazone january group commence grant number european country follow withdrawal bayer glaxosmithkline revocation action respect patent trial action teva court infringement majority base original danish approval name defendant thousand lawsuit file state revocation action complete january patent basic compound patent currently expire mutual recognition process generic product contain federal court usa behalf individual judge decision expect shortly uk seretide expiry expect extend paroxetine mesylate launch austria denmark putative class baycol user number suit patent example relate diskus device patent trademark office grant patent term restoration france germany ireland italy netherlands sweden allege plaintiff suffer personal injury include cfcfree mdi device expire respectively product austria denmark withdraw rhabdomyolosis use baycol claim person augmentin challenge follow award patent interim injunction group take baycol injure risk future august group commence proceeding initiate litigation challenge approval danish injury suffer economic damage purchase geneva pharmaceuticals biochemie gmbh biochemie spa product liability medicine agency ground authorisation baycol plaintiff seek remedy include compensatory parent novartis ag international trade paxil grant abridge procedure paroxetine punitive statutory damage creation fund medical commission colorado state court alleging group receive purport class action individual mesylate essentially similar seroxat question monitor glaxosmithkline bayer corporation principal manufacture sale usa genevas generic augmentin lawsuit file state federal court usa alleging case refer european court justice subsidiary bayer ag sign allocation agreement product production strain steal early paroxetine active ingredient paxil addictive cause february bayer corporation agree pay cent glaxosmithkline constitute misappropriation group trade dependency withdrawal reaction plaintiff seek remedy settlement compensatory damage judgement secret unfair competition proceeding seek marketing authorisation issue european include compensatory punitive statutory damage party retain responsibility attorney fee prevent importation sale usa generic augmentin country product contain paroxetine hydrochloride cost fund medical monitoring federal judge punitive damage federal case consolidate contain clavulanate steal glaxosmithkline anhydrate variant group product generic district court central district california deny multidistrict litigation proceed district court production strain colorado action seek damage product contain anhydrate market class action certification nationwide class california district minnesota numerous case schedule trial additional action bring lek pharmaceutical austria denmark finland france germany italy netherlands statewide class case file federal court district state federal court date class action novartis affiliate october north carolina state portugal spain sweden uk glaxosmithkline believe subsequently petition plaintiff counsel federal court glaxosmithkline name defendant court july group reach settlement agreement marketing paroxetine hydrochloride anhydrate product case transfer district court consolidation certify oklahoma september plaintiff class novartis affiliate company name group paroxetine mesylate product party european multidistrict litigation mdl remain lawsuit action certification motion consolidate federal multidistrict complaint itc complaint relate state court country infringe patent litigate position action early stage certain state court trial litigation deny action term agreement group receive european country outside usa june schedule start determination singledigit percentage royalty sale generic version european patent office opposition division reject lawsuit pende mdl state fenphen augmentin sell novartis affiliate company july opposition file synthon group european patent court permit proceed class action fda aware report cardiac valvular june similar state court action cover crystal form paroxetine mesylate problem individual fenfluramine dexfenfluramine decade litigation initiate teva pharmaceuticals usa inc ranbaxy synthon product decision appeal combination phentermine prescribe manufacturer prozac selective serotonin reuptake pharmaceuticals inc august philadelphia county regimen weight reduction request voluntary uk follow revocation action initiate synthon inhibitor ssri products paxil homicidal suicidal court common plea affect novartis withdrawal fenfluramine dexfenfluramine market court appeal uphold validity correspond uk behaviour exhibit user product group settlement november cafc affirm decision report cardiac valvular problem subsequent patent decision overturn instance decision receive number claim lawsuit respect district court eastern district virginia hold withdrawal product market spawn numerous hold patent invalid synthon petition leave paxil purport class action group patent cover augmentin invalid product liability lawsuit file manufacturer appeal house lords accept february phenylpropanolamine distributor fenfluramine dexfenfluramine phentermine ceftin dutch court revoke correspond dutch patent follow report yale haemorrhagic stroke project number manufacturer phentermine group group file action infringement patent decision appeal find suggestion association use defendant thousand lawsuit state federal cefuroxime axetil active ingredient group ceftin anti response challenge basf group uk patent phenylpropanolamine ppa decongestant haemorrhagic district court usa lawsuit seek relief include infective product ranbaxy pharmaceutical paroxetine hydrochloride anhydrate uk high court july stroke group manufacturers voluntarily combination compensatory punitive damage district court new jersey preliminary injunction grant judge decide patent partly valid partly withdraw consumer healthcare product ppa medical monitoring refund purchase drug favour group cafc subsequently vacate invalid claim hold valid assert apotex neolab active ingredient ppa product withdrawal group judicial panel multidistrict litigation issue order injunction remand case district court waymade healthcare interim injunction prevent sale name defendant numerous personal injury consolidate transfer federal action district trial merit ranbaxy launch generic version version product grant november class action lawsuit file state federal court allege court eastern district pennsylvania court approve march trial conclude august june uk court appeal uphold instance personal injury increase risk injury use product global settlement propose defendant wyeth sell date report decision announce decision hold process claim patent valid contain ppa unfair deceptive business practice fenfluramine dexfenfluramine settlement subsequently patent group claim infringement expire infringement action apotex continue plaintiff seek remedy include compensatory punitive confirm circuit court appeal include group seek monetary damage base patent uk high court rule december favour damage refund federal case consolidate phentermine defendant include group ranbaxys sale group file similar action apotex hold patent infringe invalid multidistrict litigation proceed district court individual plaintiff elect opt class settlement apotex second distributor generic pharmaceutical product glaxosmithkline file appeal decision district washington judge responsible pursue claim individually ten thousand district court northern district illinois hearing schedule ndrd march proceeding deny class certification strike class plaintiff elect wyeth continues settle preliminary injunction grant favour group june interim apotex launch generic version seroxat uk allegation federal personal injury consumer refund individual state court case trial group continue apotex subsequently obtain fda approval january class action limit number case group dismiss lawsuit settle wyeth generic product trial judge rule apotex willfully manufacturer defendant reach trial state infringe group patent award attorney fee seretide court class certification deny california state court glaxosmithkline january cipla neolab file action uk high pennsylvania state court putative class action court seek revocation group uk patent dismiss leave putative class action pende relate asthma treatment seretideadvair group litigation glaxosmithkline note financial statement note financial statement glaxosmithkline legal proceeding continue civil suit file state court state attorney general legal proceeding continue commercial matter class action plaintiff initially remove federal court otsuka pharmaceutical co ltd initiate arbitration proceeding thimerosal august cafc issue decision affirm district conditionally transfer federal court december concern group unilateral withdrawal glaxosmithkline number pharmaceutical court judgement invalidity decline rule massachusetts attorney general case new york grepafloxacin raxarvaxar october safety reason company name defendant numerous individual judgement inequitable conduct nevada connecticut private payer class action otsuka allege product withdrawal simultaneous personal injury lawsuit purport class action state case remand respective state court follow district court decision antitrust claim allege public announcement constitute material breach license federal district court usa courts canada allege remand motion pende action competitive injury overcharge file teva eon supply agreement thimerosal preservative vaccine cause early stage pharmaceutical generic manufacturer nabumetone neurodevelopmental disorder injurie plaintiff seek group believe underlie product withdrawal purport class direct indirect purchaser payer remedy include compensatory punitive statutory damage cidra puerto rico manufacturing site consistent term agreement valid individual retail chain cost fund medical monitoring research october fda begin investigation group defence exist claim uk arbitration panel conclude lawsuit early stage manufacture facility cidra puerto rico cidra site plaintiff claim base allegation fraudulent hearing liability december date determination purport class action engage tablete packaging range procurement patent wrongful listing patent issue determination event panel find favour permit proceed class action glaxosmithkline product primarily market include fda orange book prosecution sham patent infringement otsuka liability separate hearing hold later paxil paxil cr coreg avandia avandamet subsequently litigation case originally file district determine damage lotronex fda issue form observation possible court district massachusetts eastern district follow voluntary withdrawal lotronex usa deficiencies manufacturing practice group pennsylvania transfer district massachusetts environmental matter november number lawsuit file group settle case file teva eon group glaxosmithkline notify potential responsibility group state federal district court include individual fda observation relate certain aspect production major retail pharmacy chain january group reach relate past operation past waste disposal practice personal injury action purport class action assert control process validation laboratory investigation primarily settlement class direct purchaser pursuant certain site primarily usa matter product liability consumer fraud claim plaintiff seek remedy respect activity occur group agree pay million settlement subject litigation include proceeding initiate include compensatory punitive statutory damage group respond observation contain form subject approval district court litigation continue federal state government waste disposal site remediation substantial number claim settle date fda advise group class indirect purchaser court trial cost tort action bring private party remain action early stage tentative trial action indicate group continue work set june date case set summer fall closely fda address concern implement glaxosmithkline advise responsible date class certify class action change require agency arise forms augmentin party approximately site appear matter west virginia state court reject plaintiff request fda investigation group receive indication district court eastern district virginia national priority list create comprehensive environmental certify national refund class certify class west ongoing supply site affect find patent cover augmentin invalid hold response compensation liability act superfund virginia consumer suffer economic injury result subsequently affirm cafc immediately follow proceeding seek require operator hazardous individual purchase lotronex note damage antitrust adverse trial court decision purport antitrust class action waste facility transporter waste site generator prove limit cost medication paxil file behalf consumer party payer hazardous waste dispose site clean site november federal trade commission ftc staff federal court transfer consolidated reimburse government cleanup cost government investigation advise group conduct nonpublic district court eastern district virginia plaintiffs instances glaxosmithkline involve allege generator colorado attorney subpoena investigation determine group violate allege group knowingly obtain invalid patent hazardous waste site february glaxosmithkline receive subpoena section federal trade commission act monopolize engage anticompetitive conduct prevent entry glaxosmithkline involve current operator attorney office colorado group sale attempt monopolize market paroxetine generic product violation monopolization section facility superfund provide defendant promotional practice relate number large selling hydrochloride prevent generic competition paxil antitrust law plaintiff seek declaratory injunctive relief jointly severally liable cleanup cost proceeding product period january present group request group submit certain information connection treble damage allege overcharge frequently resolve basis nature quantity cooperate investigation early stage investigation october ftc closed determination putative class action waste dispose site generator glaxosmithkline investigation basis finding action permit proceed class action new complaint average wholesale price proportionate liability cleanup cost substantially warrant file shortly cafc decision complaint file glaxosmithkline respond subpoenas office determine site refer december district court eastern district inspector general department health human follow public reference ftc investigation paxil virginia lek pharmaceuticals whollyowne subsidiary glaxosmithkline potential liability vary greatly site site service department justice states texas purport class action file district court novartis seek lose profit treble damage injunctive relief cost investigation study remediation site california connection allegation pharmaceutical eastern district pennsylvania behalf indirect attorney fee second purport class action file time substantial glaxosmithkline routinely accrue company include glaxosmithkline violate federal fraud purchaser include consumer party payer direct court behalf direct purchaser primarily wholesaler amount related share liability matter abuse law federal false claim act purchaser plaintiff claim group monopolize respect texas california comparable state law result market paxil bring allegedly sham patent litigation wellbutrin legal charge provision way certain drug price base average allegedly abuse regulatory procedure list separately group prosecute patent infringement suit legal expense incur relate defence group wholesale price awp way medicare medicaid patents fda orange book treble damage seek company file anda seek permission intellectual property litigation cost provision relate programme reimburse drug allege overcharge flow conduct case sell generic bupropion wellbutrin srzyban usa product liability claim exist product charge sell schedule trial december motion certification case summary judgement enter subsequently state nevada montana new york general administration cost litigation cost provision class direct indirect purchaser group follow adverse ruling patent litigation connecticut respective attorney general relate legal claim withdraw product antitrust decide patent infringement litigation glaxosmithkline purport class action initially file behalf county new york state file civil lawsuit state matter charge operating incomeexpense provision generic drug company file antitrust counterclaim purchaser party payer district court federal court glaxosmithkline drug take appropriate legal advice reasonable base allegation october antitrust claim eastern district pennsylvania allege group engage company action claim behalf state payer estimate likely outcome dispute file asahi glass co dismiss district court anticompetitive conduct include prosecution sham patent behalf instate patient consumer damage information provision take payment northern district illinois asahi appeal decision infringement litigation prevent entry generic product restitution base defendant awpbase pricing provision set note cafc glaxosmithkline motion dismiss portion seek declaratory injunctive relief treble damage undefined set pharmaceutical product cover state counterclaim file apotex sumika district court allege overcharge case subsequently ultimate liability legal claim vary amount medicaid programmes addition private payer class action eastern district pennsylvania decide consolidated single action district court plaintiff provide dependent outcome litigation lawsuit file glaxosmithkline federal group enter agreement plaintiff proceeding investigation possible settlement negotiation district state court federal case relafen dismiss consolidated case prejudice refile consolidate multidistrict litigation proceed august district court district dismissal paper pende court tax matter district court district massachusetts massachusetts rule group patent nabumetone relafen pende tax matter describe note invalid anticipatory art unenforceable ground inequitable conduct glaxosmithkline note financial statement note financial statement glaxosmithkline acquisition disposal acquisition disposal continue detail acquisition disposal subsidiary associate undertaking joint venture give book fair value net asset goodwill cost book fair value net asset goodwill cost acquisition valu e ms adjustme n mts acqui md capitalis e md acquisit io mn value adjustment acquire capitalise acquisition acquisition block drug europharm shionogi joint venture europharm group complete buyout minority interest europharm holding sa group subsidiary locate romania million give rise goodwill million capitalise block drug company inc iterfi sterilyo january group acquire block drug cash consideration million represent fair value asset payment million pursuant acquisition agreement base financial performance acquire acquire company include defer compensation shionogi joint venture disposal group establish joint venture shionogi develop commercialise number compound contribute sb clinical laboratory party group acquire cent equity share capital cash consideration million commit additional cash refund million receive respect indemnify liability arise sb clinical laboratory contribution certain development milestone achieve disposal occur refund follow successful outcome case court appeal disposal iterfi sb clinical sterilyo europharm laboratory total quest diagnostic inc cash flow group disposed million share investment quest diagnostic inc cash proceed million cash consideration pay reduce group hold st december cent recognise charge goodwill previously write reserve million profit million recognise net cash proceed disposal affymax group complete sale affymax business affymax inc new hold company million nonvoting book fair value net asset goodwill cost preference share affymax inc represent value million million recognise charge goodwill previously value adjustment acquire capitalise acquisition acquisition write reserve million loss million disposal cost million incur completing sale iterfi sterilyo tagamet human kft february group sell tagamet japan sumitomo pharmaceutical co ltd cash consideration million recognise charge goodwill previously write reserve million loss million recognise quest diagnostic affymax tagamet block drug shionogi total iterfi sterilyo cash flow group acquire iterfisterilyo group initial cash consideration million payment pay cash consideration pay million base financial performance acquire company net asset iterfisterilyo cash acquire incorporate financial statement provisional fair value adjustment value net cash payment acquisition human kft net cash proceed disposal group acquire vaccine relate asset human kft manufacturing business locate hungary cash consideration million disposal sb clinical laboratory cash refund million receive respect indemnify liability arise sb clinical laboratory disposal occur refund follow successful outcome case court appeal sb clinical iterfi human laboratory sterilyo kft total cash flow cash consideration pay net cash proceed disposal glaxosmithkline note financial statement note financial statement glaxosmithkline financial instrument relate disclosure group apply boardapprove limit credit financial instrument relate disclosure continue exposure counterparty employ strict minimum policy classification fair value financial asset liability credit worthiness criterion choice counterparty discussion group objective policy follow table set classification financial asset liability provide reconciliation group net debt note management financial instrument associate risk shortterm debtor creditor exclude financial asset liability provision include fair value financial asset liability include treasury policy operate financial contractual obligation settle cash table present carry amount uk review prospect gaap fair value group financial asset liability st december st december investment carry fair carry fair debtor creditor year exclude value value group hold number equity investment frequently entity group enter research collaboration fair value financial asset liability include net debt group seek realise value investment instrument exchange liquid investment research collaboration help create current transaction willing party force cash bank certain investment regard available sale liquidation sale follow method assumption current asset financial instrument account current asset investment purpose estimate fair value gaap current asset investment classify equity investment market value base quote market available sale sterling note bond price case list investment market value glaxosmithkline hedge equity value reference quote price similar company recent holding large equity investment quest diagnostic inc finance information case material unliste dollar note bond private financing series variable sale forward contract contract investment note bond swap dollar equity collar structure series cash bank approximate carry currency swap million quest share mature liquid investment base quote market price similar interest rate swap company recent financing information case group liquid investment represent fund surplus marketable security approximate carry immediate operating requirement account note bond swap yen case time deposit short maturity current asset investment purpose gaap currency swap shortterm loan overdraft approximate carry investment classify available sale proceed short maturity instrument sale investment classify available sale gaap mediumterm loan market value base quote market year end st december million euro note bond price case eurobond fix rate proceed include rollover liquid fund shortterm deposit interest rate swap borrowing approximate carry case gaap gross gain loss reflect float rate bank loan loan consolidate profit loss account respect investment forward exchange contract base market price classify available sale million million mediumterm borrowing exchange rate balance sheet date respectively shortterm loan overdraft currency swap base market valuation balance sheet date total borrowing foreign exchange risk management equity collar fair value determine base option group enter forward foreign exchange contract interest rate swap pricing model order swap liquid asset borrowing currencie interest rate instrument base market valuation require group purpose st december group balance sheet date total net debt outstanding contract sell purchase foreign currency debtor creditor approximate carry total notional principal million provision approximate carry fix asset equity investment million majority contract period auction rate preference stock approximate carry current asset equity investment month case float rate instrument debtor year end group number currency swap flexible auction market prefer stock base market creditor year place respect mediumterm debt instrument borrowing valuation balance sheet date provision denominate swap foreign currency match foreign exchange derivative investment overseas group asset treat hedge fair value investment share equity collar relevant net asset exchange gain loss group st december investments share record reserve million million fair value auction rate preference stock million million difference flexible auction market prefer stock interest rate risk management carrying fair value represent unrealised total nonequity minority interest manage fixedfloate interest rate profile debt group loss million valuation shortfall consider total financial asset liability interest rate swap outstanding commercial bank represent permanent diminution value context st december length future period relate share option total financial asset exercise accordingly provision total financial liability concentration credit risk credit exposure investment exclude financial instrument disclosure appropriate currency interest rate swap present alongside underlie principal instrument carry financial instrument fair value market value base quote market price amount instrument adjust effect currency interest rate swap acting hedge group believe expose major concentration share represent purchase employee share ownership credit risk financial instrument group expose difference carry fair value equity fix current asset liquid investment represent gross trust satisfy future exercise option award creditrelate loss event nonperformance unrealise gain million million respectively employee incentive scheme purchase match counterpartie financial instrument expect option predetermine exercise price gain loss counterpartie fail meet obligation recognise measured exercise price market value glaxosmithkline note financial statement note financial statement glaxosmithkline financial instrument relate disclosure continue financial instrument relate disclosure continue currency interest rate risk profile financial liability currency exposure net monetary assetsliabilitie financial liability take account currency interest rate swap analyse group currency exposure rise net currency gain loss recognise profit loss account arise principally company sterle functional currency monetary asset liability denominate overseas functional currency total financial liability comprise total borrowing million million creditor year borrowing designate hedge overseas net asset exclude table million million provision million million nonequity minority interest preference share million million creditor year exclude st december benchmark rate determine interest payment float rate financial liability table libor functional currency group operation net monetary assetsliabilitie sterle euro yen total fix rate float rate noninterest bearing hold nonfunctional currency weighted weight sterling average average weight dollar st december interest year average rate rate year total euro currency fix maturity japanese yen dollar sterle euro japanese yen currency st december functional currency group operation net monetary assetsliabilitie sterle euro yen total hold nonfunctional currency fix rate float rate noninterest bearing sterling weight weight dollar average average weight euro st december interest year average japanese yen rate rate year total currency fix maturity dollar sterle euro nonequity japanese yen finance minority total total debt lease interest currency maturity financial liability year demand year currency interest rate risk profile financial asset year total financial asset comprise fix asset equity investment million million current asset equity investment year million million liquid investment million million cash bank million million debtor year million million exclude foreign exchange derivative million million benchmark rate determine interest receipt float rate asset table libor gain loss net st december fix float noninterest hedge rate rate bearing total unrecognised gain loss begin year currency unrecognised gain loss arise year dollar total unrecognised gain loss end year sterling euro expect recognise year japanese yen expect recognise year currency total unrecognised gain loss end year unrecognised gain loss represent difference carry fair value currency swap st december fi rx ae td e float ri tg e non bin et ae rr ie ns gt total interest rate swap equity collar foreign exchange derivative currency dollar commit facility sterling group commit facility commercial paper programme million million day euro duration renewable annually st december undrawn commit facility total million million japanese yen million currency glaxosmithkline note financial statement note financial statement glaxosmithkline employee cost employee cost continue pension cost accounting purpose assess accordance independent actuarial advice generally project wage salary unit method spread surplus deficit average expect remain service live respective membership social security cost certain country pension benefit provide unfunded basis administer trustee company asset hold pension postretirement cost specific purpose matching liability unfunded scheme provision include provision pension cost sharebase incentive plan postretirement benefit liability generally assess annually accordance advice independent actuary severance cost arise integration restructuring activity pension postretirement cost arise integration restructuring activity market value asset group fund define benefit pension fund date late actuarial valuation date billion actuarial value asset sufficient cover approximately cent benefit accrue member allow future salary pension increase uk define benefit pension scheme group provide benefit employee commensurate local practice individual country include market healthcare account approximately cent group plan asset valuation project benefit term define benefit pension insurance subsidise car scheme personal life assurance scheme account approximately cent group plan asset valuation project benefit term million credit relation sharebase incentive plan include benefit introduction discount provision group special funding contribution uk pension scheme totalling million group establish cost programme encourage employee convert glaxo wellcome smithkline beecham share option agree trustee certain pension scheme additional contribution dependent funding status glaxosmithkline share option scheme pension cost expect approximately information director remuneration give remuneration report page uk uk define benefit pension scheme operate benefit glaxo wellcome employee smithkline average number person employ group include director year number number number beecham employee remain separate scheme close new entrant subsequent uk employee entitle manufacture join define contribution scheme relevant assumption calculate pension cost glaxo wellcome sell general administration smithkline beecham uk define benefit scheme accounting purpose follow research development pa pa rate increase future earning average number group employee exclude temporary contract staff discount rate expect longterm rate return investment number group employee end financial year give financial record expect pension increase uk equity dividend growth na pension postretirement cost regular cost glaxo wellcome pension arrangement million reduce accounting cost uk pension scheme million allowance spread surplus disclose level percentage salary expect future work pension scheme lifetime exist member year recent triennial actuarial valuation fund purpose carry overseas pension scheme st december date asset scheme represent cent actuarial value benefit accrue unfunded postretirement healthcare scheme member allow future salary pension increase total market value asset hold scheme postemployment cost st december million regular cost smithkline beecham scheme million increase accounting cost million analyse allowance spread deficit expect future working lifetime current employee scheme fund define benefithybrid scheme year late valuation carry st december date scheme asset represent cent unfunded define benefit scheme actuarial value accrue service liability base assumption total market value asset hold scheme define contribution scheme st december million unfunded postretirement healthcare scheme postemployment cost usa usa glaxo wellcome smithkline beecham define benefit hybrid scheme merge pension postretirement cost arise integration restructure relevant assumption calculate pension cost accounting purpose follow pa pa pensions group undertaking operate pension arrangement cover group material obligation provide pension retire employee rate increase future earning arrangement develop accordance local practice country concern pension benefit provide discount rate state scheme define contribution scheme retirement benefit determine value fund arise expect longterm rate return investment contribution pay respect employee define benefit scheme retirement benefit base employee cash balance creditconversion rate pensionable remuneration length service define benefit scheme include define contribution section equity dividend growth na describe hybrid scheme table regular cost main scheme million increase accounting cost million allowance majority case contribution define benefit scheme determine accordance advice independent spread deficit expect future working lifetime current employee scheme latest professionally qualified actuary formal independent actuarial valuation group main plan undertake regularly normally valuation carry st january date actuarial value scheme asset represent cent actuarial year asset fund scheme generally hold separately administer trust insured asset value accrue service liability total market value asset hold scheme st january million invest different class order maintain balance risk return investment diversify limit financial effect failure individual investment postretirement healthcare group operate number postretirement healthcare scheme principal usa cost scheme assess assumption pension scheme assumption future medical inflation cent reduce cent year cent total provision postretirement benefit st december amount million million glaxosmithkline note financial statement note financial statement glaxosmithkline employee cost continue employee cost continue frs disclosure uk usa rest world group group continue account pension arrangement accordance ssap accounting pension cost average st december expect rate fair expect rate fair expect rate fair fair transitional provision frs retirement benefit certain disclosure require basis valuation methodology adopt return value return value return value value frs define benefit scheme fair value pension scheme asset st december compare future pension liability calculate project unit method apply follow assumption equity property uk usa rest world bond asset pa pa pa pa pa pa pa pa pa fair value asset rate increase future earning present value scheme liability discount rate expect pension increase na na na cash balance creditconversion rate na na na na na value scheme surplus inflation rate defer tax liability expect longterm rate return asset determine base actuarial advice fair value asset liability uk define benefit scheme aggregate datum define benefit scheme group follow value scheme deficit defer tax asset uk usa rest world group average st december expect rate fair expect rate fair expect rate fair fair group total return value return value return value value equity uk define benefit scheme define contribution section account balance total million st december property million million define benefit section uk scheme close new member bond project unit method value pension scheme liability current service cost increase percentage payroll asset member scheme approach retirement deficit frs reflect different basis valuing liability compare fair value asset ssap present value scheme liability liability frs postretirement healthcare scheme assess assumption pension scheme assumption future medical inflation cent reduce cent year value scheme surplus cent basis liability scheme assess million million million defer tax liability reduce million million million taking account defer tax define benefit pension postretirement benefit scheme account frs follow amount value scheme deficit record profit loss account statement total recognise gain loss year end defer tax asset st december postretirement group total pension benefit uk usa rest world group group asset uk scheme include special cash contribution pay december invest equity bond amount charge operating profit uk usa rest world group current service cost average past service cost st december expect rate fair expect rate fair expect rate fair fair curtailmentssettlement return value return value return value value equity property amount creditedcharge net interest bond expect return pension scheme asset asset interest scheme liability fair value asset present value scheme liability amount record statement total recognise gain loss value scheme surplus actual return expect return pension scheme asset defer tax liability experience lossesgain arise scheme liability change assumption relate present value scheme liability value scheme deficit defer tax asset group total glaxosmithkline note financial statement note financial statement glaxosmithkline employee cost continue employee cost continue postretirement postretirement pension benefit pension benefit history experience gain loss uk usa rest world group group uk usa rest world group group amount charge operate profit difference expect actual current service cost return scheme asset past service cost percentage scheme asset st december curtailmentssettlement experience lossesgain scheme liability percentage present value scheme liability amount creditedcharge net interest st december expect return pension scheme asset interest scheme liability total recognise statement total recognise gain loss percentage present value scheme amount record statement total liability st december recognise gain loss actual return expect return pension scheme asset experience gainslosse arise scheme liability difference expect actual change assumption relate present return scheme asset value scheme liability percentage scheme asset st december experience gainslosse scheme liability percentage present value scheme liability st december postretirement pension benefits total recognise statement total movement deficit uk usa rest world group group recognise gain loss percentage present value scheme deficit scheme st january liabilities st december exchange adjustment charge operating profit employer contribution frs valuation basis apply financial statement instead ssap valuation basis effect profit finance incomeexpense loss account reserve take account defer tax follow actuarial loss recognise statement total recognise gain loss deficit scheme st december exchange adjustment profit loss account reserve balance sheet charge operating profit pension liability frs employer contribution pension assetliability ssap balance sheet finance incomeexpense actuarial lossesgain recognise statement total postretirement healthcare scheme frs recognise gain loss postretirement healthcare scheme provision balance sheet deficit scheme st december profit loss account reserve include frs pension postretirement healthcare liability glaxosmithkline note financial statement note financial statement glaxosmithkline employee share scheme employee share scheme continue company operate share option scheme option grant employee acquire share adss glaxosmithkline plc option outstanding share option share option savingsrelate grant price share award scheme award grant employee acquire share adss glaxosmithkline plc scheme share scheme adss share option scheme st december cost subject achievement performance target weight late weight late weight late number exercise exercise number exercise exercise number exercise exercise company operate share option scheme savingsrelate share option scheme grant share option scheme normally year grant price date price date price date exercisable year date grant grant savingsrelate share option scheme normally exercisable year save option share option scheme normally grant market price ruling date grant accordance uk practice majority option savingsrelate share option scheme grant price cent market price ruling date grant accordance exemption grant uitf revise charge profit loss account relation savingsrelate share option scheme option outstanding share option share option savingsrelate scheme share scheme adss share option scheme weight weight weight number exercise number exercise number exercise price price price total st december option exercisable option share adss grant savingsrelate option grant share option grant option exercise option cancel change effective exercise price outstanding option year option grant st december st december th february option grant option exercise option exercisable share option share option savingsrelate scheme share scheme adss share option scheme option cancel weight weight weight st december number exercise number exercise number exercise option grant price price price option exercise st december option cancel st december st december range exercise price st december order encourage employee convert option exclude savingsrelate share option hold glaxo wellcome smithkline glaxosmithkline share award scheme beecham share adss glaxosmithkline share adss programme establish additional cash benefit group operate performance share plan award grant director senior executive cost percentage cent exercise price original option provide employee voluntarily leave group year award vest base performance group year measurement period performance condition date merger exercise option early month expiry date original option consist part apply cent award condition compare glaxosmithkline total year date merger cash benefit pay option expire unexercised market price shareholder return tsr period tsr company uk ftse index period second exercise price date expiry performance condition compare glaxosmithkline earning share growth increase uk retail price index year performance period share adss number share adss issuable number number st december award grant award exercise award cancel st december award grant award exercise award cancel st december award grant award exercise award cancel st december glaxosmithkline note financial statement note financial statement glaxosmithkline employee share scheme continue reconciliation accounting principle additionally group reassesse useful live exist recognise intangible asset intangible asset deem employee share ownership trust analysis reconciliation present note represent indefinite life long amortise instead test group sponsor employee share ownership trust acquire hold share glaxosmithkline plc satisfy award financial information prepare basis generally annually potential impairment separable intangible asset employee incentive plan option grant employee share option scheme trustee employee share ownership accept accounting principle gaap uk gaap finite life continue amortise useful life trust purchase share open market finance provide group way loan contribution expect cost obligation deliver share scheme normally spread period service respect award option summary material difference uk gaap group adopt sfas st january grant accelerated charge respect outstanding cost provide share award option acquisition smithkline beecham implementation sfas result impairment exercisable solely result merger combination glaxo wellcome plc smithkline beecham group goodwill initial impairment million plc account merger pooling interest million net tax indefinitelive asset show share hold share award scheme accordance uk gaap gaap business cumulative effect accounting change combination qualify pool interest accounting number share uk gaap cost incur integrate glaxo wellcome determine accounting restructuring wellcome smithkline beecham block drug acquirer purchase business combination business follow acquisition nominal value accordingly net asset smithkline beecham fair value respectively charge profit loss account post cost provision date acquisition result fair value exercise acquisition gaap certain cost consider market value increase value smithkline beecham inventory tangible allocation purchase consideration affect fix asset investment pension obligation recognise goodwill arise acquisition share hold share option scheme fair market value attribute intangible asset mainly uk gaap certain intangible asset relate specific product right inclusive patent trade mark assemble number share compound product purchase party workforce inprocess research development develop commercial application capitalise appropriate defer taxation effect difference gaap payment compound product cost acquisition fair value asset liability nominal value development receive regulatory smithkline beecham record goodwill cost provision approval charge directly profit loss time market value capitalise interest receive regulatory approval uk gaap group capitalise interest gaap trust acquire hold share meet notional dividend reinveste deferred award smithkline beecham require interest incur cost construct fix restructuring cost midterm incentive plan trustee waive right dividend share hold employee share ownership trust asset capitalise amortise life asset uk gaap restructuring cost incur follow acquisition charge profit loss account post acquisition option pricing computer software gaap purpose certain cost recognise purpose value option arrive stockbase compensation adjustment reconciliation accounting principle uk gaap group capitalise cost incur acquire liability acquisition opening balance sheet note blackschole option pricing model assumption model follow develop computer software internal use software support significant business system restructuring cost record provision uk expenditure lead creation durable asset gaap restructuring plan announce riskfree interest rate gaap group apply sop accounting cost gaap subsequent st december provision dividend yield computer software develop obtain internal use recognise criterion meet liability volatility restrict category cost capitalise incur accordingly adjustment eliminate expect life option grant uk gaap provision restructuring cost meet goodwill intangible fix asset share option scheme year year gaap requirement uk gaap goodwill arise acquisition saving relate share option scheme year year account purchase method eliminate marketable security shareholder fund additionally uk gaap require marketable security consist primarily equity security subsequent disposal closure business goodwill relate party transaction certain liquid investment uk gaap security previously take directly shareholder fund charge state low cost net realisable value glaxosmithkline hold cent interest quest diagnostic inc group quest diagnostic party income beginning group change gaap security consider available sale longterm contractual relationship quest diagnostic primary provider clinical laboratory testing support group accounting policy goodwill intangible asset uk sfas account certain investment debt equity clinical trial testing requirement worldwide gaap respect acquisition uk gaap security carry fair value unrealised gain goodwill arise acquisition capitalise group shionogi co ltd enter transaction joint venture company support loss net tax record separate component amortise period exceed year research development activity conduct joint venture company glaxosmithkline provide service joint shareholder equity venture million million st december balance glaxosmithkline joint venture million gaap goodwill arise acquisition prior equity security review annually million june capitalise amortise period temporary impairment factor consider exceed year july financial accounting dr barzach nonexecutive director glaxosmithkline plc receive fee subsidiary company standard board fasb issue statement financial accounting investee current financial performance future healthcare consultancy provide include annual remuneration remuneration report standard sfas goodwill intangible asset sfas prospect dr shapiro nonexecutive director glaxosmithkline plc receive fee require goodwill long amortise general market condition geographic industry form adss subsidiary company membership scientific advisory board include estimate useful life group instead identify value area investee operate annual remuneration remuneration report report unit purpose assess annually duration extent market value potential impairment goodwill allocate reporting unit available cost gross unrealised gain loss marketable security million million respectively st december glaxosmithkline note financial statement note financial statement glaxosmithkline reconciliation accounting principle continue require group recognise measure fair value reconciliation accounting principle continue recent financial accounting standard board fasb prospective basis certain guarantee issue modify pronouncement pension postretirement benefit dividend st december uk gaap guarantor obligation january fasb issue fasb staff position fsp key difference uk ssap gaap uk gaap dividend propose provide year recognise additional criterion meet accounting disclosure requirement relate relation define benefit pension plan respect recommend board liability incur medicare prescription drug improvement modernization director approval shareholder gaap uk gaap effect variation cost act act fsp address accounting dividend provide declare board accumulate successive valuation amortise derivative instrument implication act entity sponsor post director aggregate basis gaap amortisation sfas accounting derivative instrument hedge retirement health care plan provide prescription drug benefit transition asset cost past service benefit activity amend sfas sfas act introduce usa prescription drug benefit consolidated summary statement cash flow improvement separately track experience gainslosse interpret derivative implementation group adopt medicare federal subsidy sponsor certain post gaap cash flow statement report change cash deal aggregate basis amortise group effect st january sfas retirement health care plan fsp provide election cash equivalent include shortterm highly liquid outside cent corridor establishe accounting reporting standard derivative defer accounting implication new law investment original maturity month instrument include certain derivative instrument embed specific authoritative guidance issue address uk gaap allow measurement plan asset liability category cash flow report operating contract collectively refer derivative accounting treatment result current absence base result late actuarial valuation activity include tax interest investing activity include hedging activity uk gaap derivative instrument guidance accounting treatment measure gaap require measurement plan asset liability capital expenditure acquisition disposal hedge recognise balance sheet accumulate postretirement benefit obligation net periodic date financial statement cash flow available sale current asset investment matching principle match gain loss postretirement benefit cost include reconciliation month prior date financing activity include dividend pay summary hedge contract foreign currency transaction profit accounting principle accompany note reflect statement cash flow present pension adjustment include impact change relate sfas require entity recognise effect act authoritative guidance issue minimum pension liability include accumulate derivative asset liability consolidated balance require change previously report information cash cash equivalent comprehensive income sheet measure instrument fair value change fair uk gaap cash balance include cash bank january fasb issue interpretation fin value period record current earning hedge group decide align measurement date cash balance gaap cash cash equivalent consolidation variable interest entity december accounting obtain group designate pension postretirement benefit plan st include cash bank certain liquid investment original issue fin r revision interpretation derivative qualify hedge instrument sfas december certain group plan measurement maturity month revise interpretation certain entity know variable interest sfas prescribe requirement designation documentation date asset liability th september entity vie consolidate primary beneficiary hedge relationship ongoing assessment effectiveness comprehensive income statement entity primary beneficiary generally define impact reflect cumulative effect accounting order qualify hedge accounting requirement sfas report comprehensive income majority risk reward arise vie change million credit net tax income group evaluate contract embed derivative provide comprehensive income statement meet additionally vie significant majority consider embed derivative uk gaap statement total recognise gain loss variable interest hold certain disclosure require certain stockbase compensation bifurcate separate host contract accordance page measurement principle interpretation relate newly uk gaap share option account equity sfas requirement embed derivative exist form vie applicable financial statement exercise value issuance price gaap group clearly closely related host contract reclassification fiscal year end st december group evaluate apply sfas accounting stockbase compensation account separately host contract derivative certain prior year balance reclassify comparative potential vie newly form entity relate accounting interpretation accounting option plan purpose certain amount previously present aggregate identify item require adjustment require option fair value grant date gain loss relate fair value adjustment reconciliation profit gaap uk gaap financial statement remain disclosure requirement include profit loss vest period option derivative instrument classify consolidated statement present separately current year presentation provide interpretation effective subsequent financial income cash flow accordance nature group entitle receive tax deduction information relate adjustment statement begin glaxosmithkline derivative treat compensation tax rule employee complete assessment remain relationship stock option exercise employee fair value book value derivative instrument respect sale incentive impact disclosure include year uk gaap treat reduction tax financial asset liability st december accordance uk gaap certain amount pay group subsequent financial statement result operation expense gaap portion disclose classification fair value financial asset customer record promotional expense include financial position period credit equity liability table note operating income gaap item record reduction revenue item result net employee share ownership trust esot valuation derivative instrument impact income statement gaap uk gaap share group stock hold esot fair value derivative instrument sensitive movement classify reduction revenue record cost provision represent difference underlie market rate variable group monitor million cost option exercise price account fair value derivative instrument quarterly basis fix asset investment project loss exercise formal review month derivative include option cover share record profit interest rate swap cross currency swap value loss account life option gaap standard valuation model counterparty valuation party share group stock purchase esot account valuation standard valuation model group consider shareholder equity cost gain loss arise relevant discount rate market yield curve valuation subsequent issuance share employee satisfy share date forward currency exchange rate counterparty risk option record adjustment shareholder equity significant rate variable obtain market source valuation base remain term maturity guarantor obligation instrument foreign exchange contract value forward group adopt fasbs financial interpretation rate observe quote price relevant market fin guarantor accounting disclosure requirement possible group assume party longterm contract guarantee include indirect guarantee indebtedness economically viable reserve right exercise early effect st january termination right economically beneficial right exist contract glaxosmithkline note financial statement note financial statement glaxosmithkline reconciliation accounting principle continue reconciliation accounting principle continue follow summary material adjustment profit shareholder fund require gaap equity shareholder fund note apply instead uk gaap adjustment reflect income statement balance sheet present equity shareholder fund uk gaap accordance gaap gaap adjustment profit note goodwill profit attributable shareholder uk gaap product right b capitalise interest pension intangible asset b computer software tangible fix asset goodwill amortisation reversalcharge include goodwill associate undertaking capitalise interest amortisation impairment intangible asset b computer software acquisition licence patent etc b marketable security recognition cost sale fair value stepup inventory investment disposal purchase investment employee share ownership trust product divestment pension postretirement benefit e equity investment restructuring cost loss disposal subsidiary derivative instrument pension postretirement benefit e guarantor obligation stockbase compensation dividend provision esot share defer taxation derivative instrument shareholder equity gaap guarantor obligation restructure certain item year end st december reclassify comparative purpose tax benefit exercise stock option c defer taxation c consolidate statement cash flow gaap net incomeloss gaap cumulative effect change net cash provide operating activity accounting principle net cash investing activity cumulative effect change accounting principle net cash financing activity net incomeloss cumulative effect change accounting principle net increasedecrease cash cash equivalent exchange rate movement certain item year end st december st december reclassify comparative purpose cash cash equivalent begin year cash cash equivalent end year earning share gaap pence pence pence basic net incomeloss share cumulative effect change accounting principle gaap note profit equity shareholder fund reconciliation cumulative effect change accounting principle share goodwill gaap basic net incomeloss share cumulative effect change follow table set uk gaap adjustment require uk gaap statement profit loss balance sheet accounting principle gaap respect goodwill dilute net incomeloss share cumulative effect change income statement accounting principle gaap amortisation uk gaap include goodwill respect associate undertaking cumulative effect change accounting principle share amortisation gaap include goodwill respect associate undertaking gaap dilute net incomeloss share cumulative effect change uk gaap adjustment amortisation include goodwill respect associate undertaking accounting principle gaap balance sheet earning ad gaap goodwill uk gaap goodwill gaap basic net incomeloss ad cumulative effect change accounting principle gaap uk gaap adjustment cumulative effect change accounting principle ad gaap million million gaap goodwill balance st december million million basic net incomeloss ad cumulative effect change respect goodwill arise acquisition smithkline beecham glaxo wellcome accounting principle gaap dilute net incomeloss ad cumulative effect change accounting principle gaap cumulative effect change accounting principle ad gaap dilute net incomeloss ad cumulative effect change accounting principle gaap glaxosmithkline note financial statement note financial statement glaxosmithkline reconciliation accounting principle continue reconciliation accounting principle continue follow table present change goodwill allocate group reportable segment follow intangible asset subject amortisation consumer pharmaceutical healthcare total product product right right st december addition cost exchange adjustment accumulate amortisation impairment st december addition net exchange adjustment follow launch usa generic paxil product carry value product right relate paxil review st december impairment million record carry value certain product right review impairment million record impairment million record million related augmentin b intangible asset impair follow launch generic augmentin product fair value determine discount cash flow model follow table set uk gaap adjustment require uk gaap statement profit loss balance sheet discuss note legal proceeding number distributor generic drug file application market generic version respect intangible asset anumber group product prior expiration group patent generic version product launch future period early date group currently expect impairment carry value product arise group income statement continue position review amortisation impairment charge uk gaap estimate future amortisation expense year intangible asset subject amortisation st december amortisation impairment charge gaap follow uk gaap adjustment amortisation impairment cumulative effect change accounting principle year uk gaap adjustment amortisation impairment period follow initial implementation sfas carry value brand determined indefinite life review impairment million million net tax recognise record cumulative effect change accounting principle total addition adjustment amortisation impairment uk gaap adjustment arise year million million million respect acquisition licence patent etc capitalise uk intangible asset subject amortisation include pension asset million st december million gaap charge directly profit loss gaap st december certain product right intangible asset relate product right analyse follow balance sheet intangible asset uk gaap intangible asset gaap cost impairment uk gaap adjustment pension intangible asset net net uk gaap product right adjustment impairment charge million million recognise result change market condition management forecast certain brand intangible intangible asset gaap analyse follow group account goodwill identifiable intangible asset indefinite life sfas year end st december impact report gaap result follow acquire product licence patent etc brand net income gaap pension amortisation net tax intangible asset gaap goodwill brand follow table present detail group intangible asset differentiate subject amortisation adjust net income gaap subject amortisation adjust basic net income share penny adjust diluted net income share pence intangible asset subject amortisation intangible asset subject amortisation intangible asset gaap glaxosmithkline note financial statement note financial statement glaxosmithkline reconciliation accounting principle continue reconciliation accounting principle continue c taxation e pension postretirement cost gaap total tax expense uk pension scheme uk gaap pension scheme current tax expense overseas pension scheme defer tax expense unfunded postretirement healthcare scheme total tax expense postemployment cost gaap current tax expense analyse defer tax expense period fund define benefithybrid scheme total tax expense period unfunded define benefit scheme cumulative effect change accounting principle define contribution scheme unfunded postretirement healthcare scheme total tax expense postemployment cost uk gaap adjustment current tax expense defer tax expense period contribution estimate approximately million total tax expense period disclosure include additional information require sfas pension cost uk major overseas cumulative effect change accounting principle define benefit pension plan restate follow table accordance gaap pension cost million total tax expense million million respect minor retirement plan recalculate accordance requirement sfas exclude deferred taxation gaap net periodic pension costincome major retirement plan comprise classification glaxosmithkline defer taxation liability asset gaap follow service cost interest cost expect return plan asset liability amortisation prior service cost stock valuation adjustment amortisation transition obligation current defer taxation liability amortisation net actuarial lossgain accelerate capital allowance net periodic pension costincome gaap product right termination benefit curtailment cost time difference adjustment change accounting principle total defer taxation liability asset group decide align measurement date pension plan certain group pension plan intragroup profit measurement date pension asset liability th september group elect change measurement date time difference plan th september st december current defer taxation asset asset disposal major assumption compute pension costincome pa pa pa pensions postretirement benefit rate future pay increase tax loss discount rate manufacturing restructuring expect longterm rate return plan asset legal dispute time difference aggregate average international plan assumption vary significantly assumption total defer taxation asset net defer taxation gaap net defer taxation uk gaap uk gaap adjustment difference uk effective taxation rate effective taxation rate primarily relate fair value adjustment goodwill intangible relate acquisition wellcome smithkline beecham glaxosmithkline note financial statement note financial statement glaxosmithkline reconciliation accounting principle continue reconciliation accounting principle continue postretirement healthcare gaap change benefit obligation postretirement healthcare cost uk major overseas postretirement healthcare scheme restate benefit obligation begin year follow table accordance gaap cost million nil million adjustment change accounting principle recalculate exclude amendment service cost net healthcare cost interest cost service cost plan participant contribution interest cost actuarial loss amortisation prior service cost benefit pay amortisation net actuarial loss termination benefit curtailment cost net healthcare cost exchange benefit obligation end year major assumption calculate net healthcare cost pa pa pa benefit obligation end year pension plan accumulate benefit obligation excess plan asset rate future healthcare inflation discount rate accumulate benefit obligation st december million rate future healthcare inflation reflect fact benefit certain group participant cap change plan asset fair value plan asset begin year change benefit obligation adjustment change accounting principle benefit obligation begin year actual return plan asset adjustment change accounting principle employer contribution amendment plan participant contribution service cost benefit pay interest cost termination benefit curtailment cost plan participant contribution exchange actuarial loss benefit pay fair value plan asset end year exchange fair value plan asset end year pension plan accumulate benefit obligation excess plan asset benefit obligation end year plan asset consist primarily investment uk overseas equity fix interest security security link uk retail price index property st december uk equity include million glaxosmithkline share million share change plan asset market value million million fair value plan asset begin year employer plan participant contribution fund status benefit pay fund status fair value plan asset end year unrecognise net actuarial loss unrecognise prior service cost fund status unrecognised transition obligation fund status net recognise unrecognised net actuarial loss unrecognise prior service cost amount recognise statement financial position consist accrue postretirement healthcare cost prepay benefit cost accrue pension liability decrease increase impact cent variation rate future healthcare inflation intangible asset effect total service interest cost accumulate comprehensive income effect provision postretirement benefit net recognise glaxosmithkline note financial statement note financial statement glaxosmithkline principal group company principal group company continue follow represent principal subsidiary associated undertakings glaxosmithkline group st december europe location subsidiary undertaking segment activity detail give principal country operation location headquarters business segment business activity netherland zeist glaxosmithkline bv ph equity share capital undertaking wholly own group percentage interest show zeist glaxosmithkline consumer healthcare bv ch company incorporate principal country operation state norway oslo glaxosmithkline ph europe location subsidiary undertaking segment activity poland poznan glaxosmithkline pharmaceuticals sa ph p warsaw glaxosmithkline consumer healthcare sp zoo ch england greenford glaxo group ltd ph h brentford glaxosmithkline holding limited phch h portugal lisbon glaxosmithklineprodutos farmaceutico lda ph brentford glaxosmithkline service unlimited phch republic dublin glaxosmithkline consumer healthcare ireland limited footnote ch brentford smithkline beecham plc phch e h r p ireland carrigaline smithkline beecham cork ltd footnote ph p brentford wellcome limited phch h carrigaline smithkline beecham manufacturing ltd footnote ph p spain burgo glaxo wellcome sa ph r p brentford glaxo operation uk ltd ph p madrid smithkline beecham sa ph brentford glaxo wellcome international bv footnote iii phch h brentford glaxo wellcome investment bv footnote iii phch h sweden mlndal glaxosmithkline ab ph stockley park glaxo wellcome uk ltd ph h p switzerland muenchenbuchsee glaxosmithkline investments switzerland gmbh phch h brentford glaxosmithkline export ltd ph e muenchenbuchsee glaxosmithkline international switzerland gmbh phch h brentford glaxosmithkline research development ltd ph r muenchenbuchsee glaxo wellcome international footnote iiv phch h brentford glaxosmithkline uk ltd ph p muenchenbuchsee glaxosmithkline ag ph brentford smithkline beecham investments ltd phch f zug adechsa gmbh ph e brentford smithkline beecham swg ltd ch e turkey istanbul glaxosmithkline ilaclari sanayi ticaret ph p brentford smithkline beecham research ltd ph brentford staffordmiller ltd ch p usa greenford wellcome foundation ltd ph p usa philadelphia smithkline beecham corporation phch e h r p austria vienna glaxosmithkline pharma gmbh ph pittsburgh glaxosmithkline consumer healthcare lp ch p belgium genval glaxosmithkline sa ph new jersey block drug company inc ch h p rixensart glaxosmithkline biological sa ph e r p wilmington glaxosmithkline financial inc phch f rixensart glaxosmithkline biological manufacture sa ph e p wilmington smithkline beecham holdings corporation phch h guernsey st peter port smithkline beecham ltd sb insurance ltd phch wilmington glaxosmithkline holdings americas inc phch h denmark ballerup glaxosmithkline consumer healthcare ch brndby glaxosmithkline pharma ph americas finland espoo glaxosmithkline oy ph bermuda hamilton glaxosmithkline insurance ltd phch france marly le roi groupe glaxosmithkline sas ph h canada mississauga glaxosmithkline inc phch p r marly le roi laboratoire glaxosmithkline sas ch marly le roi glaxo wellcome production sas ph p asia pacific germany buehl glaxosmithkline consumer healthcare gmbh co kg ch p australia boronia glaxo wellcome australia ltd ph p buehl glaxosmithkline healthcare gmbh ph dandenong smithkline beecham australia pty ltd phch smithkline beecham healthcare gmbh china hong kong glaxosmithkline limit ph greece athens glaxosmithkline aebe ph h p tianjin sinoamerican tianjin smith kline french laboratories ltd ph hungary budapest glaxosmithkline kft phch india mumbai glaxosmithkline pharmaceuticals ltd ph p italy verona glaxosmithkline spa ph p r nabha glaxosmithkline consumer healthcare ltd footnote ii ch p milan glaxosmithkline consumer healthcare spa ch h malaysia selangor glaxosmithkline pharmaceutical sdn bhd ph luxembourg mamer glaxosmithkline international luxembourg sa phch f h darul ehsan mamer glaxosmithkline luxembourg sa phch f h new zealand auckland glaxosmithkline nz limited phch pakistan karachi glaxosmithkline pakistan ltd phch p glaxo wellcome pakistan ltd philippines makati glaxosmithkline philippines inc ph glaxo wellcome philippines inc singapore singapore glaxo wellcome manufacturing pte ltd ph p singapore glaxosmithkline pte ltd ph south korea seoul glaxosmithkline korea ph p taiwan taipei glaxo wellcome taiwan ltd ph p glaxosmithkline note financial statement glaxosmithkline investor information principal group company continue japan location subsidiary undertaking segment activity japan tokyo glaxosmithkline kk ph p r section include financial record discuss kobe block drug company japan inc ch shareholder return return shareholder form dividend share price movement provide latin america information shareholders argentina buenos aires glaxosmithkline argentina sa phch p financial record brazil rio de janeiro glaxosmithkline brasil lda phch p quarterly trend colombia bogota glaxosmithkline colombia sa phch year trend mexico mexico city glaxosmithkline mexico sa de cv phch p puerto rico guaynabo glaxosmithkline puerto rico inc ph shareholder return san juan sb pharmco puerto rico inc ph p shareholder return shareholder information venezuela caracas glaxosmithkline venezuela ph p share capital taxation information shareholder middle east africa egypt cairo glaxosmithkline sae glaxo wellcome egypt sae ph p south africa midrand glaxosmithkline south africa pty ltd ph p usa location associate undertaking business usa teterboro quest diagnostics inc clinical testing new jersey footnote exempt provision section company amendment act ireland ii consolidated subsidiary undertaking accordance section company act ground significant influence iii incorporate netherlands iv incorporate republic ireland directly hold wholly own subsidiary glaxosmithkline plc business segment ph pharmaceutical ch consumer healthcare business activity development e export f finance h hold company insurance marketing p production r research service detail group subsidiary associate undertaking attach company annual return file registrar company glaxosmithkline financial record glaxosmithkline financial record quarterly trend unaudite analysis provide quarter group result sterle financial year analysis comprise statutory result business performance result pharmaceutical sale therapeutic area profit loss account statutory month q month q month q q cer cer cer cer cer cer cer turnover pharmaceutical consumer healthcare total turnover cost sale sell general administrative expenditure research development expenditure operating cost trading profit pharmaceutical consumer healthcare total trading profit operating incomeexpense operate profit share profitslosse joint venture associate undertaking disposal business profit interest net interest payable profit ordinary activity taxation taxation profit ordinary activity taxation equity minority interest preference share dividend earning profit attributable shareholder basic earning share p p p p p p p profit loss account business performance turnover pharmaceutical consumer healthcare total turnover cost sale sell general administrative expenditure research development expenditure operating cost trading profit pharmaceutical consumer healthcare total trading profit operating incomeexpense operate profit share profitslosse joint venture associate undertaking profit interest net interest payable profit ordinary activity taxation taxation profit ordinary activity taxation equity minority interest preference share dividend adjust earning profit attributable shareholder adjust earning share p p p p p p p glaxosmithkline financial record financial record glaxosmithkline pharmaceutical turnover total group pharmaceutical turnover usa q q q q q q q q cer cer cer cer cer cer cer cer cns cns depression depression seroxatpaxil seroxatpaxil wellbutrin wellbutrin migraine migraine imigranimitrex imigranimitrex naramigamerge naramigamerge lamictal lamictal requip requip zyban zyban respiratory respiratory flixotide serevent seretide flixotide serevent seretide seretideadvair seretideadvair flixotideflovent flixotideflovent serevent serevent flixonaseflonase flixonaseflonase ventolin ventolin becotide becotide antiviral antiviral hiv hiv combivir combivir trizivir trizivir epivir epivir retrovir retrovir ziagen ziagen agenerase agenerase herpe herpe valtrex valtrex zovirax zovirax zeffix zeffix antibacterials antibacterials augmentin augmentin zinnatceftin zinnatceftin fortum fortum amoxil amoxil metabolic metabolic avandiaavandamet avandiaavandamet vaccine vaccine hepatitis hepatitis infanrix infanrix oncology emesis oncology emesis zofran zofran hycamtin hycamtin cardiovascular urogenital cardiovascular urogenital coreg coreg levitra levitra avodart avodart zantac zantac total total pharmaceutical turnover include copromotion income pharmaceutical turnover include copromotion income glaxosmithkline financial record financial record glaxosmithkline pharmaceutical turnover europe q q q q pharmaceutical turnover international q q q q cer cer cer cer cer cer cer cer cns cns depression depression seroxatpaxil seroxatpaxil wellbutrin wellbutrin migraine migraine imigranimitrex imigranimitrex naramigamerge naramigamerge lamictal lamictal requip requip zyban zyban respiratory respiratory flixotide serevent seretide flixotide serevent seretide seretideadvair seretideadvair flixotideflovent flixotideflovent serevent serevent flixonaseflonase flixonaseflonase ventolin ventolin becotide becotide antiviral antiviral hiv hiv combivir combivir trizivir trizivir epivir epivir retrovir retrovir ziagen ziagen agenerase agenerase herpe herpe valtrex valtrex zovirax zovirax zeffix zeffix antibacterials antibacterials augmentin augmentin zinnatceftin zinnatceftin fortum fortum amoxil amoxil metabolic metabolic avandiaavandamet avandiaavandamet vaccine vaccine hepatitis hepatitis infanrix infanrix oncology emesis oncology emesis zofran zofran hycamtin hycamtin cardiovascular urogenital cardiovascular urogenital coreg coreg levitra levitra avodart avodart zantac zantac total total pharmaceutical turnover include copromotion income pharmaceutical turnover include copromotion income glaxosmithkline financial record financial record glaxosmithkline year record record financial performance provide analysed accordance current reporting practice statutory result turnover turnover business segment profit taxation earning profit attributable shareholder pharmaceutical dividend consumer healthcare retain profit retain business healthcare service return capital employ cent return capital employ calculate statutory profit taxation percentage average capital employ year pharmaceutical turnover therapeutic area merger restructure disposal subsidiary central nervous system manufacturing restructure respiratory merger cost product divestment antibacterial item antiviral lossprofit taxation metabolic lossprofit attributable shareholder vaccine oncology emesis cardiovascular urogenital business performance result retain business turnover continue business rd expenditure divest product cent sale trading profit cent sale pharmaceutical turnover geographic area net interest payable usa profit taxation europe adjust earning profit attributable shareholder international asia pacific business performance primary performance measure management present exclude merger item japan integration restructuring cost disposal business management believe exclusion item provide well latin america reflection way business manage give indication performance group term element middle east africa revenue expenditure local management able influence information provide addition statutory canada result prepare uk gaap give assist shareholder gain clear understanding underlying performance business international increase comparability period present statutory result include item share statistic pharmaceutical turnover include copromotion income earning share p dividend glaxosmithkline share p glaxosmithkline shareholder consumer healthcare sale glaxo wellcome shareholder otc medicine smithkline beecham shareholder oral care dividend glaxosmithkline ad nutritional healthcare glaxosmithkline shareholder continue business glaxo wellcome shareholder smithkline beecham shareholder divest product dividend express term glaxosmithkline sharead merger glaxo wellcome smithkline beecham th december shareholders adr holder receive share glaxosmithkline follow ratio glaxo wellcome share glaxosmithkline share smithkline beecham share glaxosmithkline share glaxo wellcome ad glaxosmithkline ad smithkline beecham ad glaxosmithkline adss glaxosmithkline ad represent glaxosmithkline share glaxosmithkline financial record glaxosmithkline shareholder return net asset share price dividend fix asset glaxosmithkline pay dividend quarterly board declare asset liability dividend follow net operating asset st january net debt high year dividend share pence pence low year interim pay rd july st december second interim pay nd october increasedecrease interim pay th january capital employ fourth interim payable th april share capital share premium table set middle market closing price total reserve derive london stock exchange daily official list equity shareholder fund company share price increase seven cent glaxosmithkline expect similar increase total minority interest price st january dividend declare allocation quarterly st december compare increase ftse dividend rebalance glaxosmithkline intend index cent year increase interim dividend penny capital expenditure tangible fix asset pence remainder total dividend year market capitalisation allocate fourth quarter dividend number employee market capitalisation glaxosmithkline st december usa billion date glaxosmithkline dividend adss europe fourth large company market capitalisation ftse guide holder adr table set international index dividend pay ad dollar year asia pacific dividend adjust uk tax credit withholding tax japan smithkline beecham plc float rate unsecured loan stock applicable translate dollar applicable latin america exchange rate middle east africa loan stock list exchange holder th april claim refund tax credit canada require smithkline beecham plc redeem loan stock dividend uk tax authority negligible benefit international par ie loan stock hold business shareholder day march june september december holder wish year gsk gw sb redeem loan stock complete manufacturing notice loan stock certificate return selling registrar arrive day relevant administration redemption date research development taxation dividend pay glaxo wellcome smithkline beecham adr general information concern uk tax effect number employee number permanent employ staff end financial period exclude employee holder express dividend glaxosmithkline ad share ownership set taxation information employ manage glaxosmithkline contract basis shareholder dividend calendar fourth quarter exdividend date th february record date th february payable th april quarter exdividend date th record date th payable st july second quarter exdividend date th august record date th august payable th september quarter exdividend date rd november record date th november payable th january glaxosmithkline glaxosmithkline shareholder information share capital ordinary share publication nature trading market glaxo wellcome penny share company share list london stock exchange glaxosmithkline corporate responsibility report available ordinary share company list london fiscal period th december high low secretariat company head office website stock exchange th december share registrar wwwgskcom list new york stock exchange form american company share register administer lloyds tsb depositary share adss date registrar provide follow service annual general meeting dollar ad follow table set period indicate high fiscal period th december high low glaxosmithkline investment plan low middle market closing quotation pence queen elizabeth ii conference centre th plan enable shareholder reinvest quarterly dividend share london stock exchange derive daily broad sanctuary westminster andor monthly investment company ordinary official list high low report sale price london swp ee share special dealing arrangement dollar adss new york stock exchange derive glaxosmithkline individual saving account annual general meeting company principal forum new york stock exchange composite tape smithkline beecham pence share communication private shareholder addition formal glaxosmithkline individual saving account isa information relate share ad price glaxo fiscal period th december high low resolution meeting presentation taxefficient way invest company ordinary share wellcome smithkline beecham prior date chief executive officer performance business merger give glaxosmithkline corporate sponsor nominee future development opportunity question corporate sponsor nominee provide facility board chairmen board committee glaxosmithkline penny share shareholder hold share need share question matter relate committee fiscal period th december high low dollar ad certificate shareholder detail hold main investor hold share company nominee service quarter end st march fiscal period th december high low share register remain confidential arrange nominee service appoint february shareview service corporate representative proxy respect shareholde january shareview portfolio service provide shareholder order attend vote meeting december information investment company shareholder november adr holder wish attend meeting obtain proxy register service wwwshareviewcouk october bank new york enable attend september meeting vote business transact adr holder share deal facility quarter end st december instruct bank new york share hoare govett limited operate postal share deal service quarter end th september represent adrs vote complete company ordinary share enable investor buy sell quarter end th june return voting card provide bank new york share competitive commission charge transaction quarter end st march accordance instruction give execute settle pershe security limit detail quarter end st december service purchase sale form quarter end th september financial reporting obtain telephoning quarter end th june financial reporting calendar quarter end st march smith barney citigroup offer share deal service company ordinary share adss detail announcement st quarter result th april quarter end st december quarter end th september service obtain contact contact detail announcement nd quarter result th july quarter end th june inside cover announcement rd quarter result th october quarter end st march provision detail intend preliminary announcement annual result th february th st december invitation inducement engage investment activity publication annual reportreview march advice share dealing obtain stockbroker dollar ad independent financial adviser fiscal period th december high low result announcement result announcement issue london stock quarter end st march share price information exchange lse available lse news service february share price information available company website time shortly issue medium january wwwgskcom information available ceefax teletext available website usa send december ft cityline call securities exchange commission new york stock november call charge p minute plus vat times exchange october september american depositary share financial report quarter end st december company share list new york stock exchange company publish annual report investor quarter end th september form american depositary share adss need detail report annual review quarter end th june evidence american depositary receipt adr available date publication quarter end st march represent ordinary share glaxosmithkline website quarter end st december quarter end th september annual review send shareholders date adr programme administrator quarter end th june publication shareholder elect receive report adr programme administer bank new york quarter end st march provide follow service writing company registrar alternatively shareholder quarter end st december elect receive notification email publication quarter end th september global buydirect financial report register wwwshareviewcouk quarter end th june global buydirect direct ad purchasesale dividend copy previous financial report available website quarter end st march reinvestment plan adr holder print copy obtain registrar uk th st december customer response center usa th february glaxosmithkline share capital glaxosmithkline taxation information shareholder analysis shareholding information shareholder stamp duty number total total number uk stamp duty stamp duty reserve tax sdrt subject analysis shareholding st december account account share share summary main tax consequence holder share certain exemption payable purchase share hold share adr citizen resident uk usa rate cent purchase price minimum set complete analysis possible tax charge stamp duty liability arise consequence purchase ownership security intend general guide holder advise consult shareholder adviser respect tax consequence purchase ownership share adr follow summary certain uk taxation usa consequence state local tax law usa federal income tax consideration relevant total implication new ukus income tax convention holder share adrs summary apply hold shareholder hold share adr capital asset nominee company statement base uk tax law practice citizen resident usa domestic corporation investment trust company date report subject united states federal income taxation insurance company new ukus income tax convention come force net income basis respect share adr individual corporate body st march provision new treaty apply uk resident uk uk tax purpose hold share bny nominees limit tax purpose st april uk corporation tax th april purpose trade profession vocation carry total uk income tax capital gain tax st uk branch agency withholding taxis tax purpose provision bank new york hold hold bny nominees limited represent company adr programme ad new treaty apply st withhold taxis taxation dividend represent ordinary share p nominal value st january tax holder share gross dividend receive include amount th february number holder record share usa holdings share adr ability elect continue use respect associate tax credit uk withholding tax treat number register holder adr holding adr certain share adr provision previous treaty month follow foreign source dividend income tax purpose hold broker nominee result number holder record register holder usa representative new treatys entry force election eligible dividend receive deduction allow number beneficial holder residence beneficial holder advance event new treaty apply corporation dividend adr payable dollar dividend share payable sterling dividend pay holder adrs generally treat owner control company underlie share purpose current usauk pound sterling include income dollar calculate reference exchange rate day far know company directly indirectly own control corporation government double taxation convention relate income gain dividend receive holder uk taxis withhold company know arrangement operation result change control company income tax convention estate gift taxis estate gift dividend distribution eligible credit holder tax convention purpose internal revenue federal income tax liability subject generally applicable substantial shareholding code amend code limitation holder tax position determine th february company receive notification follow interest cent share follow analysis deal dividend pay th april effective use special foreign tax advance corporation tax act abolish credit tax liability bny nominees limited hold share represent cent share hold behalf holder american depositary receipt evidence american depositary share uk shareholder th april rate tax credit reduce ninth act abolish claim refund tax credit legal general investment management limited hold share represent cent taxation dividend dividend pay date negligible benefit barclays plc hold share represent cent th april rate tax credit reduce shareholder ninth result compensate reduction rate tax far know company person owner cent share company dividend income increase tax bear uk taxation capital gain resident individual shareholder tax credit generally holder subject uk capital gain tax director officer long repayable shareholder tax liability subject tax capital gain realise sale associate tax credit disposal share adr interest director officer company define company act share option company give remuneration report page taxation capital gain estate gift taxis uk shareholder liable uk tax gain estate gift tax convention shareholder exchange control limitation affect security holder disposal share adrs entitle generally subject uk inheritance tax currently uk law decree regulation restrict import export capital affect remittance dividend indexation relief taper relief sale indexation relief payment holder companys share nonresident uk limitation relate calculated market value share st march stamp duty nonresident uk english law company memorandum article association right holder cost subsequent purchase date uk stamp duty sdrt subject certain exemption vote respect company share purchase indexation relief individual shareholder payable issue transfer share adr custodian cease th april taper relief available individual depository rate cent price issue document display shareholder hold deem hold share consideration provide transfer year sell sale value transfer consideration document refer annual report available inspection register office company sdrt payable transfer adr uk inheritance tax stamp duty payable transfer adr individual shareholder liable inheritance tax provide instrument transfer execute remain transfer share adrs tax charge time outside uk stamp duty transfer value shareholder estate reduce adr payable rate cent result transfer way gift disposal consideration transfer sale underlie share market value gift disposal subject result liability uk stamp duty case uk inheritance tax estate gift tax estate gift sdrt rate cent minimum charge tax convention generally provide tax pay usa stamp duty liability arise credit tax payable uk glaxosmithkline glossary term contact detail term annual report equivalent brief description internet accelerate capital allowance tax allowance excess depreciation arise purchase fix asset delay information investor company charge payment tax equivalent tax depreciation available glaxosmithkline corporate website advance corporation tax act advance payment uk tax dividend pay direct wwwgskcom equivalent american depositary receipt adr receipt evidencing title ad glaxosmithkline adr represent ordinary head office register office share glaxosmithkline plc american depositary share adss ordinary share register new york stock exchange great west road calledup share capital ordinary share issue fully pay brentford middlesex tw gs cer growth growth constant exchange rate tel combine code guideline require listing rule financial service authority address principal aspect corporate governance united kingdom united states america company glaxosmithkline plc investor relation investor relation creditor account payable great west road franklin plaza currency swap exchange currency couple subsequent reexchange currency brentford po box agree exchange rate date middlesex tw gs philadelphia pa debtor account receivable tel tel toll free fax tel outside usa define benefit plan pension plan specific employee benefit call final salary scheme fax define contribution plan pension plan specific contribution level pension dependent growth registrar pension fund lloyds tsb registrar adr programme administrator causeway bank new york derivative financial instrument financial instrument derive value price rate underlie item worthe shareholder relation dilute earning share diluted income share west sussex bn da po box dividend cover profit attributable shareholdersnet income divide dividend payable shareholder wwwshareviewcouk church street station earning share basic income share new york ny general enquiry annual report orderline wwwadrbnycom employee share ownership trust trust establish group satisfy share base employee incentive plan corporate nominee service tel toll free equity shareholder fund aggregation share reserve own shareholder equivalent tel inside uk tel outside usa shareholders equity tel outside uk customer response center finance lease capital lease shareholder investment plan tel toll free dividend reinvestment enquiry freehold ownership absolute right perpetuity tel inside uk corporate share deal facility gearing ratio net debt percentage shareholder fund net debt minority interest tel outside uk ordinary holder smith barney group glaxosmithkline plc subsidiary undertaking tel outside uk employees attn gsk services hedging reduction risk normally relation foreign currency interest rate movement state street make offset commitment monthly saving plan enquirie th floor tel inside uk intangible fix asset asset physical substance brand licence patents knowhow boston tel outside uk marketing right purchase outside party tel toll free isa enquiry tel outside usa interest cover number time profit interest exceed net interest payable tel inside uk fax interest payable interest expense tel outside uk thetaylorgroupsmithbarneycom interest receivable interest income glaxo wellcome smithkline beecham corporate pep nonequity minority interest preference share issue subsidiary outside party share centre limited preference share share issue vary dividend rate treat outside interest oxford house profit income oxford road aylesbury profit loss account reserve retain earning buck hp sz profit attributable shareholder net income tel share capital ordinary share capital stock common stock issue fully pay corporate share deal facility share option stock option smith barney share premium account additional paidup capital paidin surplus distributable attn gsk services citigroup centre level share issue share outstanding canada square canary wharf statement total recognise gain loss statement comprehensive income london e lb stock inventory tel subsidiary undertaking affiliate glaxosmithkline hold majority shareholding andor exercise control fax thebalaesgroupcitigroupcom tangible fix asset property plant equipment turnover revenue print midas press uk paper production document pulp harvest sustainable forest sawmill residue forest thinning elemental chlorinefreedo feel well live long improve performance day annual report troper launna enilkhtimsoxalg wwwgskcom annual review